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Optimization of Weight and Glycemic Control 
(Under the direction of Elizabeth J. Mayer-Davis) 
Obesity is an increasing concern in the clinical care of youth with type 1 diabetes 
(T1D). Standard approaches to co-optimize weight and glycemic control are challenged 
by profound population-level heterogeneity. Therefore, the goal of the dissertation was 
to apply novel analytic methods to understand heterogeneity in the co-occurrence of 
weight, glycemia, and underlying patterns of minute-to-minute dysglycemia among 
youth with T1D.  
Data from the SEARCH for Diabetes in Youth study were used to characterize 
subgroups of youth with T1D showing similar weight status and level of glycemic control 
as distinct ‘weight-glycemia phenotypes’ of T1D. Cross-sectional weight-glycemia 
phenotypes were identified at the 5+ year follow-up visit (n=1,817) using hierarchical 
clustering on five measures summarizing the joint distribution of body mass index z-
score (BMIz) and hemoglobin A1c (HbA1c), generated by reinforcement learning tree 
predictions. Longitudinal weight-glycemia phenotypes spanning eight years were 
identified with longitudinal k-means clustering using baseline and follow-up BMIz and 
HbA1c measures (n=570). Logistic regression modeling tested for differences in the 
emergence of early/subclinical diabetes complications across subgroups. Seven-day 
blinded continuous glucose monitoring (CGM) data from baseline of the Flexible 
Lifestyles Empowering Change randomized trial (n=234, 13-16 years, HbA1c 8-13%) 
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was clustered with a neural network approach to identify subgroups of adolescents with 
T1D and elevated HbA1c sharing patterns in their CGM data as ‘dysglycemia 
phenotypes.’  
We identified six cross-sectional weight-glycemia phenotypes, including four 
normal-weight, one overweight, and one subgroup with obesity. Subgroups showed 
striking differences in other sociodemographic and clinical characteristics suggesting 
underlying health inequity. We identified four longitudinal weight-glycemia phenotypes 
associated with different patterns of early/subclinical complications, providing evidence 
that exposure to co-occurring obesity and worsening glycemic control may accelerate 
the development and increase the burden of co-morbid complications. We identified 
three dysglycemia phenotypes with significantly different patterns in hypoglycemia, 
hyperglycemia, glycemic variability, and 18-month changes in HbA1c. Patient-level 
drivers of the dysglycemia phenotypes appear to be different from risk factors for poor 
glycemic control as measured by HbA1c. These studies provide pragmatic, clinically-
relevant examples of how novel statistics may be applied to data from T1D to derive 
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CHAPTER 1. INTRODUCTION AND RESEARCH AIMS 
 
1.1 Introduction 
The prevalence of obesity in youth and young adults with type 1 diabetes now 
parallels that of the general population, while the prevalence of overweight in type 1 
diabetes is even higher.1,2 Within this same population, adherence to the complex 
regimen required to achieve optimal blood glucose is challenging, resulting in various 
degrees of glycemic control3-5 and dysglycemia6,7 (i.e. glycemic variability). Both excess 
adiposity and poor glycemic control increase the risk of cardiovascular disease later in 
life.8-11 Thus, there is a great need for new clinical strategies to co-optimize weight and 
glycemia among youth with type 1 diabetes to improve long-term cardiovascular 
outcomes in this heterogenous and high-risk population.  
However, the goals and suitability of specific clinical strategies to mitigate 
cardiovascular disease risk may vary markedly across the spectrum of weight and 
glycemia seen day-to-day in clinical settings, as well as the specific patterns in 
dysglycemia that may underlie these outcomes. Thus, the type 1 diabetes patient 
population is a good candidate for precision medicine. Precision medicine is an 
emerging field that aims to support personalized medicine decisions with reproducible 
research, the goal of which is to match subgroups of patients to therapies based on the 
markers that indicate differential response.12,13 Targeted application of interventions 
across population subgroups may increase efficiency and efficacy of prevention and 
treatment whilst reducing costs of care.14,15 However, new data-driven approaches to 
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identify subgroups of type 1 diabetes based on heterogeneity in key clinical features are 
needed to pave the way for precision medicine interventions to optimize weight and 
glycemia in type 1 diabetes. Thus, the objective of the dissertation is to apply novel 
analytic methods to understand heterogeneity in the co-occurrence of weight, glycemia, 
and underlying patterns of minute-to-minute dysglycemia among youth with type 1 
diabetes. There were two main goals: 1) use partially supervised and unsupervised 
machine learning approaches to identify clinically relevant patient phenotypes of type 1 
diabetes; 2) evaluate the clinical utility of data-driven phenotypes to predict clinical 
outcomes. 
 
1.2 Research Aims 
In Aims 1 and 2, we use a data from a large, nationally-representative 
observational cohort to study a type 1 diabetes phenotype that is observed in the clinic 
but not well-characterized in epidemiological research. We identify subgroups of youth 
with type 1 diabetes who have a similar weight status and level of blood glucose control 
as distinct ‘weight-glycemia phenotypes’ of type 1 diabetes. It is likely that these 
subgroups with similar weight-status and blood glucose control would benefit from 
similar therapeutic strategies and can be targeted more efficiently as groups for clinical 
recommendations. In Aim 3, we shift to a smaller, high-dimensional dataset collected at 
baseline of a clinical trial to study heterogeneity underlying observed BMIz and HbA1c. 
We focus on a phenotype defined by shared patterns in measures of dysglycemia 
obtained from continuous glucose monitoring (CGM) data. We then test how 
‘dysglycemia’ phenotypes of type 1 diabetes are associated with baseline and 18-month 
changes in BMIz and HbA1c.  
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Aim 1. To determine an optimal classification system for cross-sectional 
subgroups of youth who share clinical phenotypes based on body mass index z-
score (BMIz) and hemoglobin A1c (HbA1c). Aim 1 uses cross-sectional data from the 
5+ year follow-up visit of the large, nationally-representative SEARCH for Diabetes in 
Youth study (SEARCH, n=1,817, ages 7-30). There are three main components to the 
study.  
1A: Cluster individuals in SEARCH by the joint distribution of BMIz and HbA1c 
and describe the relative prevalence of each subgroup.  
1B: Examine aspects of type 1 diabetes and its clinical care, sociodemographic 
characteristics, and health behaviors/psychosocial features associated with 1A 
subgroups.  
1C: Compare data-driven weight-glycemia subgroups against a-priori 
classifications based on clinical cut-points3,16-18 and determine the extent to 
which simple classifications adequately characterize the heterogeneity in weight 
and glycemia across the population. 
 
Aim 2: To test how longitudinal clinical phenotypes based on weight and 
glycemia are susceptible to different early or subclinical diabetes complications. 
Aim 2 uses data from the baseline visit and the 5+ year follow-up visit of the SEARCH 
study (n=570, diabetes duration>12 months at the baseline visit). There are two main 
components to the study.  
2A: Identify subgroups in SEARCH sharing patterns in BMIz and HbA1c from 
baseline through the follow-up visit.  
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2B: Compare the prevalence of early and subclinical complications of diabetes 
(hyperlipidemia, arterial stiffness, hypertension, diabetic kidney disease, 
retinopathy, peripheral neuropathy, and cardiovascular autonomic neuropathy) 
across subgroups at the follow-up visit.  
 
Aim 3: To identify subgroups of youth who share ‘dysglycemia phenotypes’ 
based on shared patterns derived from CGM measures at baseline of a clinical 
trial and test how subgroups differ in terms of baseline and 18-month changes in 
BMIz and HbA1c. Aim 3 uses data from the Flexible Lifestyles Empowering Change 
trial (FLEX, n=257, ages 13-16), an NIH-funded 18-month randomized clinical trial 
testing the efficacy of an adaptive behavioral intervention to promote self-management 
and improve glycemic control19. Participants wore a blinded CGM for 7 days at baseline, 
at 6 mo-, and at 18-mo visits. There are three main components to the study. 
3A: Assess how baseline CGM measures of glucose exposure, hyperglycemia, 
hypoglycemia, and glycemic variability cluster and how participants can be 
grouped within these dysglycemia phenotypes.  
3B: Characterize dsglycemia clusters according to their baseline 
sociodemographic, clinical, and psychosocial characteristics.  
3C: Test how dysglycemia phenotypes are associated with longitudinal BMIz and 
HbA1c, accounting for FLEX study site and randomization assignment.  
 Together, these studies leverage high-dimensional data from two contemporary 
studies of youth with type 1 diabetes, including a population-based cohort study and a 
randomized clinical trial, to discover and understand clinically important patient 
phenotypes and the clinical implications of each. Early recognition of these phenotypes 
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in youth and adolescents will allow clinicians to offer a tailored care plan that 
appropriately integrates glycemia and weight-oriented recommendations and strategies. 
This dissertation provides pragmatic, clinically-relevant examples of how novel statistics 
and analytic methods may be applied to data from T1D to derive patient subgroups that 
are sufficiently different to warrant tailored and targeted interventions. Giving voice to 
the emerging yet vague notion of precision medicine in chronic disease, these results 




CHAPTER 2. BACKGROUND AND MOTIVATION 
 Chapter 2 first provides an overview of type 1 diabetes, including the 
pathophysiology and etiology, epidemiology, its presentation and clinical care, and key 
glycemic control outcomes. The chapter then provides an overview of obesity in the 
setting of type 1 diabetes, including the epidemiology, proposed mechanisms and 
clinical significance, and the current approaches to clinical management. An overview of 
precision medicine follows. The chapter concludes with a discussion of the identified 
clinical needs and research priorities, current gaps in the literature, and key research 
questions that serve as motivation for the dissertation studies. 
 
2.1 Background on Type 1 Diabetes 
 
2.1.1 Pathophysiology and etiology 
Type 1 diabetes is an autoimmune disease that is characterized by an absolute 
insulin deficiency caused by T-cell–mediated autoimmune destruction of pancreatic β-
cells.20 Defects in insulin secretion result in chronic hyperglycemia and lead to 
abnormalities of carbohydrate, fat, and protein metabolism.21 Prior to disease onset, the 
rate of autoimmune-mediated pancreatic β-cell destruction is variable.20,22 It has been 
proposed that youth progress through three distinct stages.22 Stage 1 is characterized 
by the presence of β-cell autoimmunity with normoglycemia and a lack of clinical 
symptoms that lasts from months to years, Stage 2 progresses to measurable 
dysglycemia, but remains asymptomatic, and Stage 3 is defined as the onset of 
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symptomatic disease.22 Individuals become clinically symptomatic when approximately 
90% of pancreatic β-cells are destroyed.22  
The etiology of type 1 diabetes is multifactorial.21 However, the specific roles for 
genetic susceptibility, environmental factors, immune response, and β-cell physiology in 
the pathogenic processes underlying type 1 diabetes remain unclear.21 In general, 
individuals at increased risk of developing type 1 diabetes can be identified by a 
combination of diabetes associated autoantibodies, genetic markers, intravenous 
glucose tolerance test and/or oral glucose tolerance test.23-27 Diabetes associated 
autoantibodies are serological markers of β-cell autoimmunity and include antibodies to 
GAD65, IA2, ZnT8, and insulin.28 HLA genotype confers approximately 30-50% of risk 
for type 1 diabetes.22,29-31 Genome-wide association studies have also identified 
numerous non-HLA genes or loci that contribute small to moderate effects on disease 
risk.32,33 Environmental triggers of type 1 diabetes are under study and may include 
infectious diseases such as enterovirus infection34,35 or other nutritional and chemical 
exposures months to years before the manifestation of clinical symptoms.25,36,37 
Of note, the pathophysiology and etiology of type 1 diabetes is distinct from type 
2 diabetes, which is characterized by resistance to insulin action and defective tissue 
response, as well as an inadequate compensatory insulin secretory response for the 
degree of insulin resistance;21 type 2 diabetes has only recently emerged among youth 
and the prevalence is highest among children with obesity and in high risk ethnic 
populations.38,39 Autoimmune type 1 diabetes is also distinct from monogenic forms of 
diabetes, which result from genetic mutations in key genes for the development or 
function of β-cells.40,41 The latter is marked by the presentation of mild diabetes with a 
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significant family history during late youth or adolescence and accounts for less than 4% 
of pediatric diabetes cases.42-45 
 
2.1.2 Epidemiology  
The incidence and prevalence of type 1 diabetes varies greatly between different 
countries, and within countries, between different ethnic populations.21 Approximately 
80,000 children under the age of 15 years are estimated to develop type 1 diabetes 
annually worldwide.46 An increase in incidence of type 1 diabetes has been observed 
globally in recent decades,39,47-63 with a disproportionately greater increase in those 
under the age of 5 years47,64 and in developing countries or those undergoing recent 
economic transition.47,55 In most western countries, type 1 diabetes accounts for over 
90% of childhood and adolescent diabetes, while across the lifespan, type 1 diabetes 
accounts for 5-10% of individuals with diabetes.21 
In the United States, recent data show that the incidence of type 1 diabetes is 
increasing.39 The rate of increase is higher among non-Hispanic white youth compared 
to non-Hispanic white youth (4.2% vs. 1.2%).39 The  prevalence of type 1 diabetes in the 
United States was highest among white youth and lowest in American Indian youth, with 
prevalence rates of 2.55 per 1000 (95% CI, 2.48-2.62) versus 0.35 per 1000 (95% CI, 
0.26-0.47), respectively.65  
 
2.1.3 Presentation and clinical care  
Type 1 diabetes in childhood typically presents with characteristic symptoms 
including polyuria, polydipsia, nocturia, enuresis, weight loss, which may be 
accompanied by polyphagia, behavioral disturbances, and blurred vision.20 In advanced 
cases, diagnosis may present with diabetic ketoacidosis and coma.20 Impairment of 
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growth and susceptibility to certain infections may also accompany chronic 
hyperglycemia.21 Diagnostic criteria for diabetes are based on laboratory-based blood 
glucose measurements and the presence or absence of symptoms.66,67 
Sustained hyperglycemia in type 1 diabetes is linked to the development of 
chronic complications of the disease, which represent the major source of morbidity and 
mortality. Complications associated with type 1 diabetes include including microvascular 
disease (i.e. retinopathy, diabetic kidney disease, neuropathy) and macrovascular 
disease (i.e. cardiovascular disease).68 Cardiovascular disease risk is elevated up to 10-
fold in type 1 diabetes,10,11,69 as compared to individuals without type 1 diabetes, and 
cardiovascular disease is currently the leading cause of death in type 1 diabetes.70 The 
benefits of intensive insulin therapy for the prevention of long-term microvascular and 
microvascular complications of diabetes were demonstrated by the Diabetes Control 
and Complications Trial (DCCT),71,72 with persistent benefit over 30 years later.73,74 In 
the DCCT, intensive insulin therapy consisted of multiple daily injections or continuous 
subcutaneous insulin infusion therapy aimed at normal or near-normal blood glucose 
levels based on frequent self-monitoring and intensified patient education and follow-
up.75 In youth and adolescents, multiple studies have shown that the risk for these 
outcomes is associated with glycemic control as measured by hemoglobin A1c 
(HbA1c).10,74,76,77 Therefore, the daily management of type 1 diabetes is centered on 
intensifying insulin therapy and engaging patients to maintain blood glucose levels in 
near-normal ranges to delay or prevent the development of cardiovascular disease risk 
factors and diabetes-related complications.78  
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To this end, the type 1 diabetes self-management regime includes monitoring 
blood glucose, dosing insulin, measuring and regulating carbohydrates, and responding 
to episodes of hypoglycemia with appropriate intake of rapid-acting carbohydrate.79 
Major aspects of clinical care include blood glucose monitoring, which can be 
accomplished with frequent blood glucose checks or use of newly-developed 
continuous glucose monitoring systems, and insulin replacement, which is typically 
accomplished with multiple daily injections or insulin infusion (i.e. insulin pumps).80 
Current American Diabetes Association Standards of Care recommend intensive insulin 
therapy that consists of multiple-dose insulin injections (3-4 injections/day of basal and 
prandial insulin) or insulin pump therapy.81 Optimal nutrition is an important component 
of the recommended treatment plan for individuals with diabetes,80,82 although literature 
on specific diets for type 1 diabetes, including low and very low carbohydrate diets, is 
mixed and lacking in rigorous, randomized studies.83 Non-insulin adjuvants have 
recently been evaluated in combination with insulin to improve glycemic control in the 
setting of type 1 diabetes, including amylin analogues, metformin, sodium–glucose 
cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists.84 
 Overall, medical standards of care acknowledge the profound inter-individual 
differences and suggest individualized care considering patient factors and preferences 
in the selection of clinical goals, glycemic targets, and therapeutic approach.80,85 
Specific aspects of the type 1 diabetes care plan that can be individualized include 
insulin regimen, the degree of meal-planning and carbohydrate restriction, physical 
activity routines, and other supportive aspects of care including psychosocial support 
and self-management strategies. Within any given self-management strategy, there is 
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potential for high variability in effect size due to multifactorial, patient-specific 
characteristics, preferences, values, and abilities.86  Other key components of the 
medical management of type 1 diabetes includes the regular screening for subclinical or 
early complications of diabetes and prompt intervention upon positive findings.80,85 
 
2.1.4 Glycemic control outcomes 
Glycemic control is a complex clinical outcome related to physiological factors 
such as insulin sensitivity87 and residual beta cell function,88 as well as diabetes 
treatment regimens and self-management strategies,89 psychosocial well-being,90 and 
behavioral factors.91,92 Glycemic control is assessed via laboratory measures, which 
capture sustained exposure to hyperglycemia, and continuous glucose monitoring 
systems, which capture more transient features of hyperglycemia, hypoglycemia, and 
glycemic variability.  
 
2.1.4.1 Hemoglobin A1c 
Hemoglobin A1c (HbA1c) is the most widely used measure of medium-term 
glycemic control in type 1 diabetes.78 As the ‘gold-standard’ clinical assay, HbA1c 
shows high within-person reliability, is standardized internationally, and represents 
approximately 8-12 weeks of glucose control in individuals with normal hematological 
profiles.93 As described in Section 2.1.3, HbA1c has been directly associated with the 
risk for long-term diabetic complications in large trials and cohort studies such as the 
DCCT/EDIC study.94,95 
The youth and adolescent type 1 diabetes population is characterized by variable 
degrees of suboptimal glycemic control as measured by HbA1c.3,4,96 Glycemic control 
can vary considerably from diabetes onset through adolescence,97-99 where fluctuations 
 
 12 
are known to occur during puberty77,97,100-106 and during early adulthood. Recent data 
demonstrate elevated HbA1c levels that peak to >9.0% in 17-year-olds and remain 
elevated >8.0% until a mean age of 30 years.107 Poorer glycemic control during early 
adulthood or from childhood to young adulthood has been attributed to a lack of 
continuity in diabetes-related clinical care97,105,106 as well as changes in self-care as 
children and adolescents with type 1 diabetes grow into adulthood.102-104 
Among adolescents and young adults, there is evidence of health inequity that 
affects glycemic control outcomes. Mean HbA1c levels differs by racial and ethnic 
subgroups.108 African-American, American Indian, Hispanic, and Asian/Pacific Islander 
youth with type 1 diabetes are more likely to have higher HbA1c levels compared with 
non-Hispanic white youth.3,109 Our research group reported that compared to non-
Hispanic white youth, youth with black race or Hispanic ethnicity were at higher risk of 
being in the highest and most rapidly increasing HbA1c trajectory group over 9 years 
after diabetes diagnosis; these associations persisted among males and those with 
diagnosis at age under 9 years.109 Individual, community, and societal level factors have 
been posited to drive disparity in diabetes outcomes, such as socioeconomic status or 
other barriers to health care access3,96,110 which may result in complex patterns in 
healthcare utilization and inconsistences in the availability of resources or support for 
glucose management.111,112  
There is a substantial body of literature that describes the clinical care and 
behavioral correlates of HbA1c. Decreasing HbA1c has been associated with insulin 
pump therapy4,113,114 and increased frequency of blood glucose monitoring.89 Among 
youth, higher diet quality is associated with better glycemic control measured by 
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HbA1c.115,116 The association between HbA1c and physical activity is controversial;117 
multiple reports among youth suggest that physical activity generally does not lead to 
significant reductions in HbA1c,118,119 which may be attributable to increased food 
consumption to avoid hypoglycemia or rebound hyperglycemia following exercise.118 
HbA1c is correlated with measures of psychosocial well-being;120 HbA1c levels have 
been shown to be positively associated with depressive symptoms121 and negatively 
associated with perceived quality of life122-127 among youth with type 1 diabetes. In 
addition, disturbed eating behaviors in type 1 diabetes occur at a higher prevalence 
than in the general population and are associated with suddenly increasing or very high 
HbA1c levels.128-131  
The validity of HbA1c as a measure of average glycemic control is affected by 
co-occurring conditions or drugs that change the glycation of hemoglobin or red blood 
cell lifespan and turnover, such as anemia and hemoglobinopathies.93,132 Moreover, 
there are known racial and ethnic differences in the validity of HbA1c as a measure of 
average glycemia, presumably owing to racial differences in the glycation of hemoglobin 
or other factors affecting red blood cell turnover and iron status.133-135 
 
2.1.4.2 Continuous Glucose Monitoring  
Aside from sustained, chronic hyperglycemia, dysglycemia can manifest as acute 
glucose fluctuations93 and glycemic variability;136 yet HbA1c reflects average glucose 
level rather than these transient glycemic excursions.136 Continuous glucose monitoring 
(CGM) collects and displays measurement of interstitial glucose in an ongoing fashion, 
providing high amounts of information relating to real-time blood glucose approximately 
every five minutes for optimal treatment decisions throughout the day and night.137 CGM 
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studies have shown that youth with type 1 diabetes may have significant glycemic 
variability, even at ‘well-controlled’ HbA1c levels.138 Moreover, even at the same HbA1c 
level, individuals may show vastly different measures of short-term dysglycemia 
measured by CGM.139 
In particular, CGM data capture two key aspects of dysglycemia that are not 
represented by HbA1c, including hypoglycemia and glycemic variability. Hypoglycemia 
is the major barrier to achieving tight glucose control in type 1 diabetes and has been 
linked to anxiety, decreased quality of life, and excessive morbidity and mortality.140 
Youth with type 1 diabetes are particularly vulnerable to hypoglycemia due to 
unpredictable food consumption, erratic activity, and problems with accurate insulin 
dosing and detecting hypoglycemia.3,7 Glycemic variability quantifies variation in blood 
glucose levels over time.139 Multiple measures have been proposed to quantify glycemic 
variability using CGM data, including standard deviation (SD), percentage coefficient of 
variation (CV), interquartile range (IQR), mean amplitude of glucose excursion (MAGE), 
mean of daily differences (MODD), and continuous overlapping net glycemic action over 
an n-hour period (CONGAn).141 Futher, there may be within-day variability that is 
depdendent on the time of day141 as well as between-day variability within one 
individual.  
Emerging evidence suggests that glycemic variability may be a stronger predictor 
of diabetes complications than sustained hyperglycemia,93 consistent with findings from 
the DCCT study showing that patients with same HbA1C levels in the intensive and 
conventional arms of therapy had differing rates of microvascular complications.95 The 
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mechanism for the link between glycemic variability and cardiovascular disease has 
been proposed as increased oxidative stress93,142 and vascular damage.136  
 In scientific literature, it has been proposed that incorporating new glucose 
sensing technologies and metrics of glycemia will be important to better understand the 
dynamic nature of glucose, which may ultimately help to decrease complications and 
the burden of type 1 diabetes management on patients.6 In clinical practice, there is a 
call to use HbA1c in combination with other metrics of dysglycemia to ultimately tailor an 
individualized approach that will result in better outcomes and patient empowerment.6 
With wider adoption of continuous glucose monitoring143 and an increase in the 
availability of this type of data,144 recent research has focused on reconciling CGM 
measures with HbA1c, yielding formulas for converting CGM-derived mean glucose 
values to a glucose management indicator (CGMI) measure for use in diabetes care 
and research.145  
 
2.2 Background on Obesity in the Setting of Type 1 Diabetes 
 
2.2.1 Epidemiology 
In the past, children with type 1 diabetes were thin or normal weight due to 
impaired glucose utilization associated with insufficient tools and therapies for 
management and restricted diets to facilitate glucose management.146 Since the 
widespread adoption of intensified insulin therapy for the prevention of complications in 
1993 based on evidence from the DCCT, the technologies meant to keep blood glucose 
normal have also promoted weight gain.146-149 
Today, approximately 36% of adolescents with type 1 diabetes are 
overweight/obese.2,150 The prevalence of obesity in youth and young adults with type 1 
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diabetes parallels that of the general population at approximately 12.6%.151 The 
prevalence of overweight is even higher than the general population: 22.1% of 
adolescents with type 1 diabetes are overweight.151 Similar prevalence rates have been 
reported in other US-based cohorts and registries, Canada,152 and Europe.2,153-155 The 
prevalence of obesity increases in people with type 1 diabetes as they age107,156,157 and 
has been reported as high as 50% in adults with type 1 diabetes.107,156-158 For example, 
the T1D Exchange found that 50% of adults with type 1 diabetes are 
overweight/obese,159 consistent with other large scale studies.160,161  
Multiple studies have shown that females with type 1 diabetes are more likely to 
be overweight and/or obese than males.153,162-164 The highest prevalence of overweight 
and obesity in the setting of type 1 diabetes has been reported among those of 
Hispanic/Latino descent at approximately 46.1%.163 Additional socioeconomic predictors 
of overweight/obese status in type 1 diabetes include lower household income163 and 
lower parental education level,162 although these associations are stronger in females 
than males.165 
Epidemiologic correlates of overweight and obesity in type 1 diabetes also 
include longer type 1 diabetes duration162,163, higher HbA1c163,166, and higher insulin 
dose.163,164. Studies investigating insulin pump use and weight gain are mixed; some 
studies have demonstrated that insulin pump use and higher basal rates lead to 
overweight/obese status,164,167 whereas others have not.168-170. A physically active 
lifestyle has been associated with lower BMI and percentage of body fat in type 1 
diabetes171. Similarly, increased sedentary time is associated with increased 
adiposity172,173. Psychosocial aspects that are associated with overweight or obese 
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status among individuals with type 1 diabetes include higher depressive 
symptoms,174,175 lower quality of life,162,173,176 and decreased social support, self-
esteem, and body image.177 
 
2.2.2 Proposed mechanisms and clinical significance 
Obesity is a heterogeneous disease that is driven by many factors.178,179 In a 
given individual, weight status represents a complex interaction of biological, behavioral, 
and cultural factors.180 Among individuals with type 1 diabetes, there are diabetes-
specific and non-diabetes specific mechanisms proposed to explain the increasing 
prevalence of obesity.181 Epidemiologic evidence shows a clear link between intensive 
insulin therapy and weight gain in adults182,183 and youth with type 1 diabetes,116 
possibly owing to the ‘unphysiologic’ metabolic effects of insulin replacement.184 For 
example, exogenous insulin in type 1 diabetes immediately circulates systemically, 
instead of making a first pass through the portal vein, increasing the anabolic influence 
on muscle and adipose tissue.185 This association of insulin therapy and weight gain 
has also been attributed to decreased glucosuria with tighter glucose control,186,187 
increased caloric intake to treat hypoglycemia,188,189 increased lipogenesis and fat 
accumulation and decreased catabolism associated with peripheral 
hyperinsulinemia,185,186 which are needed to suppress hepatic glucose production.190 
Type 1 diabetes itself may also be associated with alterations in total energy 
expenditure and metabolic flexibility, as well as disruption of appetitive hormone 
signaling, although literature is sparse.181 
In addition, there are behavioral and psychosocial factors specific to type 1 
diabetes and its daily management that may promote unhealthy weight status,189 
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including fear of hypoglycemia,191 diabulimia,192 or hypoglycemia-induced binging.10 
Fear of hypoglycemia has been reported as a patient-perceived barrier to physical 
activity among some youth;193 several studies have demonstrated that children with type 
1 diabetes engage in less physical activity than their peers.194-196 Youth with type 1 
diabetes are at an increased risk of developing disordered eating behaviors, ranging 
from subclinical behaviors to insulin manipulation in the form of complete omission or 
intentional under-dosing results for weight loss.197,198 Finally, it has been posited that 
recurrent hypoglycemia and its associated intense hunger and permission to eat 
discouraged sugary foods may lead to over-eating, guilt, restriction, and possibly more 
episodes of hypoglycemia, creating a self-perpetuating cycle of disordered eating 
behavior resembling binge eating disorder and bulimia130,199,200 that may interfere with 
weight loss and maintenance efforts. 
Trends in the type 1 diabetes population parallel epidemiological shifts in the 
general population associated with the childhood obesity epidemic.201 In addition, youth 
with type 1 diabetes share risk factors for overweight and obesity with youth who not 
have type 1 diabetes,189 suggesting a role of an obesigenic environment and behavioral 
aspects that are not specific to diabetes management.  
The clinical implications of obesity in type 1 diabetes largely center around long 
term cardiovascular disease risk.10,11 Excess adiposity contributes to central obesity, 
dyslipidemia, elevated blood pressure, and insulin resistance, all of which increase the 
risk for long-term cardiovascular events.8,11,202 Recent reviews propose that weight gain 
associated with insulin therapy may reduce or nullify the benefits of good metabolic 
control,155 where individuals in the DCCT who received intensive insulin therapy and 
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gained the most weight had a significantly higher incidence of major cardiovascular 
disease events compared to those with minimal weight gain after 14 years of follow-up 
study.149 In addition, evidence suggests that the development of other chronic 
complications of type 1 diabetes may be accelerated by obesity, including retinopathy 
and neuropathy.203-205 
 
2.2.3 Current approaches to clinical management 
There are a breadth of clinical strategies and recommendations for general 
weight loss and weight gain prevention in youth and young adults,206 ranging from diet 
alone, diet and exercise, exercise alone, meal replacements, very-low-energy diets, to 
weight-loss medications and bariatric surgery.207 Due to heterogeneous response to 
these interventions,208 best-practices for weight management emphasize selection of 
weight-oriented strategies that are tailored to the individual child and family, including 
dietary goals, physical activity, the home environment, and other self-management 
behaviors.209  
For youth with type 1 diabetes, weight management must be integrated with 
glycemic control, where insulin therapy remains central to medical management.181 
However, recommendations to this end often lack intentional considerations of long-
term metabolic effects or energy balance, inadvertently promoting insulin intensification 
at the expense of weight gain or increased hypoglycemia/carbohydrate rescue. 
Conceivable weight management approaches for type 1 diabetes include an array of 
options including lifestyle recommendations as well as non-insulin adjunct therapeutics 
that may be applied depending on the severity of obesity and ultimate weight 
goals.146,189 Currently, however, there are no clinical practice recommendation specific 
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for type 1 diabetes weight management informed by rigorous, randomized research 
studies,181  although a pilot trial funded by the National Institutes of Health is currently 
underway.  
 
2.3 Background on Precision Medicine  
 
2.3.1 Overview of precision medicine 
Precision medicine is an emerging field that aims to support personalized 
medicine decisions with reproducible research,12,13 the goal of which is to match 
subgroups of patients to therapies based on the markers that indicate differential 
response.14,15 Such research is imperative particularly when disease presentation, 
including clinical features and etiologic correlates, or responses to disease treatment 
are expressed with great heterogeneity across patients.12,210 The idea at the core of 
personalized medicine, which seeks to target treatments to individual patients to 
account for patient heterogeneity, is not new; physicians engage in this work as part of 
clinical practice.13,211 Precision medicine, which extends personalized medicine to a 
population level and seeks to target treatments (or preventative steps) to patients in an 
empirically-based, scientifically-rigorous, reproducible, and generalizable way, is 
novel.12  
Since the rollout of the national Precision Medicine Initiative to personalize 
approaches toward improving health and treating disease,13 this paradigm has been 




2.3.2 Precision medicine for population health  
A precision medicine framework can be applied to improve population health via 
a subgroup approach, which matches patients or subgroups of patients to therapies 
based on the markers that indicate differential response to therapy.15,215-217 Subgroup-
based precision medicine attempts to segment the population by risk or response into a 
number of individual strata, to each of which differential interventions may be applied.14 
Application of interventions across population subgroups may increase efficiency and 
efficacy of prevention and treatment,14,15 while also reducing costs of care.218  
Three factors are necessary for precision medicine to improve the health of a patient 
population. First, there needs to be underlying disease variability with multiple relevant 
targets for intervention. Second, there must be multiple treatment options that have 
sufficiently heterogenous responses. Finally, there must be clear clinical markers to link 
therapies to subgroups of patients likely to exhibit a positive response.14   
 
2.3.2.1 Disease phenotyping 
A central interest of precision medicine for population health is the stratification of 
complex diseases, such as diabetes, into more homogeneous patient phenotypes, or 
subtypes of disease, for targeted therapies or treatment strategies.219,220 The term 
phenotype describes ‘any observed quality of an organism, such as its morphology, 
development or behaviors’, and may include traits that are controlled by genes as well 
as those that reflect environmental factors.221 Historically, phenotype was used to 
describe observable characteristics of a person corresponding to a specific genotype.220 
In recent years, however, the term has been adopted and expanded to describe groups 
of patients who share a disease diagnosis but are distinct regarding their genomic, 
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biochemical, or clinical data.220 Phenotypes can consist of a single parameter (i.e. 
glycemia) or a group of related features to represent a more complex pathologic state 
(i.e. metabolic health). Related to the concept of a disease phenotype is a disease 
‘endotype’; an "endotype" is proposed to be a subtype of a condition defined by a 
distinct pathophysiological mechanism. While disease ‘phenotype’ describes ‘clinically 
observable characteristics’ of a disease without direct relationship to an underlying 
pathophysiology, ‘endotypes’ describe subtypes of a disease defined by an intrinsically 
‘distinct pathogenetic mechanism’ and are discussed heavily in the context of precision 
medicine for asthma.222,223 
A challenge for precision medicine is identifying phenotypic subgroups that are 
meaningfully different from each and sufficient homogenous such that differentiated 
recommendation or therapies may be provided to each stratum that is effective, cost-
effective, and minimizes the prevention of harm.14,220 
 
2.3.2.2 Biomarkers 
Related to the concept of a phenotype are biomarkers. Biomarkers are broadly 
defined as any characteristic of an individual that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.224 In a precision medicine framework, an 
appropriate biomarker is essential to identify patients similar to other cohorts who have 
historically presented or responded in a specific way.12,225 Biomarkers can serve a 
prognostic role, conferring information about a patient’s long-term prognosis or disease 
status, a predictive role, conferring information about the likelihood that a given 
intervention will benefit or harm a patient, or a prescriptive role, conferring information 
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on which course of intervention is preferred for a patient.12 Like phenotypes, biomarkers 
are not constrained to a biological basis, but defined by their reliable correlation with 
differential clinical outcomes or response to intervention.15,219 The selection of markers 
depends directly on the way in which patient subgroups are conceptualized or the 
method by which the population is stratified; a challenge in the field of precision 
medicine is the transformation of high-dimensional and high-volume data into singular 
biomarkers or a subset of biomarkers that can predict outcomes and responses with 
accuracy and robustness.225  
 
2.3.2.3 Dynamic treatment regimes 
Precision medicine is most clearly operationalized as a dynamic treatment 
regime, a sequence of decision rules in which a patient is assigned to an intervention 
based on other available covariates, referred to as ‘tailoring variables.’12 An optimal 
dynamic treatment regime is estimated from data and maximizes the mean of a 
specified clinical outcome, or multiple outcomes, when applied to a patient population.12 
Precision medicine recommendations can be based on decision rules estimated from 
observational data or from clinical trials designed specifically to generate data for this 
purpose.12 226,227 
 
2.3.3 Precision medicine in diabetes care 
 Diabetes has been described as a heterogeneous disease in which there is a 
need for more precise ‘cataloging of risk factors, identification of pathophysiological 
pathways and prognostic course, selection of effective therapies, and prediction of 
outcomes or complications’.228 Precision medicine in the setting of diabetes has been 
explored primarily in the context of type 2 diabetes, including pharmacogenetics229,230 
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and attempts to characterize more precise T2D patient populations.231,232 A notable 
study by Ahlqvist et al. used unsupervised, data-driven approaches to stratify newly 
diagnosed patients with type 1 and type 2 diabetes in the Swedish All New Diabetics in 
Scania cohort into subgroups based on six demographic and clinical features, including 
glutamate decarboxylase antibodies, age at diagnosis, BMI, HbA1c, and homoeostatic 
model assessment  estimates of β-cell function and insulin resistance.232 The resulting 
subgroups showed differing patterns of disease progression and risk of complications 
including diabetic kidney disease and retinopathy,232 providing compelling evidence 
regarding the importance of stratified medicine to improve unequal prognosis within the 
same disease classification.233 
In type 1 diabetes, it has been suggested that future precision medicine 
approaches will require more precise patient characterization than past clinical 
phenotypes234 that may confer information about variability in further clinical, 
physiological, and molecular features that vary across the patient population.235,236 To 
date, efforts to capture more granular phenotypes have resulted in the conception of 
new subtypes of type 1 diabetes, including latent autoimmune diabetes and genetic 
forms which may be responsive to different treatment regimens (i.e. sulfonylureas).228 
However, the majority of research to date is represented by conceptual reviews and 
viewpoints.236,237 234,238,239 There are few examples of applied precision medicine 
research for the clinical care of type 1 diabetes.   
 
 25 
2.4 Motivation for Dissertation Studies  
 
2.4.1 Identified clinical needs and research priorities 
A thorough review of the literature reveals new priorities for research in type 1 
diabetes. First, recent epidemiologic evidence suggests a need for new care paradigm 
to optimize two outcomes, weight and glycemic control, for which treatment is inherently 
related and potentially antagonistic. Second, profound heterogeneity suggests that a 
deeper understanding of more precise disease subtypes within the complex population 
is imperative for a precision health system for diabetes.240,241 Therefore, research is 
needed to characterize the type 1 diabetes patient population in terms of the major 
clinical phenotypes who can be approached as subgroups for strategies to tailored to 
the presentation of key clinical outcomes and the drivers thereof. It is important that an 
understanding of disease subtypes must be reproducible, interpretable, and 
actionable,242 thereby moving the field towards established markers for subgroup-based 
precision medicine approaches to integrate weight management with the complexities of 
routine type 1 diabetes care, including both weight loss and prevention of obesity.  
 
2.4.2 Current gaps in the evidence and rationale of approach 
 Several key gaps in understanding the clinically-relevant phenotypes for weight 
management and glycemic control in type 1 diabetes were identified. First, although 
epidemiological evidence suggests population-level associations between BMI and 
HbA1c,2,128,243,244 the clinical evolution of type 1 diabetes to include overweight and 
obesity poses an opportunity to extend the type 1 diabetes etiological classification of 
disease into a study of the patient subgroups based on weight and glycemic control and 
understand the clinical utility of this classification system. Second,  the majority of 
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published CGM data in youth and adolescent populations have come from diabetes 
technology clinical trials where study criteria excluded participants with elevated HbA1c 
levels,245 thus, the generalizability to the larger type 1 diabetes population is severely 
limited3,143 and there is a need to understand how CGM data can be used to derive 
clinical phenotypes integrating multiple measures of dysglycemia. Such multifaceted 
dysglycemia may facilitate a more robust way to study how patterns in transient blood 
glucose levels act as underlying drivers of weight and glycemic control over time. 
 
2.4.3 Key research questions 
There are three key research questions addressed in the following three 
chapters. Each chapter represents an original research manuscript that is currently 
under review. Chapter 3 addresses the research question: Are there subgroups of youth 
with type 1 diabetes who share an observed clinical phenotype based on weight status 
and glycemic control? Chapter 4 addresses the research question: Are these weight-
glycemia phenotypic subgroups susceptible to different cardiovascular disease risk 
factors and diabetes complications? Finally, Chapter 3 addresses the research 
questions: Are there further subgroups of youth with type 1 diabetes who share a 
clinical phenotype based on continuous glucose monitoring measures of dysglycemia? 
How are dysglycemia phenotypes associated with cross-sectional and longitudinal 
weight and glycemic control? 
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CHAPTER 3. CHARACTERIZING THE WEIGHT-GLYCEMIA PHENOTYPE OF TYPE 
1 DIBETES IN YOUTH AND YOUNG ADULTHOOD 
Individuals with type 1 diabetes present with diverse body weight status and 
degrees of glycemic control, which may warrant different treatment approaches. The 
aim of the study was to identify subgroups sharing phenotypes based on both weight 
and glycemia and compare characteristics across subgroups. Participants with type 1 
diabetes in the SEARCH Study cohort (n=1,817, 6.0-30.4 years) were seen at a follow-
up visit ≥5 years after diagnosis. Hierarchical agglomerative clustering was applied to 
five measures summarizing the joint distribution of BMI z-score (BMIz) and hemoglobin 
A1c (HbA1c), estimated by reinforcement learning tree predictions from 28 covariates. 
Interpretation of cluster weight status and glycemic control was based on mean BMIz 
and HbA1c, respectively. The sample was 49.5% female and 55.5% non-Hispanic white 
(NHW); mean±SD age=17.6±4.5 years, diabetes duration=7.8±1.9 years, BMIz= 
0.61±0.94, and HbA1c=76±21 mmol/mol (9.1±1.9%). Six weight-glycemia clusters were 
identified, including four normal-weight, one overweight, and one subgroup with obesity. 
No cluster had a mean HbA1c <58 mmol/mol (7.5%). Cluster 1 (34%) was normal-
weight with the lowest HbA1c and comprised 85% NHW participants with the highest 
socioeconomic position, insulin pump use, dietary quality, and physical activity. 
Subgroups with the very poor glycemic control (i.e. ≥108 mmol/mol (≥12.0%); Cluster 4, 
4.4%, and Cluster 5, 7.5%) and obesity (Cluster 6, 15.4%) had a lower proportion of 
NHW youth, lower socioeconomic position, and reported decreased pump use and 
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poorer health behaviors (p<0.01). The study shows that there are distinct subgroups of 
youth and young adults with type 1 diabetes that share weight-glycemia phenotypes. 
Subgroups may benefit from tailored interventions addressing differences in clinical 
care, health behaviors, and underlying health inequity. 
 
3.1 Introduction 
As the prevalence of obesity increases worldwide, recent data have shown that 
the prevalence of overweight and obesity in youth and young adults with type 1 diabetes 
is even higher than in the general population.1,2 Excess adiposity increases the risk of 
cardiovascular disease later in life which is already elevated up to 10-fold in persons 
with type 1 diabetes. Therefore, there are early efforts to integrate weight management, 
including both weight loss and prevention of overweight and obesity, with the 
complexities of routine type 1 diabetes care.146 
However, the rising numbers of youth and young adults with type 1 diabetes who 
are overweight or obese has also contributed to the heterogeneity in the type 1 diabetes 
patient population. Given that appropriate treatment algorithms may vary markedly 
across the broad spectrum of body weight and glycemia,236 the type 1 diabetes patient 
population is a good candidate for precision medicine, which matches interventions to 
different subgroups of patients expected to show a positive response.12,15 
Epidemiological evidence suggests population-level associations between BMIz and 
HbA1c;2,243 however, surprisingly little is known about how weight status and glycemic 
control are co-distributed across the population and interact to form more nuanced 
clinical phenotypes of type 1 diabetes. The weight-glycemia phenotype may confer 
information about goals for treatment and effectiveness of specific therapeutic strategies 
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for optimizing outcomes simultaneously, especially given that weight gain may be an 
unintended consequence of intensive insulin therapy in some individuals.184  
Previous work used data-driven approaches to stratify adults with type 1 diabetes 
and type 2 diabetes into subgroups based on six ‘raw’ clinical and physiologic 
features.246 Subgroups showed differences in progression of type 2 diabetes and risk for 
complications.246 However, few studies have characterized heterogeneity in weight and 
glycemia within the etiologic diagnosis of type 1 diabetes. Therefore, our objective was 
to use data from a large, diverse cohort of youth and young adults with type 1 diabetes 
to identify and characterize subgroups sharing clinical phenotypes of type 1 diabetes 
based on weight status, measured by BMIz, and glycemic control, measured by HbA1c.  
 
3.2 Materials and Methods 
 
3.2.1 Study population 
The SEARCH for Diabetes in Youth Study began in 2000 with an overarching 
objective to describe the incidence and prevalence of youth-onset diabetes in the US by 
age, sex, and race/ethnicity. Youth and young adults with diabetes diagnosed <20 years 
of age (“youth”) were identified from a population-based incidence registry network at 
five U.S. sites (South Carolina; Cincinnati, Ohio and surrounding counties; Colorado 
with southwestern Native American sites; Seattle, Washington and surrounding 
counties; and Kaiser Permanente Health Plan, Inc., Southern California).247 A subset of 
participants with newly diagnosed diabetes between 2002 and 2006 and in 2008 were 
recruited for a follow-up ‘cohort’ visit between 2012-2015 if they had attended a baseline 
visit, had >5 years of diabetes duration, and were aged >10 years. The subset of youth 
who were included the SEARCH cohort visit were not significantly different than all other 
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SEARCH youth diagnosed between the years of 2002 and 2008 in terms of average 
diabetes onset age, demographics, or clinical measures.74  
Inclusion criteria for this report consisted of incident cases of type 1 diabetes 
between 2002-2006 and 2008 who attended the SEARCH cohort visit. Diabetes type for 
these analyses was based on an etiological classification using diabetes autoantibodies 
and estimated insulin sensitivity score (euglycemic clamp-validated equation including 
waist circumference, HbA1c and triglyceride levels) from the baseline visit.248 
Participants who were missing BMIz or HbA1c measures at the cohort visit (n=183) 
were excluded. The study was approved by Institutional Review Boards with jurisdiction, 
and the parent, adolescent or young adult, or both provided consent or assent for all 
participants. 
 
3.2.2 Research visits 
Trained personnel administered questionnaires; measured height, weight, and 
blood pressure; and obtained fasting blood samples. BMI was defined as weight 
(kilograms) divided by height (meters2) and converted to a Z-score based on US growth 
reference data.249 To facilitate study across youth and young adults, BMIz for individuals 
>20 years was estimated assuming an age of 20 years (the maximum age represented 
in the growth reference); this approach has been operationalized in previous SEARCH 
studies74,250 and elsewhere.251 A blood draw occurred after an 8 hour overnight fast, and 
medications, including short-acting insulin, were withheld the morning of the visit. 
 
3.2.3 Laboratory measures 
Blood samples were obtained under conditions of metabolic stability, defined as 
no episodes of diabetic ketoacidosis in the preceding month and the absence of fever 
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and acute infections. They were processed locally and shipped within 24 hours to the 
central laboratory (Northwest Lipid Metabolism and Diabetes Research Laboratories, 
Seattle, WA). HbA1c was measured by a dedicated ion exchange high–performance 
liquid chromatography instrument (TOSOH Bioscience, San Francisco, CA).  
 
3.2.4 Other measures 
Demographic measures included sex and self-reported race and ethnicity, 
categorized as non-Hispanic white, non-Hispanic black, Hispanic, Asian, Native 
American, Pacific Islander, and other. Highest education by either parent was classified 
as less than high school degree, high school graduate, some college through associate 
degree, and bachelor’s degree or more. Annual household income was classified as 
>$75,000, $50,000-75,000, $25,000-49,999 and <$25,000. Socioeconomic position 
measures included parental education and household income. Healthcare access was 
measured by health insurance type, classified as none, private, Medicaid, or other.  
Insulin regimen was classified as pumps, long-acting with short/rapid-acting 
insulin injections with ≥3 injections per day, and any other form of multiple or singular 
daily injections. Self-reported frequency of self-monitoring of blood glucose (SMBG) was 
categorized as <1, 1-3, and >3 times per day. Diabetes care provider was classified as 
pediatric endocrinologist, adult endocrinologist, and all other healthcare providers 
(pediatrician, family practice doctor, nurse practitioner, etc.).  
Depressive symptoms were measured using the Center for Epidemiological 
Studies Depression Scale (CESD).252 Quality of Life was measured using the Center for 
Pediatric Quality of Life Inventory™ (PedsQL).125 The CESD and PedsQL were 
modeled as continuous variables. Physical activity and screen time were assessed 
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using questionnaires. High physical activity was classified as vigorous activity 3–7 days 
weekly. High screen time was classified as 2 or more hours of screen-time per day. 
Data from a validated food frequency questionnaire (FFQ) was available for 1,643 
participants. Dietary quality was assessed by adherence to the Dietary Approaches to 
Stop Hypertension (DASH) diet using an index score ranging from zero to 80. 
 
3.2.5 Statistical methods 
We used cluster analysis to identify and characterize subgroups sharing clinical 
phenotypes of T1D based on weight status and glycemic control.  As opposed to 
unsupervised clustering analysis, where there is no outcome measure or data labels, 
we wished to perform a semi-supervised cluster analysis guided by the two outcomes of 
interest. A challenge in identifying supervised clusters is that noise in a given outcome 
may obscure true subgroups of clinical interest.253 Therefore, rather than cluster 
individuals based on the observed values of BMIz and HbA1c at the cohort visit, we 
employed a novel, semi-supervised clustering technique to group individuals in 
SEARCH by five measures of the joint distribution of BMIz and HbA1c at the cohort 
visit: the means and variances of BMIz and HbA1c and their covariance. Although the 
data used for analysis are cross-sectional, we can obtain an estimate of the within-
patient variance by fitting a model for the patient's deviation from their expected 
outcome, which is the formal definition of variance.  The five values summarizing the 
joint distribution of BMIz and HbA1c were predicted for each individual using 
reinforcement Learning Trees (RLTs), a type of tree-based machine learning 
technique,254 and 28 other characterizing variables that were available for each patient 
(X-variables). The 28 X-variables were chosen to capture a breadth of individual 
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characteristics available at the cohort visit including sociodemographic, clinical, 
anthropometric, laboratory, psychosocial and behavioral measures (see Supplemental 
Table 3.1). Any given X-variable was missing from at most 12% of individuals and 
imputed by a multiple imputation method, missForest.255 The resulting RLT-estimated 
outcomes represent smoothed outcome measures, de-noised by the X-variables, which 
maintain the individual level signal with reduced noise or measurement error.254 (Of 
note, the 28 X-variables were only used to predict measures of the joint distribution of 
BMIz and HbA1c for each individual and were not used directly in the cluster analysis.) 
The five clustering variables (RLT-predicted means and variances of BMIz and 
HbA1c and their covariance) were standardized and a hierarchical clustering algorithm 
with Ward’s D2 method and Euclidean distance was applied. The number of clusters 
was chosen using the NbClust package in R 256 and restricted to considering between 
four and nine clusters. The smallest cluster was restricted to greater than 50 people for 
adequate statistical power (>85%) to detect small to medium effects in cluster 
comparisons.257 Clustering stability was assessed by sequentially omitting individual 
clusters, one at a time, and evaluating the agreement of the remaining clusters using 
the Adjusted Rand Index (ARI).258 For more information on imputation methods, RLT 
parameters, clustering methods, stability assessments, and additional analyses, see 
Section 3.6, Supplemental Material.  
Clusters were ordered by increasing weight status and then by increasing mean 
HbA1c. Clusters were named based on mean BMIz and HbA1c using traditional clinical 
cut-point for ease of interpretation. Cluster weight status was classified as underweight 
(mean BMIz <-1.64), normal weight (mean BMIz -1.64-<1.04), overweight (mean BMIz 
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1.04-<1.64), and obesity (mean BMIz ≥1.64), corresponding to <5th, 5-<85th, 85th-<95th, 
and ≥95th percentile for age and sex, respectively.18 Cluster glycemic control was 
defined as good (mean HbA1c <58 mmol/mol (<7.5%)), moderate (mean HbA1c 58-<75 
mmol/mol (7.5-<9.0%)), poor (mean HbA1c 75-<108 mmol/mol (9.0-<12.0%)), and very 
poor (mean HbA1c ≥108 mmol/mol (≥12.0%)).3 This method of cluster nomenclature 
does not necessarily represent the weight status and glycemic control of each individual 
within cluster and instead was selected to facilitate cluster-level phenotypic 
interpretation and comparisons thereof.  
The cross-sectional correlates of each cluster were summarized using 
descriptive statistics. Date are presented as mean±standard deviation (SD). Overall-
tests of difference as well as pairwise comparisons were carried out using ANOVA, t-
tests, and chi-squared tests, or Fisher's exact tests, where appropriate. We accounted 
for multiple comparisons in 1) overall tests of difference, and 2) post-hoc pairwise 
comparisons between individual clusters. Overall tests were corrected via a Bonferroni 
adjustment. For pairwise comparisons, we report q-values, which control for the positive 
False Discovery Rate259 (pFDR) (see Section 3.5, Supplemental Material). p-values 
and q-values were evaluated at the 0.05 significance level. Data analyses were 
performed using the statistical analysis software package R version 3.4.1 and SAS 9.4 
(SAS Institute, Cary, NC). 
 
3.3 Results 
The study included 1,817 individuals with type 1 diabetes, with a mean age of 
17.6 (range 6.0-30.4 years) and a mean type 1 diabetes duration of 7.8 years (Table 
3.3.1). Six weight-glycemia phenotypic clusters were identified based on measures of 
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the joint distribution of BMIz and HbA1c (Figure 3.1). Based on mean measures, 
Cluster 1 (n=618, 34.0%) was normal weight with moderate glycemic control (mean 
BMIz 0.59±0.59, mean HbA1c 61±12 mmol/mol (7.7±1.1%)). Cluster 2 (n=195, 10.7%) 
was also classified as normal weight with moderate glycemic control but showed a 
slightly lower mean BMIz and higher mean HbA1c than Cluster 1 (mean BMIz -
0.68±0.66, mean HbA1c 68±10 mmol/mol (8.4±0.9%)). Cluster 3 (n=509, 28.0%) was 
normal weight with poor glycemic control (mean BMIz 0.56±0.62, mean HbA1c 86±12 
mmol/mol (10.0±1.1%)). Cluster 4 (n=79, 4.4%%) was normal weight with very poor 
glycemic control (mean BMIz -1.05±0.83, mean HbA1c 113±15 mmol/mol (12.5±1.4%)). 
Cluster 5 (n=137, 7.5%) was overweight with very poor glycemic control (mean BMIz 
1.29±0.69, mean HbA1c 109±15 mmol/mol (12.1±1.5%)). Cluster 6 (n=279, 15.4%) was 
those with obesity and moderate glycemic control (mean BMIz 1.74±0.42, mean HbA1c 
70±11 mmol/mol (8.6±1.0%)). Figure 3.2A depicts the density distribution of BMIz and 
HbA1c within each weight-glycemia cluster. 
Cluster 1 (normal weight with moderate glycemic control) was the largest cluster, 
comprising 34% of the sample. Based on mean BMIz and HbA1c measures closest to 
clinical targets, this group was selected as the referent group for individual 
comparisons. Tables 3.1 and 3.2 depict the sociodemographic characteristics and the 
diabetes care, psychosocial, and behavioral factors according to the six weight-
glycemia clusters. Participants in Cluster 1 were 46% female, 88% non-Hispanic white 
and were characterized by the highest measures of socioeconomic position, including 
74% having parents with a bachelor’s degree or more and 85% with private health 
insurance. This group also had the highest prevalence of insulin pump use and 
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frequency of SMBG, the lowest level of depressive symptoms, the highest quality of life, 
the highest dietary quality, and the highest levels of physical activity (overall p<0.001).  
One cluster emerged with poor glycemic control (Cluster 3, normal weight with 
poor glycemic control) and two with mean HbA1c >108 mmol/mol (12.0%) (Cluster 4, 
normal weight with very poor glycemic control; Cluster 5, overweight with very poor 
glycemic control). The latter two were the smallest subgroups, comprising 
approximately 4% and 8% of the sample, respectively. Compared to Cluster 1, these 
clusters included a significantly higher proportion of non-white individuals (58% and 
50%), with the highest proportion of non-Hispanic black individuals in Cluster 4 (28%) 
and highest prevalence of Hispanic individuals in Cluster 5 (23%) (q<0.001). Clusters 4 
and 5 also had lower measures of socioeconomic position and significantly lower insulin 
pump use and less frequent SMBG (Table 3.2; all q<0.001). Approximately 38% of 
individuals in Cluster 4 and 41% of Cluster 5 experienced an episode of diabetic 
ketoacidosis in the past 6 months compared to 10% in Cluster 1. Finally, Clusters 4 and 
5 were characterized by higher depressive symptoms, lower quality of life, poorer 
dietary quality, and greater a proportion of high screen time (all q<0.001).  
Two clusters were classified as overweight and having obesity (Cluster 5, 
overweight with very poor glycemic control; Cluster 6, obesity with moderate glycemic 
control). Compared to Cluster 1, both subgroups contained a higher proportion of 
females (66% in Cluster 5 and 55% in Cluster 6) and non-white youth. Cluster 6 was 
also characterized by moderately lower measures of socioeconomic position compared 
to Cluster 1 (all q<0.001). 
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Additional post-hoc pair-wise comparisons were made between Cluster 5 and 
Cluster 6, the two overweight/obesity subgroups (Supplemental Tables 3.2, 3.3, and 
3.4). Compared to Cluster 6 (obesity with moderate glycemic control), Cluster 5 
(overweight with poor glycemic control) comprised more female (q=0.028) and non-
white participants (q<0.001). Individuals in Cluster 5 were older at the follow-up visit 
(q<0.001) and had lower socioeconomic position (q<0.001 for parental education, 
income, and insurance type) with no significant differences in diabetes duration 
(p=0.15). These participants were also less likely to use an insulin pump or report 
frequent SMBG (q<0.001). There was a higher prevalence of high screen time in Cluster 
5 (p=0.001) with no significant differences in physical activity (q=0.34). 
Table 3.3 depicts other clinical measures across the weight-glycemia clusters. 
Compared to Cluster 1, Clusters 3, 4, 5, and 6 showed significantly higher blood lipids 
levels. Cluster 5 showed higher total cholesterol, LDL cholesterol, and triglycerides 
compared to both the referent Cluster 1 and Cluster 6 (obesity). This group also 
exhibited higher mean systolic and diastolic blood pressure levels than Cluster 1 and a 
higher mean diastolic blood pressure compared to Cluster 6 (all q<0.001).  
 
3.4 Discussion 
In a large, diverse cohort of youth and young adults with type 1 diabetes, we 
found evidence of subgroups that share distinct weight-glycemia phenotypes including 
varying combinations across BMIz and glycemic control parameters. None of the 
clusters that were identified had a mean Hba1c <58 mmol/mol to be classified as good 
glycemic control, underscoring that youth and young adults with type 1 diabetes are not 
meeting the targets put forward by the American Diabetes Association and International 
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Society for Pediatric and Adolescent Diabetes.260 Based on mean measures, four 
clusters were largely normal weight, with the remaining two clusters classified as 
overweight and having obesity, although there were individuals across all weight status 
categories who were captured in each cluster based on measures of the joint 
distribution. Examination of the latter two subgroups reveal that while overweight and 
poor glycemic control can co-occur in young people with diabetes (i.e. the weight-
glycemia phenotype of Cluster 5, comprising 8% of the sample), obesity is not always 
associated and does not necessarily account for those with poor or very poor glycemic 
control (i.e. the weight-glycemia phenotype of Cluster 6, comprising 15% of the sample).  
Clinical recommendations for individuals with HbA1c levels above target may 
differ based on weight status, especially given the complicated physiologic relationships 
between weight and glycemia.181 For example, approaches for under or normal weight 
individuals may be centered on insulin intensification while approaches for overweight 
individuals could balance the glycemic benefits of insulin intensification with the 
potential for weight gain via concurrent behavioral modifications or 
pharmacological/surgical intervention.84  
Given the high-risk for long-term complications, we focus our discussion on 
Clusters 4 and 5, the subgroups with the poorest glycemic control (HbA1c >108 
mmol/mol), as well as Cluster 6, the subgroup with obesity and moderate glycemic 
control. Together, they account for approximately 27% of the study population. 
The results corroborate previous reports that glycemic control differs by race and 
ethnicity among youth and young adults with type 1 diabetes3,236 and is also associated 
with lower measures of socioeconomic position including parental education, income, 
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and health insurance type. The results also substantiate other studies showing that 
lower household income and parental education level associate with overweight/obesity 
status in type 1 diabetes189 and are consistent with reports that youth with type 1 
diabetes who are of Hispanic ethnicity and females are at the highest risk of overweight 
or obesity.163 This finding is particularly concerning given recent data suggesting that 
the incidence of type 1 diabetes is increasing most rapidly among Hispanic youth.39 
Weight-glycemia clusters also showed significant differences in several aspects 
of clinical care, psychosocial outcomes, and health behaviors that were measured 
concurrently with BMIz and HbA1c. In our study, the best mean glycemic control was 
associated with higher use of insulin pump therapy4 and increased frequency of blood 
glucose monitoring.89  
The psychosocial correlates of clusters were consistent with previous studies, 
including a positive relationship between mean HbA1c levels and mean depressive 
symptoms and a negative association between mean HbA1c levels and mean perceived 
quality of life measures.261 Differences in potentially modifiable behavioral factors 
underscore that physically active lifestyle and decreased sedentary time are associated 
with lower BMI and percentage of body fat among people with type 1 diabetes.189 
Unfortunately, overall dietary quality measures were low, even among youth and young 
adults with the most favorable weight-glycemia phenotype, consistent with previous 
findings.121  
The significant differences in clinical parameters across weight-glycemia clusters 
implicate potential disparity in long-term cardiovascular disease risk across these 
subgroups.184 The combination of very high HbA1c and increased insulin needs of 
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Cluster 5, the overweight subgroup with very poor glycemic control, is suggestive of 
insulin resistance.163,184 This group also exhibited the worst cardiovascular disease risk 
profile including elevated lipid and blood pressure levels. Laboratory measures were 
significantly elevated compared to Cluster 6, despite the higher mean BMIz of Cluster 6. 
More work is needed to understand how adiposity and hyperglycemia jointly contribute 
to cardiovascular disease risk profiles. 
One of the most striking results is the pattern with which all other demographic, 
socioeconomic, clinical care, psychosocial, and behavioral factors track across the 
clusters derived from measures of the joint distribution of weight and glycemia. It is 
relevant to note that nonwhite race/ethnicity, lower socioeconomic position and 
healthcare access, and poorer psychosocial well-being have been shown to be 
associated with each other and with glycemic control elsewhere in SEARCH 
studies.4,261 A maximally effective precision medicine approach to co-optimize weight 
and glycemia will concern itself with underlying biology as well as characteristics of 
individuals and resource constraints that may influence outcomes over time. Although 
the cross-sectional cluster analysis is not designed for causal conclusions, future 
research is needed to develop the specific interventional strategies to impact weight and 
glycemia outcomes that considers the close relationships among these economic, 
social, and cultural factors.  
The study has several weaknesses. Despite the collective use of gap statistics 
and supporting graphs, selection of the number of clusters is subjective. Additional 
external validation studies are required to understand the generalizability of major 
weight-glycemia phenotypes across other observational cohort studies of T1D. In 
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addition, BMIz was used as a proxy for weight status, although this measure may not 
reflect adiposity.262,263 and the large age range necessitated imputation of BMIz for 
participants over 20 years of age using z-score data for age 20 years. To assess for 
differential error of BMIz on participant age (i.e. youth versus young adults), we stratified 
the sample by age at follow-up visit (<21 years, n=1,399, ≥21 years, n=418) and 
independently evaluated clusters in each sample (Supplemental Table 3.6, 
Supplemental Figure 3.1). Despite significant differences in sample sizes, we found 
largely consistent clustering results in both strata, suggesting that the measure of BMIz 
did not bias the nature of the clusters across different age ranges. Finally, the current 
study is cross-sectional and cannot elucidate temporal associations with the weight-
glycemia phenotypes nor the longitudinal clinical outcomes. Studies that test these 
subgroups show different rates or patterns in the emergence of type 1 diabetes 
complications and cardiovascular disease risk factors may help to inform clinical utility 
of this weight-glycemia phenotype.  
The study also has several strengths. One is inherent in the analytic design; this 
approach to characterize a phenotype based on two outcomes allows real-life 
phenotypes to emerge rather than forcing a fit based on a-priori clinical cut-points for 
weight and glycemic control. In additional analyses, the six weight-glycemia clusters 
were compared to strata of the same sample defined by clinical cut-points for 
overweight/obesity and poor glycemic control (see Supplemental Tables 3.6 and 3.7). 
The strata corroborated main descriptive results (i.e. differences in sociodemographic 
characteristics across subgroups with differing levels of glycemic control), providing face 
validity to the weight-glycemia clusters. However, the use of a priori cut-points was 
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found to be less well-suited to identify subgroups sharing clinically-significant yet more 
nuanced weight-glycemia phenotypes who may otherwise distinguish themselves in a 
clustering approach, such as the subgroups with very poor glycemic control. For 
example, clinical cut-points collapsed all individuals in Clusters 3, 4, and 5 in the same 
strata of glycemic control, despite the notable differences in glycemia (refer to these 
subgroups in relation to the dashed line denoting poor glycemic control at HbA1c 75 of 
mmol/mol (9.0%) in Figure 3.1B.) A further strength of the study was the novel semi-
supervised statistical methods used to identify a phenotype based on two clinical 
outcomes and their relationship to each other, using all patient information to adjust for 
potential measurement error and within-person heterogeneity. Additional analyses 
explored clusters based on the raw (i.e observed) measures of BMIz and HbA1c, 
denoted “Y-clusters,” for comparison (Figure 3.2B). The Y-clusters showed multiple 
nodes of density and larger within-cluster distribution of BMIz and HbA1c, suggesting 
higher within-cluster variability due to noise in the raw or observed outcomes that 
obscures underlying clustering structure in the data. The advantage of clusters driven 
by predicted measures of the joint distribution is that this method uses X-variables to 
denoise the raw outcome measures, thereby maximizing data available in the cohort 
study to understand the underlying variance in weight and glycemia, and their 
relationship as a clinical phenotype. Finally, to our knowledge, this is the first study to 
investigate the spectrum of the weight-glycemia phenotypes of type 1 diabetes and their 
broad epidemiologic correlates using the large, diverse SEARCH cohort. The study 
complements previous efforts to address heterogeneity in adult diabetes246 with a focus 




In conclusion, we show that the heterogeneous population of youth and young 
adults with type 1 diabetes is comprised of identifiable subgroups with shared weight-
glycemia clinical phenotypes based on measures of the joint distribution of BMIz and 
HbA1c. Importantly, overweight and obesity present with varying degrees of glycemic 
control in this population, implicating different therapeutic and clinical strategies to 
concurrently address weight and glycemia across subgroups. To this end, a precision 
medicine framework may facilitate a systems-based approach to address health 
inequity and deliver targeted strategies needed to optimize obesity and dysglycemia, 






Table 3.1. Sociodemographic Characteristics According to Weight-Glycemia Phenotype Clusters 1-6 
Characteristics,  
Mean (SD) or n (%) 
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Weight Status‡        <0.0001 
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Health insurance type        <0.0001 























































11 (3.9)**  
All measures are from the cohort visit, unless stated otherwise. 
Abbreviations: SD – standard deviation; BMIz – body mass index z-score; HbA1c – hemoglobin A1c.   
†Bonferroni-corrected p-value for overall test of difference, based on use of ANOVA, Chi-squared or Fisher’s exact test 
as appropriate. *significant pairwise comparison Cluster 1, where q<0.05. **significant pairwise comparison to Cluster 1, 
where q<0.001. Pairwise comparisons controlled for the positive false discovery rate. 
‡Weight status defined based on BMIz. Underweight was defined as cluster mean BMIz <-1.64 corresponding to the 5th 
percentile for age and sex. Normal weight was defined as cluster mean BMIz ≥-1.64 and <1.04, corresponding to ≥-the 
5th and <85th percentile for age and sex. Overweight was defined as cluster mean BMIz ≥ 1.04 and <1.64, 
corresponding to ≥85th percentile and <95th percentile for age and sex. Obesity was defined as cluster mean BMIz ≥ 






§Glycemic control was based on HbA1c and defined as good (mean HbA1c <58 mmol/mol (<7.5%)), moderate (mean 
HbA1c 58 - <75 mmol/mol (7.5 - <9.0%)), poor (mean HbA1c 75 - <108 mmol/mol (9.0 - <12.0%)), and very poor (mean 
HbA1c ≥108 mmol/mol (≥12.0%)) 







Table 3.2. Diabetes Care, Psychosocial, and Behavioral Factors According to Weight-Glycemia Clusters 1-6 
Characteristics,  
Mean (SD) or n (%) 
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Diabetes Care Provider        0.507 



















































































        













































































































All measures are from the cohort visit. 
Abbreviations: DASH – Dietary Approach to Stop Hypertension.  
Missing Data: n=4 for 1+ Diabetic Ketoacidosis episodes. N=174 for DASH Score, total energy, total energy from 
carbohydrate, total energy from protein, and total energy from fat. Missingness not different across clusters (p>0.05) 
†Bonferroni-corrected p-value for overall test of difference, based on use of ANOVA, Chi-squared or Fisher’s exact test 
as appropriate. *significant pairwise comparison Cluster 1, where q<0.05. **significant pairwise comparison to Cluster 1, 






‡Includes 2+ Times/Day OR Any Insulin Combination (Excl. Long), 3+ Times/Day OR Any Insulin(s) taken 1x/Day, or 
any Insulin combination (Excl. Long) 2+/Day 
§Self-reported, in the past 6 months  
¶Includes family practice doctor, general practice doctor, internist, nurse diabetes educator, nurse 
practitioner/physician’s assistant, dietician/nutritionist, other, unknown, and none 
††Center for Epidemiologic Studies Depression Scale, total score  
‡‡Peds QL, total score 
§§Dietary Approach to Stop Hypertension diet, total score 








Table 3.3. Clinical Characteristics According to Weight-Glycemia Phenotype Clusters 1-6 
Characteristics,  
Mean (SD) or n (%) 













































































































































Abbreviations: HDL– High Density Lipoproteins; LDL – Low Density Lipoproteins. VLDL – Very Low Density 
Lipoproteins.  
†Bonferroni-corrected p-value for overall test of difference, based on use of ANOVA, Chi-squared or Fisher’s exact test 
as appropriate. *significant pairwise comparison Cluster 1, where q<0.05. **significant pairwise comparison to Cluster 1, 
where q<0.001. Pairwise comparisons controlled for the positive false discovery rate. 
*significant pairwise comparison Cluster 1, where q<0.05. **significant pairwise comparison to Cluster 1, where 





Figure 3.1. Weight-glycemia phenotypic clusters from the SEARCH for Diabetes in 
Youth Study. Panel A: Scatter plot by body mass index (BMIz) and hemoglobin A1c 
(HbA1c); each point represents an individual. Panel B: Bubble plot by BMIz and HbA1c; 
size of circle represents number of individuals within the cluster. Panel C: Box and 
Whisker plot for BMIz and HbA1c. On the X-axis, the dotted line denotes the BMIz cutoff 
for underweight (BMIz <-1.64, corresponding to<5th percentile for age and sex), the 
solid line denotes BMIz cutoff for overweight (BMIz ≥ 1.04, corresponding to ≥ 85th 
percentile for age and sex), and the dashed lined denotes the BMIz cutoff for obesity 
(BMIz ≥ 1.64, corresponding to ≥ 95th percentile for age and sex). On the Y-axis, the 
solid line denotes HbA1c cutoff for moderate glycemic control (HbA1c ≥ 7.5% [58 
mmol/mol]), the dashed line denotes the HbA1c cutoff for poor glycemic control (HbA1c 
≥ 75 mmol/mol (9.0%)), and the dotted line denotes the HbA1c cutoff for very poor 
glycemic control (HbA1c ≥ 108 mmol/mol (12.0%)). Clusters include: Cluster 1 (n=618, 
34.0%): normal weight with moderate glycemic control (mean BMIz 0.59±0.59, mean 
HbA1c 61±12 mmol/mol (7.7±1.1%)); Cluster 2 (n=195, 10.7%): normal weight with 
moderate glycemic (mean BMIz -0.68±0.66, mean HbA1c 68±10 mmol/mol (8.4±0.9%)); 
Cluster 3 (n=509, 28.0%): normal weight with poor glycemic control (mean BMIz 
0.56±0.62, mean HbA1c 86±12 mmol/mol (10.0±1.1%)); Cluster 4 (n=79, 4.4%%): 
normal weight with poor glycemic control (mean BMIz -1.05±0.83, mean HbA1c 113±15 
mmol/mol (12.5±1.4%)); Cluster 5 (n=137, 7.5%): overweight with poor glycemic control 
(mean BMIz 1.29±0.69, mean HbA1c 109±15 mmol/mol (12.1±1.5%)); Cluster 6 (n=279, 
15.4%): obesity with moderate glycemic control (mean BMIz 1.74±0.42, mean HbA1c 







Figure 3.2. Density distribution plots of body mass index z-score (BMIz) and hemoglobin A1c (HbA1c). Panel A 
depicts weight-glycemia phenotypic clusters, based on predicted measures of the joint distribution of BMIz and HbA1c. 
A1: Density distribution of BMIz by weight-glycemia cluster. A2: Density distribution of HbA1c by weight-glycemia cluster. 
A3: Density distribution plot of BMIz and HbA1c by weight-glycemia cluster. Panel B depicts Y-clusters, based on raw, 
observed measures of BMIz and HbA1c. B1: Density distribution of BMIz by Y-cluster. B2: Density distribution of HbA1c 
by Y-cluster. B3: Density distribution plot of BMIz and HbA1c by Y-cluster. Ideal clustered subgroups should show distinct, 




3.6 Supplemental Material 
 
3.6.1 Imputation methods 
The clinical outcomes of interest to guide the formation of clusters include BMIz 
(Y1) and HbA1c (Y2) at the cohort visit. We denote other variables including modifiable 
and non-modifiable characteristics as 𝑋-variables; 28 patient co-variates were chosen to 
capture a breadth of individual characteristics available at the follow-up visit including 
sociodemographic, clinical, anthropometric, laboratory, psychosocial and behavioral 
measures (see Supplemental Table 3.1).  
To perform Reinforcement Learning Trees (RLT), only complete data can be 
used. To avoid bias due to possible missing not at random (MNAR) data (i.e. the reason 
X is missing is related to its missing values), missing X-variables were imputed. In short, 
a model for each covariate was constructed using all other covariates as predictors. 
Missing values were replaced with their model predicted values recursively until 
convergence. As opposed to basic linear models, random forest models were used to 
capture more complicated relationships between the predictors. This missForest 
algorithm255 is described in further detail as follows: 
Consider that there are p covariates, X1, . . ., Xp. 
1. A Strawman imputation is performed for all variables initially: each missing 
value of X1 is replaced by the median of all observed values of Xi if the 




2. For all records where X1 is observed, build a random forest model to predict 
X1 using the remaining p-1 covariates, which are either observed or 
Strawman imputed.  
3. Repeat step 2 for all p covariates. 
4. Update all Strawman imputed values with their model predicted values from 
steps 2-3. 
5. Repeat the model building and updating steps until desired convergence is 
observed. 
This relatively new method imputes missing values using a random forest 
prediction model instead of a typical regression and has been shown to work well with 
highly correlated features. Simulations on this imputation algorithm was performed to 
show that the joint distribution of covariates is roughly preserved, using Kolmogorov-
Smirnov test on the imputed missing at random (MAR) data and the original data. The 
performance of this imputation method was found to be comparable to that of widely 
used methods such as multiple imputation by chained equations.264 
 
3.6.2 Reinforcement learning trees 
The primary objective of the cluster analysis was to group individuals based on a 
precise weight-glycemia phenotype, i.e. two outcomes that exist across a continuum 
with variable relationships to each other. To avoid limitations of conventional supervised 
clustering,265 we employed a novel, semi-supervised clustering technique to group 
individuals by five measures of joint distribution of BMIz and HbA1c measured at the 
follow-up visit: the means and variance of BMIz and HbA1c and their covariance. These 
measures were estimated by RLT using the 𝑋-variables described above (see 
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Supplemental Table 3.1). Variables that were derived from multiple primary measures 
were not problematic for RLT as they represented nontrivial derivations of the primary 
measures. 
After imputation, five RLTs were constructed to predict the outcomes and model 
the variances of and the covariance between BMIz and HbA1c, based on the 𝑋-
variables. RLT is a tree-based machine learning method that uses bootstrapping and 
reinforcement learning and exhibits significantly improved performance over traditional 
tree-based methods, such as random forests.266 An advantage of RLT is that it assigns 
a variable importance (VI) value to each variable at each node, selects the variable with 
highest VI upon which to split, and mutes those with the smallest VI. VI allows for the 
identification of the factors which most differentiate between subgroups. RLT was 
performed using primarily default settings from the RLT package in R, Version 3.4.2., 
with the exception of using 500 trees for stability, and permitting linear combination 
splits of up to two variables.  
 
3.6.3 Clustering methods 
Instead of using the entire covariate space which could be computationally 
expensive, we thus lowered the dimension to 5 where we believe the following 
conditional joint distribution of the two outcomes (assuming multivariate normal 
distribution of the two outcomes) is sufficient to represent the clinical situation of patient 
features. We define the measure ?̂?𝑖 for each individual 𝑖 = 1, … , 𝑛 as follows. 







𝑛 (?̂?𝑖,𝑘 − ?̂̅?𝑘)′ for 𝑘 = 1, 2, ?̂̅?𝑘 is the average of ?̂?𝑖,𝑘’s for all 𝑖 = 1, … , 𝑛, 
and 𝐶𝑜𝑟?̂?𝑍 is the Fisher’s z-transformation on the correlation, which is calculated from 
the covariance estimate.  
We standardized the means, variances, and covariance so that they are all 
comparable on the same unit scale; more specifically, we standardized by scaling over 
the standard deviation and then take Fischer’s z-transformation on the correlation 
calculated from the covariance.  
Because the values in ?̂? were standardized to the same scale, we used 
Euclidean distance measure to determine the dissimilarity between individuals 𝑖 and 𝑗, 
for 𝑖, 𝑗 = 1, … , 𝑛:  
𝐷𝑖𝑗 = √(?̂?𝑖 − ?̂?𝑗)′ (?̂?𝑖 − ?̂?𝑗)     (Eq. 3.2) 
This measure directly informs how far two individuals are based on their 
outcomes, denoised by the 𝑋-variables. 
A hierarchical clustering algorithm with Ward’s D2 method and Euclidean 
distance was applied to the standardized ?̂?. The number of clusters was chosen using 
the NbClust package in R,256 which takes a vote from 30 methods for choosing number 
of clusters, including commonly used methods such as gap statistics and average 
silhouette. The algorithm was restricted to considering clusters between 4 and 9 to 
characterize the wide range of BMIz and HbA1c at the SEARCH cohort visit but avoid 
overfitting issues or obscure clinical interpretation. The smallest cluster was restricted to 
contain at least 50 individuals for adequate statistical power to detect differences in 
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characteristics between groups. Multiple members of the analysis team provided 
judgment using all the available information. 
 
3.6.4 Clustering stability  
To assess clustering stability, the analysis was repeated sequentially omitting 
individuals from the same cluster one cluster at a time and observing the distribution of 
remaining individuals into five clusters. In other words, all individuals from the first 
cluster are removed, and the analysis is repeated, clustering the remaining individuals 
into five clusters. Individuals from the first cluster are then brought back in while 
individuals from the second cluster are removed, and the analysis is repeated again, 
and so on. For each iteration, the Adjusted Rand Index (ARI) was reported as a 
measure of clustering stability.258 ARI measures how similar two clustering methods are, 
correcting for chance. The mean ARI observed from these six analyses was 
0.785±0.05. We interpret the limited variation and a high mean ARI as evidence that our 
identified clusters are sufficiently stable; the cluster assignments are not sensitive to the 
removal of other clusters. 
 
3.6.5 Adjustments for multiple comparisons 
For each characterizing variable, pairwise comparisons between each cluster 
and the referent cluster (Cluster 1) were carried out using t-tests and chi-squared or 
Fisher’s exact tests, where appropriate. To control for the positive False Discovery Rate 
(pFDR)259 associated with the pairwise comparisons, appropriate adjustments were 
made separately to continuous and categorical variables, with an additional Bonferroni 
correction to account for the two categories (continuous and categorical). q-values 
reported in Supplemental Tables 3.2-3.4 can be considered as “posterior Bayesian p-
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values,” or the posterior probability that the null hypothesis is falsely rejected. q-values 
have been reported in place of p-values, because q-values control for the pFDR 
whereas p-values control for the Family Wise Error Rate (FWER), or the probability that 
at least one false rejection has been made. q-values were evaluated at the significance 
level of 0.05. 
 
3.6.6 Additional analyses 
 
3.6.6.1 Comparison to clusters based on raw, observed measures of BMIz and HbA1c 
RLT estimates of the outcomes were selected to capture the joint distribution of 
and provide smoothed outcome measures informed by the 𝑋-variables, as each 
individual is expected to exhibit some level of within-patient heterogeneity; the 
smoothed outcomes maintain the individual level signal with reduced noise 254. 
Additional analyses to test the validity of clustering methodology explored clustered 
subgroups based on the raw, observed outcome measures Y1 (BMIz) and Y2 (HbA1c). 
These clusters were denoted as “Y-Clusters” and are depicted in Figure 3.2B. 
Compared to the weight-glycemia cluster, these clusters showed multiple density nodes 
for BMIz and HbA1c within clusters, as well as a representation of all outliers within a 
single cluster (Figure 3.2B). Although the Y-clusters based on the raw outcome 
measures displayed significantly different mean measures of BMIz and HbA1c, the 
clusters showed a larger within-group distribution of BMIz and HbA1c measures 
(Supplemental Table 3.6). Together, this analysis suggested that noise in the raw, 
observed outcome variables may obscure the true subgroups of interest.253  
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3.6.6.2 Age-stratified analyses 
To facilitate study across youth and young adults, BMIz for individuals >20 years 
was estimated assuming an age of 20 years (the maximum age represented in the 
growth reference); this approach has been operationalized in previous SEARCH 
studies74,250 and elsewhere.251 Given known challenges in the use of BMIz and in the 
context of the present analysis, further analyses were undertaken to assess whether the 
use of BMIz may bias the nature of the clusters. To check the validity of the imputed z-
scores and assess for possible differential bias in the results by age (i.e. youth versus 
young adults), we stratified the sample by age at follow-up visit (<21 years, n=1,399, 
≥21 years, n=418) and independently evaluated clusters in each sample. The number of 
clusters was chosen using the NbClust package in R256 and restricted to considering 
between four and nine clusters. Clusters across age strata were compared for 
consistency in BMIz and HbA1c. We found six clusters in the Under 21 Years stratum 
and five clusters in the 21 Years and Older stratum (Supplementary Table 3.6, 
Supplementary Figure 3.1). No evidence of differential bias from BMIz was found; the 
resulting weight-glycemia phenotypes were largely consistent in the stratified samples, 
where Clusters 3 and 4 in the Under 21 stratum merged to form one aggregated cluster 
(Cluster 3) in the 21 and Older stratum. Cluster 3 and 4 merged among the ≥21-year-old 
strata to show one combined cluster (normal weight with poor-very poor glycemic 
control); this result likely reflects increases in HbA1c known to occur around 17 years of 




3.6.6.3 Comparison to a priori Weight-Glycemia Classifications 
An additional, exploratory study used clinical cut-points for BMIz and HbA1c to 
classify youth and young adults with type 1 diabetes into six weight-glycemia classes 
and study the proportion and correlates of each subgroup. This analysis was meant to 
provide context for the cluster analysis, to check the validity of clustered subgroups, and 
to test if clusters may be useful in gleaning additional insights into the weight-glycemia 
phenotype of type 1 diabetes.  
The study sample from the main cluster analysis was used. Participants were 
excluded if they were missing a measure of BMIz (n=151) or HbA1c (n=32). A very 
small proportion of participants were classified as underweight (BMIz<-1.64; ~2%); 
these participants were excluded to prevent misclassification bias associated with 
combining subgroups in the analysis.  
One and two cut-points were operationalized for weight status and glycemic 
control, respectively. Weight status was classified as normal weight (BMIz <1.04, 
corresponding to <85th percentile for age and sex) versus combined overweight/obesity 
(BMIz ≥1.04, corresponding to ≥85th percentile). Glycemic control was classified as 
good (HbA1c <7.5% [58 mmol/mol], moderate (HbA1c 7.5-<9.0% [58 - <75 mmol/mol], 
and poor (HbA1c ≥9.0% [75 mmol/mo]).3 Crosstabulation of the cut-points yielded six 
weight-glycemia classes. Descriptive statistics were used to summarize and compare 
BMIz, HbA1c, and a subset of sociodemographic and clinical characteristics measured 
at the cohort visit across subgroups. All analyses used a two-sided p-value of 0.05. 
The final sample included 1785 youth and young adults with type 1 diabetes 
(50% female, 76.1% non-Hispanic white, mean age 17.6±4.5 years, mean diabetes 
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duration 7.8±1.9 years.) The mean BMIz was 0.66±0.87 and the mean HbA1c was 
9.1±1.8%. Shown in Supplemental Table 3.7, the normal weight subgroup with poor 
glycemic control represented 1/3 of the sample, comprising the largest weight-glycemia 
class (Class 1C, 30%). Only 11% of the of SEARCH sample was classified as normal 
weight with good glycemic control (Class 1A). By contrast, approximately 17% of the 
sample was classified as overweight or obese with poor glycemic control. The smallest 
subgroup was overweight or obese with adequate glycemic control (5.6%). The 
proportion of youth classified as overweight and obese was not significantly different 
across strata of glycemic control (p=0.60).  
There were significant differences in sociodemographic and clinical 
characteristics across weight-glycemic classes (Supplementary Table 3.8). Compared 
to subgroup with ideal weight and glycemia (Class 1A), subgroups with poor glycemic 
control (1C and 2C) had lower parental education, income, and private insurance use; 
these subgroups reported significantly lower pump use and frequency of glucose 
monitoring (p <0.001). The overweight/obese subgroup with poor glycemic control 
(Class 2C) also had the highest proportion of females (66.1% versus 44.3% in Class 
1A), non-Hispanic Black youth (18.1% versus 2.5%), and Hispanic youth (16.4% versus 
9.9%; all p <0.0001).  
These results reinforce profound heterogeneity in the clinical presentation of type 
1 diabetes; all degrees of glycemic control are represented in normal weight as well as 
overweight/obese youth. Second, relatively few youths show appropriate weight and   
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glycemia. Finally, the unequal distribution of socioeconomic position and aspects of 






Supplemental Table 3.1. 28 X-variables for Reinforcement Learning Trees. All 
measures are from the 5+ year follow-up visit unless specified 
Sociodemographic 
measures  
Age at diagnosis, diabetes duration, sex (baseline), 
race/ethnicity (baseline), parental education 
attainment, household income level, insurance type 
Clinical measures  insulin dose, insulin regimen, frequency of blood 
glucose monitoring, severe hypoglycemic episodes in 
the last 6 months, emergency room visits in the last 6 
months, hospitalizations in the last 6 months 
Anthropometric and 
laboratory measures 
waist circumference, waist to height ratio, systolic and 
diastolic blood pressure, total cholesterol, non-HDL 




depressive symptoms, quality of life score, physical 










Supplemental Table 3.2. q-values† for Pairwise Comparisons of Sociodemographic Characteristics According to 
Weight-Glycemia Phenotype Clusters 1-6 
Characteristics   Weight-Glycemia Cluster  
Cluster 1 vs. 
Cluster 2 
Cluster 1 vs. 
Cluster 3 
Cluster 1 vs. 
Cluster 4 
Cluster 1 vs. 
Cluster 5 
Cluster 1 vs. 
Cluster 6 
Cluster 5 vs. 
Cluster 6 
Weight-Glycemia       
BMIz  4.15E-71 0.144659 5.67E-29 1.76E-21 2.28E-148 1.41E-10 
HbA1c (%) 4.88E-16 1.08E-181 3.35E-47 3.68E-75 5.43E-31 1.91E-63 
Weight Status‡ 7.20E-18 0.335682 1.88E-08 2.29E-39 5.89E-112 9.72E-17 
Glycemic Control§ 4.61E-11 6.17E-154 3.78E-62 4.28E-93 2.56E-22 9.65E-40 
Age at follow-up 
(years) 0.024023 0.16736 0.002432 5.69E-04 0.228048 0.004529 
Age at diagnosis 
(years) 0.070913 0.065987 0.006348 0.008597 0.269702 0.007673 
Diabetes duration 
(months) 0.037604 0.075612 0.114815 0.009293 0.037353 0.146216 
Female 6.62E-04 4.09E-04 0.016631 2.74E-05 0.008735 0.027848 
Race/ethnicity¶ 0.335682 1.03E-15 1.24E-12 1.20E-21 1.47E-07 2.93E-05 
Parental Education 0.388102 1.30E-36 1.54E-22 1.44E-30 2.03E-18 4.09E-04 
Household Income 0.249101 1.20E-21 6.11E-19 1.70E-20 1.64E-05 3.33E-06 
Insurance type 0.045741 6.97E-18 1.35E-13 1.41E-23 1.90E-06 5.79E-07 
Blank cells indicate variables where the overall test of difference was not statistically significant and no pairwise 
comparisons were performed.  
†Controlled for the positive False Discovery Rate (pFDR). q-values can be considered as “posterior Bayesian p-values,” 
or the posterior probability that the null hypothesis is falsely rejected. q-values have been reported in place of p-values, 
because q-values control for the pFDR. q-values were evaluated at the significance level of 0.05. 
‡Weight status defined based on body mass index z-score (BMIz). Underweight was defined as cluster mean BMIz <-
1.64 corresponding to the 5th percentile for age and sex. Normal weight was defined as cluster mean BMIz ≥-1.64 and 
<1.04, corresponding to ≥-the 5th and <85th percentile for age and sex. Overweight was defined as cluster mean BMIz 
≥ 1.04 and <1.64, corresponding to ≥85th percentile and <95th percentile for age and sex. Obesity was defined as 






§Glycemic control was based on hemoglobin A1c (HbA1c) and defined as good (mean HbA1c <58 mmol/mol (<7.5%)), 
moderate (mean HbA1c 58 - <75 mmol/mol (7.5 - <9.0%)), poor (mean HbA1c 75 - <108 mmol/mol (9.0 - <12.0%)), and 
very poor (mean HbA1c ≥108 mmol/mol (≥12.0%)) 









Supplemental Table 3.3. q-values† for Pairwise Comparisons of Diabetes Care, Psychosocial, and Behavioral 
Factors According to Weight-Glycemia Clusters 1-6 
Characteristics Weight-Glycemia Cluster 
Cluster 1 vs. 
Cluster 2 
Cluster 1 vs. 
Cluster 3 
Cluster 1 vs. 
Cluster 4 
Cluster 1 vs. 
Cluster 5 
Cluster 1 vs. 
Cluster 6 
Cluster 5 vs. 
Cluster 6 
Diabetes Care Factors       
Insulin Regimen 0.042984 4.47E-16 3.01E-14 7.44E-28 9.96E-04 6.98E-13 
Insulin dose (daily 
units/Kg) 0.185203 1.34E-05 1.14E-04 3.48E-06 0.043848 2.01E-04 
Blood Glucose 
Monitoring Frequency 0.003068 5.60E-25 1.60E-18 5.09E-30 9.06E-04 1.35E-12 
Use of CGM  0.335682 0.203666 0.28288 0.393682 0.036694 0.069077 
Acute Complications 
(Past 6 Mo)‡ 
      
Severe Hypoglycemic 
Episodes -- -- -- -- -- -- 
Diabetic Ketoacidosis 
Episodes 0.159907 1.45E-10 1.51E-11 1.13E-18 0.118738 2.70E-10 
Diabetes Care Provider -- -- -- -- -- -- 
Psychosocial Factors        
Depressive Symptoms 
(CEDS Score)§ 0.145573 1.83E-17 1.45E-04 1.40E-13 3.75E-04 1.67E-07 
Quality of Life (Peds 
QL Score)¶ 0.302841 5.31E-12 1.55E-04 2.79E-11 4.45E-04 2.42E-05 
Lifestyle Behavioral 
Factors 
      
Adherence to DASH 
Diet‡‡ 0.004454 3.19E-11 1.34E-05 3.60E-06 1.34E-05 0.142206 
Total Energy Intake 
(kcal) 0.109875 0.130658 0.034153 0.090996 0.00527 0.002503 
Total Energy from Fat 






Total Energy from 
Carbohydrate (%) -- -- -- -- -- -- 
Total Energy from 
Protein (%) -- -- -- -- -- -- 
Physically Active§§ 0.016989 2.66E-09 3.22E-05 2.74E-05 1.82E-06 0.335682 
High Screen Time§§ 0.312454 5.29E-14 1.28E-08 1.51E-11 1.05E-05 0.001483 
Smoking Status 0.109654 1.78E-04 2.22E-09 7.16E-04 0.420621 0.001878 
Blank cells indicate variables where the overall test of difference was not statistically significant and no pairwise 
comparisons were performed.  
†Controlled for the positive False Discovery Rate (pFDR). q-values can be considered as “posterior Bayesian p-values,” 
or the posterior probability that the null hypothesis is falsely rejected. q-values have been reported in place of p-values, 
because q-values control for the pFDR. q-values were evaluated at the significance level of 0.05. 
‡Self-reported, in the past 6 months  
§Center for Epidemiologic Studies Depression Scale, total score  
¶Peds QL, total score 
‡‡Dietary Approach to Stop Hypertension diet, total score 








Supplemental Table 3.4. q-values† for Pairwise Comparisons of Clinical Characteristics According to Weight-
Glycemia Phenotype Clusters 1-6 
Characteristics Weight-Glycemia Cluster  
Cluster 1 vs. 
Cluster 2 
Cluster 1 vs. 
Cluster 3 
Cluster 1 vs. 
Cluster 4 
Cluster 1 vs. 
Cluster 5 
Cluster 1 vs. 
Cluster 6 
Cluster 5 vs. 
Cluster 6 
Lipids       
Total Cholesterol, mg/dL 0.164053 6.18E-31 2.58E-09 1.88E-21 6.14E-14 5.99E-12 
HDL Cholesterol, mg/dL 0.205732 0.192699 0.027915 4.94E-06 1.05E-10 0.312837 
LDL Cholesterol, mg/dL 0.04247 1.06E-20 4.68E-07 6.99E-18 1.27E-17 4.88E-06 
VLDL Cholesterol, 
mg/dL 0.071374 1.45E-32 1.21E-10 1.55E-19 4.15E-18 5.13E-13 
Triglycerides, mg/dL 0.075612 1.25E-32 5.12E-07 1.68E-17 2.72E-18 4.10E-12 
Blood Pressure       
Systolic Blood Pressure, 
mmHg 0.008237 0.211486 0.243499 2.84E-10 1.98E-10 0.155705 
Diastolic Blood 
Pressure, mmHg 0.135977 7.46E-05 0.018749 4.07E-14 5.13E-13 0.021609 
Blank cells indicate variables where the overall test of difference was not statistically significant and no pairwise 
comparisons were performed.  
†Controlled for the positive False Discovery Rate (pFDR). q-values can be considered as “posterior Bayesian p-values,” 
or the posterior probability that the null hypothesis is falsely rejected. q-values have been reported in place of p-values, 








Supplemental Table 3.5. Measures of Weight and Glycemic Control According to Y-Clusters 1-6 
Characteristics,  
Mean (SD) or n 
(%) 


























        




0.84 (0.72) 0.00 (0.81) 1.16 (0.60) -0.81 (0.61) <0.001 
HbA1c (%) 9.1 (1.9) 14.0 (1.1) 11.8 (0.8) 7.6 (0.9) 10.5 (0.8) 9.4 (0.4) 8.4 (0.63) <0.001 
Weight Status‡        <0.001 
Underweight 36 (2.0) 5 (8.3) 0 (0.0) 0 (0.0) 13 (4.1) 0 (0.0) 18 (10.7)  
Normal Weight 1152 (63.4) 52 (88.7) 54 (32.5) 491 (60.9) 285 (90.2) 120 (38.9) 150 (89.3)  
Overweight 390 (21.5) 2 (3.3) 63 (38.0) 189 (23.6) 18 (5.7) 118 (39.2) 0 (0.0)  
Obese 239 (13.2) 5 (8.3) 0 (0.0) 0 (0.0) 13 (4.1) 0 (0.0) 18 (10.7)  
Glycemic 
Control§ 
       <0.001 
Good 306 (16.8) 0 (0.0) 0 (0.0) 292 (36.2) 0 (0.0) 0 (0.0) 14 (8.3)  
Moderate 656 (36.1) 0 (0.0) 0 (0.0) 514 (63.8) 0 (0.0) 27 (9.0) 115 (68.5)  
Poor 704 (38.8) 0 (0.0) 93 (56.0) 0 (0.0) 298 (94.3) 274 (91.0) 39 (23.2)  
Very Poor 151 (8.3) 60 (100.0) 73 (44.0) 0 (0.0) 18 (5.7) 0 (0.0) 0 (0.0)  
Abbreviations: BMIz – body mass index z-score. HbA1c – Hemoglobin A1c.  
Y-clusters were generated based on the raw, observed measures of outcomes Y1 (BMIz) and Y2 (HbA1c). 
†Bonferroni-corrected p-value for overall test of difference, based on use of ANOVA, Chi-squared or Fisher’s exact test 
as appropriate.  
‡Weight status defined based on body mass index z-score (BMIz). Underweight was defined as cluster mean BMIz <-
1.64 corresponding to the 5th percentile for age and sex. Normal weight was defined as cluster mean BMIz ≥-1.64 and 
<1.04, corresponding to ≥-the 5th and <85th percentile for age and sex. Overweight was defined as cluster mean BMIz 
≥ 1.04 and <1.64, corresponding to ≥85th percentile and <95th percentile for age and sex. Obesity was defined as 
cluster mean BMIz ≥ 1.64 corresponding to ≥ 95th percentile for age and sex. 
§Glycemic control was based on hemoglobin A1c (HbA1c) and defined as good (mean HbA1c <58 mmol/mol (<7.5%)), 
moderate (mean HbA1c 58 - <75 mmol/mol (7.5 - <9.0%)), poor (mean HbA1c 75 - <108 mmol/mol (9.0 - <12.0%)), and 






Supplementary Table 3.6. Body Mass Index Z-Score (BMIz) And Hemoglobin A1c (HbA1c) According To Weight-


























BMIz  0.61 (0.94) 0.59 (0.59) -0.68 (0.65) 0.56 (0.62) -1.05 (0.83) 1.29 (0.69) 1.74 (0.42) <0.0001 
HbA1c 
(mmol/mol) 
76 (21) 61 (12) 68 (10) 86 (12) 113 (15) 109 (15) 70 (11) <0.0001 
HbA1c (%) 9.1 (1.9) 7.7 (1.1) 8.4 (0.9) 10.0 (1.1) 12.5 (1.4) 12.1 (1.5) 8.6 (1.0) <0.0001 
 























BMIz  0.60 (0.93) 0.32 (0.59) -1.00 (0.61) 0.51 (0.5) -0.01 (0.96) 1.71 (0.39) 1.44 (0.49) <0.0001 
HbA1c 
(mmol/mol) 
77 (20) 62 (10) 70 (13) 83 (12) 113 (16) 89 (13) 67 (11)  
HbA1c (%) 9.2 (1.8) 7.8 (0.9) 8.6 (1.2) 9.7 (1.1) 12.5 (1.5) 10.3 (1.2) 8.3 (1.0) <0.0001 
 




















BMIz  0.64 (1.00) 0.90 (0.49) -0.22 (0.64) -0.32 (1.12) 1.03 (0.70) 1.80 (0.46) <0.0001 
HbA1c 
(mmol/mol) 
73 (22) 56 (13) 64 (13) 104 (16) 91 (14) 67 (13)  
HbA1c (%) 8.8 (2.0) 7.3 (1.2) 8.0 (1.2) 11.7 (1.5) 10.5 (1.3) 8.3 (1.2) <0.0001 
Abbreviations: BMIz – body mass index z-score. HbA1c – Hemoglobin A1c. 
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Supplemental Table 3.7. Six Weight-Glycemia Classifications for Youth and 
Young Adults with Type 1 Diabetes Based on 1 Cut-Point for Weight Status and 2 





























































2. Overweight/Obese  
(BMIz ≥1.04) 







































Abbreviations: BMIz – body mass index z-score. HbA1c – Hemoglobin A1c. Class 
Nomenclature: 1 versus 2 signifies Normal Weight versus Overweight/Obese. A, B, and 










Mean (SD) or n (%) 
Weight-Glycemia Class 
































 N=1785 N=203 N=415 N=537 N=99  N=233 N=298  
Weight and Glycemia 
Measures 
        















HbA1c, % 9.1 
(1.8) 
6.8 (0.6) 8.2 (0.4) 10.7 (1.5) 6.6 (0.7) 8.2 (0.4) 10.5 (1.2) <0.0001 
Demographic 
Characteristics  

































































Race/ethnicity        <0.0001 










184 (79.0) 189 
(63.4) 
 





































        
Parental Bachelor’s 
















































Diabetes Care Factors         
Insulin pump use (versus 















































17 (5.7) 0.0235 














64 (21.5) <0.0001 
Abbreviations: Nw - normal weight. Ow/Ob – overweight and obese. SD – standard deviation; BMIz – body mass index 
z-score; HbA1c – hemoglobin A1c 
†P-value for overall test of difference, based on use of ANOVA, Chi-squared, of Fishers Exact test as appropriate. 












Supplementary Figure 3.1. Box and whisker plot for BMIz and HbA1c of the age-stratified weight-glycemia 
phenotypic clusters from the SEARCH for Diabetes in Youth Study. Participants were stratified by age at the cohort 
visit (<21 and ≥21 years, i.e. 21 years and over) and clustered based on the joint distribution of body mass index z-score 
(BMIz) and hemoglobin A1c (HbA1c) at the 5+ year cohort visit of the SEARCH study. For the 21 Years and Over Strata, 






CHAPTER 4. LONGITUDINAL PHENOTYPES OF ESTABLISHED TYPE 1 DIABETES 
IN YOUTH BASED ON WEIGHT AND GLYCEMIA AND THEIR ASSOCIATION WITH 
EARLY AND SUBCLINICAL COMPLICATIONS OF DIABETES 
The aim of the study was to test whether longitudinal ‘weight-glycemia’ 
phenotypes increase susceptibility to early or subclinical complications of type 1 
diabetes. Youth with type 1 diabetes (n=570) were clustered based on body mass index 
z-score (BMIz) and hemoglobin A1c (HbA1c) from a baseline visit (mean diabetes 
duration: 1.4±0.4 years) and 5+ year follow-up visit (mean diabetes duration: 8.2±1.9 
years) using k–means clustering for longitudinal data. Logistic regression modeling 
tested cluster associations with seven early or subclinical complications measured at 
follow-up, adjusting for sex, race/ethnicity, age, and duration. Four longitudinal weight-
glycemia clusters were identified: The Referent Cluster (n=195, 34.3%), The 
Hyperglycemia Only Cluster (n=53, 9.3%), the Adiposity Only Cluster (n=206, 36.1%), 
and the  Adiposity and Increasing Hyperglycemia Cluster (n=115, 20.2%).  After 
adjustment and compared to the Referent Cluster, the Hyperglycemia Only Cluster had 
elevated odds of dyslipidemia (odds ratio (OR) 2.22, 95% CI 1.15-4.29), retinopathy 
(OR 9.98, 95% CI 2.49-40.0) and diabetic kidney disease (DKD) (OR 4.16, 95% CI 
1.37-12.62). The  Adiposity and Increasing Hyperglycemia Cluster had elevated odds of 
hypertension (OR 2.18, 95% CI 1.19-4.00), dyslipidemia (OR 2.36, 95% CI 1.41-3.95), 
arterial stiffness (OR 2.46, 95% CI 1.09-5.53), retinopathy (OR 5.11, 95% CI 1.34-
19.46), DKD (OR 3.43, 95% CI 1.29-9.11), and a 3.4 times higher odds of having two or 




there are distinct weight-glycemia phenotypes over the first decade of type 1 diabetes. 
Exposure to obesity and worsening glycemic control may increase the overall burden of 
co-morbid complications.  
 
4.1 Introduction 
Subclinical and clinical complications emerge early in type 1 diabetes.74 In youth 
and adolescents, multiple studies have shown that the risk for these outcomes is 
associated with glycemic control as measured by HbA1c.10,74,76 However, the rising 
prevalence of overweight and obesity is a recently emerging problem in the clinical care 
of type 1 diabetes.1,2,181 Studies suggest that obesity in the setting of type 1 diabetes 
can contribute to adverse cardiovascular disease outcomes and microvascular 
complications in adults with long-standing diabetes.149,203,204 
There are gaps in the current understanding of how excess adiposity and 
degrees of suboptimal glycemic control jointly contribute to the emergence of early and 
subclinical diabetes complications, including both macrovascular and microvascular 
outcomes, among youth and young adults in the first decade of having diabetes. This 
information is critical given shifts in the epidemiology of overweight and obesity within 
this patient population and the potential for intensive insulin therapy to induce weight 
gain,267 which may warrant a more flexible and integrated clinical approach that 
considers both weight and glycemic control for identifiable patient subgroups.  
While the association between weight status and glycemic control among youth 
and adolescents have been studied in the first few years of disease,243,268 few studies 
have characterized the co-evolution of these outcomes over a longer disease duration, 




glucose management is particularly challenging 269. Therefore, we employed a data-
driven approach to capture the major patterns of longitudinal exposure of both weight 
status and glycemic control. The first objective of this study was to identify the main 
longitudinal ‘weight-glycemia’ phenotypes of established type 1 diabetes, or clusters of 
youth and young adults with type 1 diabetes showing similar weight status and glycemic 
control measures collected at two time-points: a baseline>1 year after diabetes onset 
and a follow-up visit at a mean of eight years disease duration. The second objective 
was to test how the longitudinal weight-glycemia phenotypes of type 1 diabetes were 
associated with different subclinical and early complications, or combinations thereof, 
measured at the follow-up visit.  
 
4.2 Methods  
 
4.2.1 Participants  
Individuals diagnosed with diabetes before 20 years of age were identified by the 
SEARCH for Diabetes in Youth study through a population-based registry network at 5 
sites in the United States (South Carolina; Cincinnati, Ohio and surrounding counties; 
Colorado with southwestern American Indian sites; Seattle, Washington, and 
surrounding counties; and Kaiser Permanente Southern California membership in 7 
counties). Individuals who received a new diagnosis of type 1 diabetes in 2002-2006 or 
2008 were invited to complete a baseline SEARCH visit to measure risk factors for 
diabetes complications. In 2011-2015, participants with >5 years diabetes duration who 
had previously completed a baseline visit were invited to participate in a follow-up visit, 
at which diabetes risk factors and early diabetes-related complications and 




socioeconomic characteristics of participants who completed the follow-up visit were 
similar to that of the larger SEARCH registry population.74 The study was approved by 
Institutional Review Boards with jurisdiction, and the parent, adolescent or young adult, 
or both provided consent or assent for all participants. 
Inclusion criteria for the present analysis consisted of incident cases of type 1 
diabetes between 2002-2006 and 2008 who attended the SEARCH baseline and cohort 
visit (n=2,869). Diabetes type was based on an etiological classification using diabetes 
autoantibodies and estimated insulin sensitivity score (euglycemic clamp-validated 
equation including waist circumference, HbA1c and triglyceride levels) measured at the 
baseline visit.248 Participants were excluded if they were missing measures of BMIz or 
HbA1c at the baseline or cohort visit (n=1,106) or if the baseline visit occurred <12 
months after type 1 diabetes diagnosis (n=1,193) to remove non-informative variability 
or within-person instability in baselines measure that may occur in the first year 
following diagnosis (Supplemental Figure 4.1). The latter exclusion cut-off was 
selected to ensure participants were not in partial remission, or the “honeymoon period”, 
at their baseline visit based on data showing that more than a half and a third of youth 
>5 years are classified as being in remission at 3 and 6 months, respectively, based on 
insulin needs (U/kg/dose)270 as well as longitudinal patterns in HbA1c, insulin dose, and 
C-peptide levels in the first 12 months of disease.271 Compared to individuals included 
in the analysis, excluded participants showed a lower mean age, HbA1c, and pump use 
at baseline, with no significant differences in BMIz or age at diagnosis (Supplemental 
Table 4.1). There were no significant differences in age, BMIz, or HbA1c between these 




4.2.2 Research visits  
Trained research staff administered questionnaires, made measurements and 
obtained blood samples at the in-person baseline and follow-up research visits. 
Participants (or parents, for younger participants) self-reported date of birth, sex, race, 
ethnicity, highest parental education, annual household income, and type of health 
insurance. For reporting of race and ethnicity, U.S. census methods272 were used which 
provided a series of fixed race and ethnicity categories as well as an “other” option for 
the self-report by parent or participant, depending on age. These were further 
categorized into ‘non-Hispanic white’ and ‘minority’ racial/ethnic groups, including 
Hispanic (regardless of race), non-Hispanic black, American Indian, Asian/Pacific 
Islander and other/multiple race/ethnicities. Education and income were self-reported. 
Highest education by either parent was classified as less than high school degree, high 
school graduate, some college through associate degree, and bachelor’s degree or 
more. Annual household income was classified as >$75,000, $50,000-75,000, $25,000-
49,999 and <$25,000. Date of diagnosis obtained from medical records was used to 
calculate age of diagnosis and diabetes duration at both visits. Body mass index (BMI) 
was defined as weight (kilograms) divided by height (meters2) and converted to a Z 
score249. Weight status was classified as underweight (mean BMIz <-1.64), normal 
weight (mean BMIz -1.64-<1.04), overweight (mean BMIz 1.04-<1.64), and obesity 
(mean BMIz ≥1.64), corresponding to <5th, 5-<85th, 85th-<95th, and ≥95th percentile for 
age and sex, respectively.18 A blood draw occurred after an 8 hour overnight fast, and 
medications, including short-acting insulin, were withheld the morning of the visit. Blood 




and cystatin C at the central laboratory (Northwest Lipid Metabolism and Diabetes 
Research, Seattle, WA).  
 
4.2.3 Outcome measures 
The main outcomes for the study included seven early or subclinical diabetes 
complications measured at the follow-up visit. Definitions of outcomes complications 
were consistent with previous SEARCH studies.74,273,274  
For the outcome of hypertension, the mean of 3 systolic and diastolic blood 
pressure levels was obtained using an aneroid manometer after at least 5 minutes of 
rest. Hypertension defined based on 2017 AAP Clinical Practice Guidelines275 as blood 
pressure ≥ 130/80 mm HG or ≥ 95th percentile for ages <13 years or the use of 
antihypertensive medication. The outcome of dyslipidemia was based on National 
Cholesterol Education Program (NCEP) guidelines276 and included High-Density 
Lipoproteins (HDL) dyslipidemia (HDL <35 mg/dL) and non-HDL dyslipidemia 
(computed as total cholesterol − HDL-cholesterol >130 mg/dL), or use of a lipid-lowering 
medication. Arterial stiffness was measured with the SphgymoCor-Vx device, and 
defined as a carotid-femoral pulse wave velocity >90th percentile compared to control 
participants of the SEARCH Cardiovascular Disease (CVD) ancillary study.277 Diabetic 
retinopathy was assessed with 45o color digital fundus images taken with a 
nonmydriatic camera (Visucam Pro N, Carl Zeiss Meditech) and centered on the disc 
and macula of both eyes. Photos masked to all clinical characteristics were graded by 
the Wisconsin Ocular Epidemiology Reading Center. Diabetic retinopathy was defined 
as mild, moderate, or proliferative retinopathy in at least one eye.278 Diabetic kidney 




creatinine) or low glomerular filtration rate (<60 mL/min/1.73m2 as estimated by the 
CKD-EPI equation using serum creatinine and cystatin C).279 Peripheral neuropathy 
was defined as a score >2 on the Michigan Neuropathy Screening Instrument.280 
Cardiovascular autonomic neuropathy was assessed by heart rate variability using the 
SphygmoCor-Vx device (AtCor Medical). Electrocardiographic R-R intervals measured 
in a supine position were used to estimate five heart rate variability indices: the standard 
deviation of the intervals, root mean square differences of successive intervals, 
normalized high-frequency power, normalized low-frequency power, and the low-to-high 
frequency ratio. Cardiovascular autonomic neuropathy was defined as abnormalities in 
three or more of the five indices, based on <5th or >95th percentile (as appropriate) 
observed in age- and sex-matched control participants of the SEARCH CVD study.277  
 
4.2.4 Other measures 
Participants reported insulin regimen, classified as the use of an insulin pump 
versus any combination of multiple daily injection (MDI). Self-reported frequency of self-
monitoring of blood glucose was categorized as <1, 1-3, and >3 times per day. History 
of severe hypoglycemia (defined as any episode requiring the help of another person) 
or diabetic ketoacidosis in the past 6-months were self-reported.  
 
4.2.5 Statistical methods  
Participants were clustering using k-means clustering for joint longitudinal data 
applied to BMIz and HbA1c values from baseline and follow-up to derive clusters of 
homogenous subgroups within a larger heterogeneous population.281,282 In this 
procedure, participants who are homogenous in their BMIz and HbA1c measures at 




standardized and participants were clustered using the KmL3D package283 in R using 
Euclidean distance. Briefly, k-means is an expectation-maximization (EM) algorithm: the 
center of each cluster is determined as the mean of data points within the cluster in the 
expectation step, then data points are reassigned to the nearest cluster center in the 
maximization step. These two steps are repeated until the clusters no longer change. 
Any number of methods can be used to provide the starting cluster assignments thereby 
initializing the process; the kml3d procedure alternates through different initialization 
methods and chooses the partition with the most stability.283 To obtain optimal solutions, 
we repeated estimation 500 times, 100 times each for between four- and nine-cluster 
solutions, exploring this as the literature suggests there are multiple longitudinal 
patterns of weight and glycemia, but we do not know how many accurately represents 
the major phenotypes.281 The Calinski-Harabatz criterion284 was used to evaluate the 
various trajectory solutions and identify the optimal number of weight-glycemia 
longitudinal clusters. The Calinski Criterion is a relative metric that measures the ratio of 
the between-group variance relative to the within-group variance. The optimal clustering 
solution maximizes this ratio, representing the most compact and well-separated 
clusters.281,282,284  
Clusters were named based on primary exposure to adiposity (i.e., elevated 
BMIz) or hyperglycemia (i.e., elevated HbA1c) at both time-points. The cluster with 
BMIz and HbA1c measures closest to clinical targets was selected as the referent 
cluster.269 This method of cluster nomenclature does not necessarily represent the 
weight status and glycemic control of every individual within a cluster and instead was 




4.2.6 Cluster characteristics and associations with outcomes  
The proportion of early or subclinical diabetes complications, sociodemographic 
characteristics, and clinical care correlates of each cluster were summarized using 
descriptive statistics. Overall tests of independence across clusters were carried out 
using ANOVA for continuous features and chi-squared tests for categorical features. 
Typically, Fisher’s exact tests would be used to obtain the exact hypergeometric 
distribution for a 2x2 contingency table with low counts. However, because our tables 
have four rows (for four clusters), obtaining the exact distribution is computationally 
intensive. Therefore, we use a chi-squared test where the distribution is approximated 
using the Monte Carlo method with 9,999 random samples. In each sample, the feature 
categories are permuted, and the test statistic is computed.285,286 We accounted for 
multiple comparisons in the overall tests of difference using Bonferroni adjustment. If 
the overall test of difference was statistically significant, pairwise comparisons were 
performed for all clusters against the Referent Cluster. Additional, exploratory analyses 
for all possible pairwise comparisons are presented in Section 4.6, Supplemental 
Material, Supplemental Table 4.5. 
Logistic regression modeling was used to test how each weight-glycemia 
subgroup was associated with early or subclinical diabetes complications. Each 
outcome was modeled independently as a binary outcome, adjusting for minimum 
confounders: sex, race/ethnicity (non-Hispanic white versus all others), age, and 
diabetes duration at follow-up. Small cell sizes prohibited extensive adjustment models. 
An additional model tested the association of the clusters with the probability of having 




All p-values were evaluated at the 0.05 significance level. Data analyses were 
performed using the statistical analysis software package R version 3.4.1 and SAS 9.4 
(SAS Institute, Cary, NC). 
 
4.3 Results 
The final sample included 570 youth with established type 1 diabetes, 53.5% 
female and 70.9% non-Hispanic white race/ethnicity, with mean age at diagnosis of 
9.7±4.1 years and mean age at follow-up of 17.9±4.6 years (Supplemental Table 4.2). 
The baseline visit and follow-up visit occurred at approximately 1.4±0.4 years and 
8.2±1.9 years after diabetes diagnosis, respectively.  
Four longitudinal weight-glycemia clusters were identified over a mean of 8 years 
disease duration (Figure 4.1, Table 4.1). The Referent Cluster (n=195, 34.3%) showed 
stable low BMIz and fair glycemic control at both timepoints. The Hyperglycemia Only 
Cluster (n=53, 9.3%) showed low BMIz with stable high HbA1c at both time points, 
where mean HbA1c was 10.8±1.9% (93±21 mmol/mol) at baseline and 11.4±1.9% 
(100±20 mmol/mol) at follow-up. The Adiposity Only Cluster (n=206, 36.1%) showed 
elevated BMIz, with only 48.5% and 36.9% of individuals being classified as normal 
weight at baseline and follow-up, respectively, and moderate Hba1c levels at both time 
points (HbA1c of 7.6±1.1% (60±12 mmol/mol) and 8.1±1.0% (65±11 mmol/mol) at 
baseline and follow-up, respectively. The Adiposity and Increasing Hyperglycemia 
Cluster (n=115, 20.2%) showed high BMIz at both time points, with only approximately 
30-32% of individual being classified as normal weight across time, and with increasing 
HbA1c over time (mean HbA1c 8.4±1.5% (67±15 mmol/mol) and 11.2±1.4% (99±15 




of the longitudinal weight-glycemia clusters was created and is depicted Supplemental 
Figure 4.2. 
The longitudinal weight-glycemia clusters showed significant differences in 
sociodemographic characteristics and aspects of type 1 diabetes clinical care (Table 
4.2). Compared to the Referent Cluster, The Hyperglycemia Only Cluster and the 
Adiposity and Increasing Hyperglycemia Cluster were comprised of a significantly lower 
proportion of non-Hispanic white youth and reported lower levels of parental education, 
household income, and use of private health insurance (all p<0.05). These clusters also 
had a lower proportion of pump users and individuals who checked glucose levels four 
or more times per day (all p<0.05). There were no significant differences in sex, age, or 
diabetes duration at follow-up.  
The prevalence of dyslipidemia, retinopathy, and diabetic kidney disease was 
significantly different across clusters (all p<0.05; Table 4.2). After adjustment for sex, 
race/ethnicity, age, and diabetes duration at follow-up, and compared to the Referent 
Cluster, the Hyperglycemia Only Cluster had elevated odds of Dyslipidemia (odds ratio 
(OR) 2.22, 95% CI 1.15, 4.29), Retinopathy (OR 9.98, 95% CI 2.49, 40.0) and DKD (OR 
4.16, 95% CI 1.37, 12.62) (Table 4.3). The Adiposity and Increasing Hyperglycemia 
Cluster had elevated odds of hypertension (OR 2.18, 95% CI 1.19, 4.00), dyslipidemia 
(OR 2.36, 95% CI 1.41, 3.95), arterial stiffness (OR 2.46, 95% CI 1.09, 5.53), 
retinopathy (OR 5.11, 95% CI 1.34, 19.46), and DKD (OR 3.43, 95% CI 1.29, 9.11). 
There were no significant interactions by sex or race/ethnicity. 
The Hyperglycemia Only Cluster and Adiposity and Increasing Hyperglycemia 




compared to 0.7±0.8 in the Referent Cluster (p< 0.0001). In adjusted models, the 
Hyperglycemia Only Cluster had 2.17 times higher odds than the Reference Cluster of 
having two or more co-occurring early or subclinical diabetes complications (OR 2.2, 
95% CI 1.01, 4.68). The Adiposity and Increasing Hyperglycemia Cluster had 3.4 times 




We demonstrate here that there are subgroups of youth and young adults with 
established type 1 diabetes sharing longitudinal phenotypes defined by patterns in 
weight status and glycemic control over the early natural history of type 1 diabetes. 
Phenotypic clusters showed different associations with early or subclinical diabetes 
complications at a mean of eight years diabetes duration. We focus our discussion on 
the longitudinal weight-glycemia phenotypes first, and then turn to their associations 
with complications.  
The four clusters showed clinically significant differences in mean BMIz and 
HbA1c measures over time, providing phenotypes which integrate information from both 
key clinical parameters. Only 34% of the sample was captured in the Referent Cluster, 
suggesting that a relatively small proportion of youth and young adults with type 1 
diabetes have BMIz and HbA1c measures that meet or approach clinical targets for 
both weight status and glycemic control. Although the Hyperglycemia Only Cluster was 
the smallest cluster, comprising 9% of the sample, this subgroup distinguished itself by 
significant hyperglycemia at both time-points. By contrast, the Adiposity Only Cluster 




of the overall sample. Despite data showing that risk for obesity increases in people with 
type 1 diabetes as they age,157 the clusters showed relatively consistent measures of 
elevated BMIz from childhood onward. Moreover, neither age nor disease duration were 
significantly different across clusters at the follow-up visit, suggesting that the weight-
glycemia phenotypes do not appear to be age- or duration-driven subgroups, although 
this finding may also be attributed to limited variability in the study population.  
Our study was not designed to disentangled contribution of adiposity versus 
hyperglycemia to the emergence of early or subclinical complications of diabetes, but to 
provide insight to their combined real-world effects on early markers for ensuing 
vascular outcomes. At the cluster level, we found a disparity in the relative risk for 
adverse outcomes across the longitudinal weight-glycemia phenotypes. Subgroups with 
sustained poor or worsening glycemic control showed striking rates of microvascular 
complications at the follow-up visit, particularly when compared to the referent 
subgroup. For example, 15% of the Hyperglycemia Cluster and 7% of the Adiposity and 
Increasing Hyperglycemia Cluster had retinopathy compared to 2% in the Referent 
Cluster, while the prevalence of DKD in these subgroups exceeded 15% compared to 
just 4.0% in the Referent Cluster. This pattern adds to existing literature showing that 
the emergence of microvascular complications of type 1 diabetes is related to glycemic 
control.76,77 We did not find differences in the risk of peripheral or autonomic neuropathy 
across clusters, despite previous data showing these outcomes are associated with 
glycemic control and weight status.76,77,203 The null results may reflect small cell sizes 




power to detect smaller difference. It is also possible that an association may be 
detectable at a longer disease duration or older age. 
In logistic regression modeling, the Adiposity and Increasing Hyperglycemia 
Cluster had a higher risk of subclinical macrovascular complications including 
hypertension, and hyperlipidemia and arterial stiffness, in addition to the microvascular 
complications seen in the Hyperglycemia Only Cluster, a worrisome finding given the 
elevated risk for adverse events in this population.10 A notable finding is that this 
subgroup showed comparable or worse outcomes at the follow-up visit compared to the 
Hyperglycemia Only Cluster, the subgroup marked by sustained high HbA1c, despite 
having a significantly lower HbA1c at baseline. The pattern in which BMI accelerates the 
worsening of cardiovascular disease status, despite lower relative exposure to 
glycemia, is reminiscent of data from the Diabetes Control and Complications Trial 
showing that the incident rate of total cardiovascular disease events among individuals 
who received intensive insulin therapy and gained the most weight approximated the 
rate of those who did not receive intensive insulin therapy after 20 years of follow-up.149 
In addition, this pattern is consistent with previous SEARCH data showing that 
individuals with adverse metabolic risk profiles at baseline and cohort visit were ten 
times more likely to develop multiple complications than individuals with less adverse 
profiles,274 as well as data-driven studies in large adult cohorts showing differences in 
end-organ damage across metabolic subtypes of type 1 diabetes.287 Findings further 
resonate with the increased prevalence of these outcomes among youth with type 2 
diabetes versus type 1, suggesting that obesity may contribute to the underlying 




Given that dual exposure to adiposity and hyperglycemia may accelerate the 
development of complications, incorporation of obesity measures as part of the clinical 
phenotype of type 1 diabetes may provide useful prognostic information regarding long-
term, adverse outcomes (particularly the macrovascular ones). Future epidemiological 
studies should examine the risk associated with longitudinal BMI and HbA1c, by testing 
individual and joint models over a longer duration, to better characterize the 
associations among these risk factors. 
The variable patterns of BMIz and HbA1c and differential risk profiles captured 
from the first eight years of diabetes underscore the tremendous challenges and 
complexity associated with diabetes management, as well as the need for clinical 
practice guidelines for weight management specifically in the setting of pediatric-onset 
type 1 diabetes.181,189,269 The heterogeneity across phentoypes regarding clinical 
presentation and outcomes, in conjunction with multiple technologic and therapeutic 
options available to optimize or co-optimize outcomes,181 suggest that a stratified 
approach, developing treatment plans according to the unique needs of each subgroup, 
may be most appropriate. For example, the use of continuous glucose monitoring 
(CGM) systems in the adolescent population has increased and shows benefit 
regarding improved glycemic control in this age range.143 Increased use of newer 
diabetes technology and devices may be useful in mitigating hyperglycemia as well as 
hypoglycemia; hypoglycemia has been implicated as a barrier to exercise and a trigger 
for overeating, leading to weight gain and elevated HbA1c.189 The stratified medicine 
approach also holds particular promise in light of newer non-insulin adjunctive 




and glycemic control and thus may be most benefical in the highest-risk subgroup. To 
this end, more work is needed to be extend this work to a clinically-relevant platform 
where risk groups can be defined by easily measured criteria. 
The current study should be considered in the context of its limitations. The 
exclusion of individials with baseline disease duration of <12 months diminished sample 
size and may limit generalizability, where the study population may be not 
representative of the full SEARCH cohort. This exclusion criteria was judged to be 
important to avoid other forms of bias that may result from combining two phases of the 
early natural history of type 1 diabetes in the baseline measures, including 
misclassification bias, and based on scientific evidence regarding the duration of partial 
remission in relevant patient populations.270,271 The resulting phenotypes are thus 
representative of known challenges in glycemia that occur after the remission period269 
rather than differences in remission itself. The k-means algorithm finds clusters of equal 
size and thus may miss smaller subgroups. Because it is not model-based, there are no 
parameters to evaluate goodness-of-fit. However, the longitudinal k-means algorithm 
with parameters used in this analysis were shown to outperform other model based 
latent trajectory class analyses.288 The selection of the final number of clusters is 
subjective. We used a criterion for this decision that have been shown to perform best in 
non-hierarchical algorithms. Only two-time points were used in the longitudinal cluster 
analysis, thus interim patterns in BMIz and HbA1c are not captured in these subgroups. 
Outcomes are prevalence measures; absolute risk difference across clusters cannot be 
reported. Low prevalence rates may increase the type 2 error rate for the outcomes. 




adults taking antihypertensive medications for renal protection. Low numbers prevented 
the addition of additional covariates to regression models, including markers of 
socioeconomic position and aspects of diabetes care. The longitudinal weight-glycemia 
clusters and their association with outcomes was not tested in a prospective way and 
thus clusters are not predictive in nature. Additional exploratory analyses tested the 
predictive validitiy of weight-glycemia clusters derived from baseline measures only and 
overlapping BMIz and HbA1c at the follow-up visit with variable associations with 
complications; this approach was deemed to be limited by the true variability in weight 
and glycemia measures over the early history of type 1 diabetes and less informative 
regarding the joint trajectory structure inherent in the data.  
There also several important strengths of this study. To our knowledge, it is the 
first to identify subgroups based on both weight and glycemia in established diabetes 
and evaluate the clinically utility for predicting long-term outcomes. The analysis takes a 
novel approach that integrates weight with glycemic control, a paradigm that offers a 
comprehensive and patient-centered approach to long-term health issues in type 1 
diabetes. Clustering BMIz and HbA1c jointly produces a single grouping single nominal 
variable (i.e. cluster) that resumes the information contained in the both sets of 
variables over both time points, offering an integrated measure of exposure to adiposity 
and glycemia as it occurs in real life. k-means is non-parametric and there requires no 
prior information for clustering.288 Capturing clinical phenotypes in youth with type 1 
diabetes reflects how clinicians work to deliver individual care plans for patients and 
offers a platform for future research towards guidelines to comprehensively reduce the 





We found evidence of four longitudinal weight-glycemia phenotypes of 
established, youth-onset type 1 diabetes in first eight years after diagnosis with diabetes 
who experience different burdens of co-morbid early or subclinical complications. More 
work is needed to identify therapeutic approaches tailored to the needs and prognoses 








Table 4.1. Weight and Glycemia at the Baseline and Follow-Up Visit Across the Longitudinal Weight-Glycemia 
Phenotypes of Established Type 1 Diabetes. 
  All Referent 
Cluster  
Hyperglycemia 








  N=570 N=195 
(34.2) 
N=r53 (9.3) N=206 (36.1) N=116 (20.4)  
Baseline  Weight and 
Glycemia, 
mean (SD)  
      
BMIz 0.54 (1.07) -0.36 (0.85) -0.21 (1.02) 1.12 (0.59)** 1.36 (0.67)** <0.0001 
HbA1c 8.1 (1.6) 7.8 (1.0) 10.8 (1.9)** 7.6 (1.1) 8.4 (1.5)** <0.0001 
Weight 
Status†, n (%) 
     <0.0001 
Underweight  15 (2.6) 10 (5.2) 5 (9.4) 0 (0.0)** 0 (0.0)**  
Normal Weight  364 (63.9) 183 (93.9) 46 (86.8) 100 (48.5)** 35 (30.2)**  
Overweight 110 (19.3) 2 (1.0) 2 (3.8) 63 (30.6)** 43 (37.1)**  
Obesity 80 (14.2) 0 (0.0) 0 (0.0) 43 (20.8)** 38 (32.8)**  
Glycemic 
Control‡, n (%) 
     <0.0001 
Adequate 192 (33.7) 72 (36.9) 1 (1.9)** 89 (43.2) 30 (25.9)**  
Fair 244 (42.8) 103 (52.8) 7 (13.2)** 93 (45.2) 41 (35.3)**  
Poor 121 (21.2) 20 (10.2) 33 (62.3)** 24 (11.7) 44 (37.9)**  
Very poor 13 (2.3) 0 (0.0) 12 (22.6)** 0 (0.0) 1 (0.9)**  
Follow-
up Visit  
Weight and 
Glycemia, 
mean (SD)  
      
BMIz 0.64 (0.97) -0.11 (0.72) -0.27 (1.07) 1.21 (0.54)** 1.30 (0.61)** <0.0001 
HbA1c 9.2 (1.9) 8.5 (1.2) 11.4 (1.9)** 8.1 (1.0)* 11.2 (1.4)** <0.0001 
Weight 
Status†, n (%) 
     <0.0001 







Normal Weight 344 (60.4) 185 (94.9) 46 (86.8) 76 (36.9)** 37 (31.9)**  
Overweight 139 (24.4) 3 (1.5) 3 (5.7) 85 (41.3)** 48 (41.4)**  
Obesity 76 (13.3) 0 (0.0) 0 (0.0) 45 (21.8)** 31 (26.7)**  
Glycemic 
Control‡, n (%) 
     <0.0001 
Adequate 85 (14.9) 36 (18.5) 1 (1.9)** 48 (23.3)* 0 (0.0)**  
Fair 213 (37.4) 90 (46.2) 4 (7.6)** 117 (56.8)* 2 (1.7)**  
Poor 225 (39.5) 69 (35.4) 26 (49.1)** 41 (19.9)* 89 (76.7)**  
Very poor 47 (8.3) 0 (0.0) 22 (41.5)** 0 (0.0)* 25 (21.6)**  
Abbreviations: BMIz- body mass index z-score. HbA1c- hemoglobin A1c.  
Data are mean ± standard deviation[continuous], or n (%) [categorical]. 
Overall p-values from Chi Squared, Fisher exact tests, and ANOVA, as appropriate. Bonferroni correction was 
applied. Pairwise comparisons were performed for significant variables, using The Referent Cluster as the referent 
group. * denotes pairwise p-value <0.05. ** denotes pairwise p=value < 0.0001. 
†Weight status defined based on body mass index z-score (BMIz). Underweight was defined as BMIz <-1.64 
corresponding to the 5th percentile for age and sex. Normal weight was defined as BMIz ≥-1.64 and <1.04, 
corresponding to ≥-the 5th and <85th percentile for age and sex. Overweight was defined as BMIz ≥ 1.04 and 
<1.64, corresponding to ≥85th percentile and <95th percentile for age and sex. Obesity was defined as BMIz ≥ 
1.64 corresponding to ≥ 95th percentile for age and sex. 
‡Glycemic Control: Adequate (Hba1c <58 mmol/mol (7.5%)), fair (HbA1c ≥58 and <75 mmol/mol (≥7.5 and 














Table 4.2. Early or Subclinical Diabetes Complications, Sociodemographic Characteristics, and Aspects of Type 1 
Diabetes and its Clinical Care at the Follow-Up Visit Across the Longitudinal Weight-Glycemia Phenotypes of 
Established Type 1 Diabetes 
 All Referent 
Cluster  
Hyperglycemia 








 N=570 N=195 
(34.2) 
N=53 (9.3) N=206 (36.1) N=116 (20.4)  















Early or Subclinical Diabetes Complications†, n (%) 
Hypertension  111 (19.5) 29 (14.9) 5 (9.6) 44 (21.4) 33 (28.5) 0.231 
Dyslipidemia  180 (31.6) 46 (23.6) 23 (43.4)* 59 (28.7) 52 (44.8)** 0.003 
Arterial Stiffness 54 (10.1) 15 (8.1) 3 (6.0) 18 (9.5) 18 (16.5) 1.000 
Retinopathy 22 (4.0) 4 (2.1) 8 (15.1)* 2 (1.0) 8 (7.3)* <0.0001 
Diabetic kidney disease 35 (6.9) 7 (4.0) 8 (15.7)* 6 (3.3) 14 (13.5)* 0.018 
Peripheral neuropathy  35 (6.2) 10 (5.2) 3 (5.7) 14 (6.9) 8 (7.0) 1.000 
Cardiovascular autonomic 
neuropathy  
63 (12.1) 24 (13.6) 9 (18.4) 21 (11.2) 9 (8.3) 1.000 
Total number of early or 
subclinical diabetes 
complications, mean (SD)  
0.9 (0.9) 0.7 (0.8) 1.1 (1.0)* 0.8 (0.9) 1.2 (1.1)** <0.0001 
Sociodemographic Characteristics  
Female (n) 305 (53.5) 94 (48.2) 27 (50.9) 107 (51.9) 77 (66.4)* 0.582 
Non-Hispanic white (n) 404 (70.9) 161 (82.6) 27 (50.9)** 154 (74.6)* 62 (53.5)** <0.0001 
Age at visit (years) 17.9 (4.6) 18.0 (4.7) 18.9 (4.8) 17.5 (4.9) 18.0 (3.8) 1.000 
Parental education of 
college graduate or higher 
264 (46.4) 115 (59.0) 15 (28.3)** 98 (47.6)* 36 (31.0)** <0.0001 
Annual household income 
>$75,000 







Private health insurance 391 (68.6) 144 (73.8) 26 (49.1)* 154 (74.8) 67 (57.8)* 0.003 
Aspects of Type 1 Diabetes and its Clinical Care 
Diabetes duration (years) 8.2 (1.9) 8.2 (2.0) 8.2 (1.8) 8.1 (2.0) 8.3 (2.0) 1.000 
Insulin dose (units/kg) 0.85 (0.43) 0.89 (0.54) 0.88 (0.48) 0.79 (0.30) 0.88 (0.39) 1.000 
Insulin pump (versus MDI)  304 (53.3) 125 (64.0) 16 (30.3)** 121 (58.7) 42 (36.2)** <0.0001 
Frequency of self-
monitoring of blood glucose 
> 4 times per day  
446 (78.3) 160 (82.1) 33 (62.3)* 172 (83.5) 81 (69.8)* 0.009 
Acute Complications‡       
1+ Severe Hypoglycemic 
Episode 
43 (7.6) 12 (6.2) 5 (9.6) 19 (9.2) 7 (6.0) 1.000 
1+ Diabetic Ketoacidosis 
Episode 
109 (19.2) 28 (14.4) 14 (26.9) 34 (16.5) 33 (28.5) 0.189 
Abbreviations: MDI – multiple daily injections. Kg – kilograms.  
Data are mean ± standard deviation[continuous], or n (%) [categorical]. 
Overall p-values from from Chi Squared, Fisher exact tests, and ANOVA, as appropriate. Bonferroni correction was 
applied. Pairwise comparisons were performed for significant variables, using The Referent Cluster as the referent 
group. * denotes pairwise p-value <0.05. ** denotes pairwise p=value < 0.0001. 
†Outcomes defined as follows:  
Hypertension defined based on AAP Clinical Practice Guidelines, 5th Report: as of 2017: Stage 1 or 2 
hypertension (blood pressure ≥ 130/80 mm HG or ≥ 95th percentile for ages <13 years) or the use of 
antihypertensive medication.  
Dyslipidemia includes High-Density Lipoproteins (HDL) HDL and non-HDL dyslipidemia (non–HDL-cholesterol 
(computed as total cholesterol − HDL-cholesterol): >130 mg/dL OR HDL-cholesterol: <35 mg/dL) or use of lipid-
lowering medication. 
Arterial stiffness was measured with the SphgymoCor-Vx device and defined as a carotid-femoral pulse wave 
velocity >90th percentile compared to control participants of the SEARCH CVD study. 
Diabetic Retinopathy based on digital fundus images and defined as mild, moderate, or proliferative retinopathy in 
at least one eye. 
Diabetic kidney disease was defined as the presence of albuminuria (>30 μg/mg of creatinine) or low glomerular 
filtration rate (<60 mL/min/1·73m2 as estimated by the CKD-EPI equations with serum creatinine and cystatin C). 







Cardiovascular autonomic neuropathy was assessed by heart rate variability using the SphygmoCor-Vx device; 
Cardiovascular autonomic neuropathy was defined as abnormalities in three or more of the five indices, based on 
<5th or >95th percentile (as appropriate) observed in age- and sex-matched control participants of the SEARCH 
CVD ancillary study.  
















Table 4.3. Odds Ratios with 95% Confidence Intervals (CI) from Multivariable Logistic Regression Models of the 
Association Between Longitudinal Weight-Glycemia Phenotype Clusters and Outcomes, with Adjustment for 
Minimum Confounder 
 Model‡ Referent 
Cluster  
Hyperglycemia 
Only Cluster  
Adiposity Only 
Cluster 






  N=195 
(34.2) 
N=53 (9.3) N=206 (36.1) N=116 (20.4)  
Early or Subclinical Diabetes Complications† 
Hypertension Unadjusted ref 0.61 (0.22, 1.65) 1.55 (0.92, 2.59) 2.26 (1.29, 3.98) 0.009 
Adjusted ref 0.45 (0.16, 1.28) 1.62 (0.95, 2.77) 2.18 (1.19, 4.00) 0.006 
Dyslipidemia Unadjusted ref 2.48 (1.32, 4.69) 1.30 (0.83, 2.03) 2.63 (1.61, 4.31) 0.003 
Adjusted ref 2.22 (1.15, 4.29) 1.31 (0.83, 2.07) 2.36 (1.41, 3.95) 0.005 
Arterial Stiffness Unadjusted ref 0.72 (0.20, 2.61) 1.19 (0.58, 2.44) 2.24 (1.08, 4.66) 0.092 
Adjusted ref 0.49 (0.12, 1.90) 1.26 (0.59, 2.69) 2.46 (1.09, 5.53) 0.045 
Retinopathy Unadjusted ref 8.40 (2.42, 29.14) 0.48 (0.09, 2.64) 3.74 (1.10, 12.73) 0.0003 
Adjusted ref 9.98 (2.49, 40.01) 0.48 (0.08, 2.73) 5.11 (1.34, 19.46) 0.0004 
Diabetic kidney 
disease 
Unadjusted ref 4.44 (1.53, 12.92) 0.82 (0.27, 2.48) 3.71 (1.45, 9.53) 0.0009 
Adjusted ref 4.16 (1.37, 12.62) 0.80 (0.26, 2.44) 3.43 (1.29, 9.11) 0.003 
Peripheral 
neuropathy  
Unadjusted ref 1.10 (0.29, 4.16) 1.36 (0.59, 3.15) 1.38 (0.53, 3.59) 0.880 




Unadjusted ref 1.43 (0.61, 3.31) 0.80 (0.43, 1.50) 0.57 (0.25, 1.28) 0.289 
Adjusted ref 1.45 (0.60, 3.50) 0.86 (0.45, 1.63) 0.72 (0.31, 1.67) 0.552 
Total Burden of Early or Subclinical Diabetes Complications  
Two or more co-
occurring 
complications  
Unadjusted ref 2.50 (1.25, 5.00) 1.20 (0.71, 2.01) 3.00 (1.75, 5.15) <0.0001 








Abbreviations: ref – reference; 
†Outcomes defined as follows:  
Hypertension defined based on AAP Clinical Practice Guidelines, 5th Report: as of 2017: Stage 1 or 2 hypertension 
(blood pressure ≥ 130/80 mm HG or ≥ 95th percentile for ages <13 years) or the use of antihypertensive medication.  
Dyslipidemia includes High-Density Lipoproteins (HDL) HDL and non-HDL dyslipidemia (non–HDL-cholesterol 
(computed as total cholesterol − HDL-cholesterol): >130 mg/dL OR HDL-cholesterol: <35 mg/dL) or use of lipid-
lowering medication. 
Arterial stiffness was measured with the SphgymoCor-Vx device and defined as a carotid-femoral pulse wave velocity 
>90th percentile compared to control participants of the SEARCH CVD study. 
Diabetic Retinopathy based on digital fundus images and defined as mild, moderate, or proliferative retinopathy in at 
least one eye. 
Diabetic kidney disease was defined as the presence of albuminuria (>30 μg/mg of creatinine) or low glomerular 
filtration rate (<60 mL/min/1·73m2 as estimated by the CKD-EPI equations with serum creatinine and cystatin C). 
Peripheral neuropathy was defined as a score >2 on the Michigan Neuropathy Screening Instrument. 
Cardiovascular autonomic neuropathy was assessed by heart rate variability using the SphygmoCor-Vx device; 
Cardiovascular autonomic neuropathy was defined as abnormalities in three or more of the five indices, based on 
<5th or >95th percentile (as appropriate) observed in age- and sex-matched control participants of the SEARCH CVD 
ancillary study.  
‡Adjusted for minimum confounders: sex, race/ethnicity (non-Hispanic white versus all others), age at follow-up, type 1 





















Figure 4.1. Longitudinal weight glycemia phenotypes in the SEARCH for Diabetes in Youth Study. Clusters were 
derived from baseline and follow-up measures of BMIz and HbA1c over a mean of 8.2 years. Clusters were named based 
on their main exposure, where high HbA1c is denoted by ‘Hyperglycemia’ (H) and elevated BMIz is denoted by ‘Adiposity’ 
(A). Four clusters were identified: the Referent Cluster (n=195, 34.2%), the Hyperglycemia Only Cluster (n=53, 9.3%), the 
Adiposity Only Cluster (n=206, 36.1%) , and the Adiposity and Increasing Hyperglycemia Cluster (n=116, 20.4%). Panel 
A: Scatter plot of BMIz and HbA1c, colored by cluster, at both time points. Panel B: Cluster trajectories of BMIz and 
HbA1c between baseline and follow-up visit. Abbreviations: BMIz=body mass index z-score. HbA1c=hemoglobin A1c. R= 










4.6 Supplemental Material  
 
Supplemental Table 4.1. Selected Characteristics Between Included/Excluded Participants (with complete 
outcomes)  
Baseline visit < 12 
months after type 1 
diabetes diagnosis 
Baseline visit ≥ 12 




 N=1,195 (67.6%) N=570 (32.4%)  
Baseline Weight and Glycemia Measures    
BMIz  0.52 (1.03) 0.54 (1.07) 0.76 
HbA1c, % 7.4 (1.3) 8.1 (1.5) <0.01 
Follow-up Weight and Glycemia Measures    
BMIz  0.60 (0.94) 0.63 (0.97) 0.45 
HbA1c, % 9.1 (1.9) 9.2 (1.9) 0.25 
Demographic Characteristics     
Female 575 (48.0) 304 (53.5) 0.03 
Non-Hispanic White 938 (78.5) 407 (70.8) <0.01 
Age at Diagnosis, years 10.1 (3.9) 9.7 (4.1) 0.06 
Diabetes Duration at Baseline Visit, Months 5.6 (3.0) 16.7 (4.9) <0.01 
Age at Baseline Visit, years 10.6 (3.9) 11.1 (4.1) <0.01 
Age at Cohort Visit, years 17.7 (4.2) 17.9 (4.6) 0.31 
Baseline Socioeconomic Position     
Parental Bachelor’s degree or more 624 (52.6) 244 (43.7) <0.01 
Private Health insurance 949 (80.0) 433 (76.9) 0.31 
Aspects of Type 1 Diabetes and its Clinical Care     
Pump Use, n (%) 29 (4.3) 52 (15.6) <0.01 
Frequency of Blood Glucose Monitoring, mean (SD) 4.8 (0.5) 4.7 (0.6) 0.13 
Abbreviations: BMIz- body mass index z-score. HbA1c- hemoglobin A1c.  









Supplemental Table 4.2. Characteristics of 570 SEARCH for Diabetes in Youth Participants at their Baseline and 
Follow-Up Visits 
 
 Baseline visit Follow up visit 
 n Mean ± SD or 
n (%) 
n Mean ± SD or n 
(%) 
Female (n) 570 35 (53.5) -- --- 
Non-Hispanic white (n) 570 404 (70.9) -- --- 
Age at diagnosis (years) 570 9.7 (4.1) -- --- 
Age at visit (years) 570 11.1 (4.1) 570  17.9 (4.6) 
Diabetes duration (years) 570  1.4 (0.4) 570 8.2 (1.9) 
Parental education (n) 561  560  
 <High school graduate  27 (4.8)  27 (4.1) 
 High school graduate   98 (17.5)  84 (15.0) 
 Some college through associates  190 (33.9)  185 (33.0) 
 Bachelor’s degree or more  246 (43.9)  264 (47.1) 
Annual household income (n) 563  566  
 <$25,000  94 (16.7)  103 (18.2) 
 $25,000 - $49,999  115 (20.4)  76 (13.4) 
 $50,000 - $74,999  110 (19.5)  83 (14.7) 
 >$75,000  198 (35.2)  202 (35.7) 
 DK/Refused  46 (8.2)  102 (18.0) 
Health insurance (n) 564  565  
 Private  433 (76.8)  291 (69.2) 
 Medicare/Medicaid  109 (19.3)  128 (22.7) 
 Other  13 (2.3)  22 (3.9) 
 None  9 (1.6)  24 (4.3) 










Supplemental Table 4.3. P-values for All Pairwise Comparisons 
 The 
Hyperglycemia 



































Baseline Weight and Glycemia measures 
Baseline BMIz 0.3304 <0.0001 <0.0001 <0.0001 <0.0001 0.0016 <0.0001 
Baseline HbA1c <0.0001 0.0932 0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Baseline Weight 
Status†, n (%) 
0.1227 <0.0001 <0.0001 <0.0001 <0.0001 0.0038 <0.0001 
Baseline Glycemic 
Control‡, n (%) 
<0.0001 0.3059 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Follow-Weight and Glycemia measures 
Follow-up BMIz 0.3336 <0.0001 <0.0001 <0.0001 <0.0001 0.1723 <0.0001 
Follow-up HbA1c <0.0001 0.0001 <0.0001 <0.0001 0.5095 <0.0001 <0.0001 
Follow-up Weight 
Status†, n (%) 




<0.0001 0.0025 <0.0001 <0.0001 0.0008 <0.0001 <0.0001 
Early or Subclinical Diabetes Complications§, n (%) 
Hypertension  0.3749 0.1199 0.0052 0.0733 0.0088 0.1740 0.231 
Dyslipidemia  0.0058 0.2582 0.0001 0.0472 1.0000 0.0048 0.003 
Arterial Stiffness 0.7707 0.7165 0.0350 0.5795 0.0806 0.0960 1.000 
Retinopathy 0.0007 0.4420 0.0323 <0.0001 0.1598 0.0045 <0.0001 
Diabetic kidney 
disease 
0.0073 0.7831 0.0082 0.0034 0.8072 0.0028 0.018 
Peripheral 
neuropathy  












Total number of 
early or subclinical 
diabetes 
complications, 
mean (SD)  
0.0078 0.2192 <0.0001 0.0429 0.5312 0.0005 <0.0001 
Sociodemographic Characteristics  
Female (n) 0.7528 0.4849 0.0022 1.0000 0.0626 0.0138 0.582 
Non-Hispanic white 
(n) 
<0.0001 0.0678 <0.0001 0.0013 0.8683 0.0001 <0.0001 
Age at visit (years) 0.2116 0.2896 0.9650 0.0565 0.2278 0.2840 1.000 
Parental education 
of college graduate 
or higher 
<0.0001 0.0275 <0.0001 0.0130 0.8569 0.0046 <0.0001 
Annual household 
income >$75,000 
0.0007 0.8397 0.0002 0.0012 0.5418 0.0004 <0.0001 
Private health 
insurance 
0.0008 0.9090 0.0039 0.0007 0.3202 0.0026 0.003 
Aspects of Type 1 Diabetes and its Clinical Care 
Diabetes duration 
(years) 
0.9898 0.3995 0.7721 0.5670 0.8190 0.3082 1.000 
Insulin dose 
(units/kg) 
0.9518 0.0347 0.8508 0.2255 0.9450 0.0622 1.000 
Insulin pump 
(versus MDI)  
<0.0001 0.3051 <0.0001 0.0003 0.4885 0.0001 <0.0001 
Frequency of self-
monitoring of blood 
glucose>4 times 
per day  
0.0045 0.7914 0.0167 0.0020 0.3776 0.0048 0.009 
Acute 
Complications|| 
















Abbreviations: BMIz- body mass index z-score. HbA1c- hemoglobin A1c.  
Overall p-values from from Chi Squared, Fisher exact tests, and ANOVA, as appropriate. Bonferroni correction was applied.  
†Weight status defined based on body mass index z-score (BMIz). Underweight was defined as cluster mean BMIz <-1.64 
corresponding to the 5th percentile for age and sex. Normal weight was defined as cluster mean BMIz ≥-1.64 and <1.04, 
corresponding to ≥-the 5th and <85th percentile for age and sex. Overweight was defined as cluster mean BMIz ≥ 1.04 and <1.64, 
corresponding to ≥85th percentile and <95th percentile for age and sex. Obesity was defined as cluster mean BMIz ≥ 1.64 
corresponding to ≥ 95th percentile for age and sex. 
‡Glycemic Control: Adequate (Hba1c <58 mmol/mol (7.5%)), fair (HbA1c ≥58 and <75 mmol/mol (≥7.5 and <9.0%)); poor (HbA1c ≥ 
75 and <108 mmol/mol (≥ 9.0% and <12.0%)); very poor (HbA1c >108 mmol/mol (≥12.0%)). 
§ Outcomes defined as follows:  
Hypertension defined based on AAP Clinical Practice Guidelines, 5th Report: as of 2017: Stage 1 or 2 hypertension (blood 
pressure ≥ 130/80 mm HG or ≥ 95th percentile for ages <13 years) or the use of antihypertensive medication.  
Dyslipidemia includes High-Density Lipoproteins (HDL) HDL and non-HDL dyslipidemia (non–HDL-cholesterol (computed as 
total cholesterol − HDL-cholesterol): >130 mg/dL OR HDL-cholesterol: <35 mg/dL) or use of lipid-lowering medication. 
Arterial stiffness was measured with the SphgymoCor-Vx device and defined as a carotid-femoral pulse wave velocity >90th 
percentile compared to control participants of the SEARCH CVD study. 
Diabetic Retinopathy based on digital fundus images and defined as mild, moderate, or proliferative retinopathy in at least one 
eye. 
Diabetic kidney disease was defined as the presence of albuminuria (>30 μg/mg of creatinine) or low glomerular filtration rate 
(<60 mL/min/1.73m2 as estimated by the CKD-EPI equations with serum creatinine and cystatin C). 
Peripheral neuropathy was defined as a score >2 on the Michigan Neuropathy Screening Instrument. 
Cardiovascular autonomic neuropathy was assessed by heart rate variability using the SphygmoCor-Vx device; Cardiovascular 
autonomic neuropathy was defined as abnormalities in three or more of the five indices, based on <5th or >95th percentile (as 
appropriate) observed in age- and sex-matched control participants of the SEARCH CVD ancillary study.  





















Supplemental Figure 4.2. Interactive visualization of BMIz and HbA1c at baseline and follow-up visit, colored by 
cluster. The X-axis represents BMIz, the Y-axis represents HbA1c, and the Z axis represents time, where 0=baseline visit 
and 1=follow-up visit. Four clusters were identified: The Referent Cluster (n=195, 34.2%), the Hyperglycemia Only Cluster 
(n=53, 9.3%), the Adiposity Only Cluster (n=206, 36.1%), and the Both Adiposity and Glycemia Cluster (n=116, 20.4%). 
Abbreviations: BMIz=body mass index z-score. HbA1c=hemoglobin A1c. R= Referent Cluster. H=Hyperglycemia Only 
Cluster. A=Adiposity Only Cluster. AH= Adiposity and Increasing Hyperglycemia Cluster. The figure is shown here as 
captured still figures.  
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CHAPTER 5. IDENTIFICATION OF CLINICALLY-RELEVANT DYSGLYCEMIA 
PHENOTYPES BASED ON CONTINUOUS GLUCOSE MONITORING DATA FROM 
YOUTH WITH TYPE 1 DIABETES AND ELEVATED HEMOGLOBIN A1C  
The aim of the study was to identify and characterize subgroups of adolescents 
with type 1 diabetes  and elevated hemoglobin A1c (HbA1c) who share patterns in their 
continuous glucose monitoring (CGM) data as ‘dysglycemia phenotypes.’ Data were 
analyzed from the Flexible Lifestyles Empowering Change randomized trial. 
Adolescents with type 1 diabetes (13-16 years, diabetes duration>1 year, HbA1c 64-119 
mmol/mol (8.0-13.0%) wore blinded CGM at baseline for 7-days. Participants were 
clustered based on eight CGM metrics measuring incidence of hypoglycemia, exposure 
to hypoglycemia, exposure to hyperglycemia, and glycemic variability in the daytime 
and over night. Clusters were characterized by their baseline features and 18-month 
changes in HbA1c using adjusted mixed effects models. For comparison, participants 
were stratified by baseline HbA1c (≤/>9.0% (75 mmol/mol)).  The study sample included 
234 adolescents (49.8% female, age 14.8±1.1, duration 6.4±3.7 years, HbA1c 81±13 
mmol/mol (9.6±1.2%). Three Dysglycemia Clusters were identified with significant 
differences across all CGM metrics (p<0.001). Dysglycemia Cluster 3 (n=40, 17.1%) 
showed severe hypoglycemia and glycemic variability with moderate hyperglycemia and 
had a lower baseline HbA1c than Clusters 1 and 2 (p<0.001). This cluster showed 
increases in HbA1c over 18-mo (p-for-interaction=0.006). No other baseline 
characteristics were associated with Dysglycemia Clusters. High HbA1c was associated 
with lower pump use, greater insulin doses, more frequent blood glucose monitoring, 
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lower motivation, and lower adherence to diabetes self-management (all p<0.05). The 
study shows that CGM data may be pooled, consolidated, and clustered to discover 
subgroups of adolescents with T1D for which glycemic control is challenged by different 
aspects of dysglycemia. Enhanced understanding of patient-factors including diabetes 
behaviors that contribute to CGM-derived dysglycemia phenotypes may reveal 
strategies to improve treatment. 
 
5.1 Introduction 
 While HbA1c is the gold standard for measuring intermediate-term glycemic 
control, CGM data captures transient glucose fluctuations to various thresholds of 
hypoglycemia and hyperglycemia, as well as overall glycemic variability in the daytime 
and overnight.6,7 These features of dysglycemia represent distinct clinical issues for 
individuals with type 1 diabetes which may be amenable to different self-management 
and medication adjustments.6 They also confer independent risk for short and long-term 
complications of type 1 diabetes.6,7,93,289 CGM data thus offers the opportunity to 
understand patterns of glycemia that are not represented by HbA1c and inform an 
individualized approach to type 1 diabetes management for decreased patient burden 
and better outcomes.6 
 The most effective strategy to both leverage the depth and integrate the breath of 
information that CGM offers remains unclear. This step is critical to inform tailored 
approaches to diabetes care. We focused on young individuals with type 1 diabetes and 
suboptimal glycemic control as it is measured by HbA1c because this population is in 
great need for improved clinical strategies.5,260 Our objective was to use longitudinal 
CGM data from adolescents with type 1 diabetes and elevated HbA1c >8.0% (65 
 
 111 
mmol/mol) to identify clinically-relevant subgroups sharing multifacteted patterns in 
hypoglycemia, hyperglycemia, and glycemic variability as distinct ‘dysglycemia 
phenotypes’. These comprehensive dysglycemia phenotypes could be used to 
characterize glycemic control across the population in a more nuanced, patient-oriented 
manner compared to HbA1c and inform the development of future interventions.7 
 To follow best practices and maximize relevance to future research, we used a 
combination of CGM metrics consistent with Advanced Technologies & Treatments for 
Diabetes (ATTD) Congress consensus statement to standardize the reporting of CGM 
variables in clinical and epidemiologic research.144 Given significant skews in the 
distribution of key CGM metrics across the sample that are important to clinical care, 
namely hypo- and hyperglycemia, it was important to identify a statistical method that 
would retain information from data at the extremes of the distribution. We chose a 
neural-network approach to clustering and grouped individuals based on their 
placement on a self-organzing map (SOM) constructed from eight CGM metrics 
selected to be maximally clinically-relevant.290 The SOM is a machine learning 
technique that is robust to different distributions of data when uncovering underlying 
clusters.291 We then tested for differences in the baseline sociodemographic, clinical, 





5.2.1 Study sample 
 Data were analyzed from the baseline visit of the Flexible Lifestyles Empowering 
Change randomized trial (FLEX) (ClinicalTrials.gov identifier: NCT01286350). FLEX 
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was a randomized clinical trial testing an adaptive, 18-month intervention including 
behavioral skills and problem solving for youth with type 1 diabetes, with respect to 
HbA1c (primary outcome), glycemic variability, cardiovascular risk factors, health-
related quality of life, and cost effectiveness.292  
 
5.2.2 Inclusion criteria 
 FLEX enrolled 258 adolescents with type 1 diabetes who were instructed to wear 
a blinded CGM for 7 days at baseline.293 Participants were recruited from 05/01/2014 to 
04/04/2016.293 Eligible participants were youth ages 13-16 years with type 1 diabetes 
for ≥1 year, literacy in English, HbA1c 8.0-13.0% (64-119 mmol/mol), and ≥1 primary 
caregiver with no other serious medical conditions or pregnancy. Detailed 
considerations of the FLEX design and baseline participant characteristics have been 
described elsewhere.293 
 Participants were excluded from the present analyses if they reported a severe 
hypoglycemic event (an episode of hypoglycemia requiring external aid) during the 
study week (n=0) or if <24 hours of CGM data were missing at the baseline visit (n=24). 
 
5.2.3 Measures 
 All data collection was standardized as per FLEX study protocol and are 
described in detail elsewhere.293 
 
5.2.3.1 Continuous Glucose Monitoring 
 A blinded CGM [iPro®2 Professional CGM; Medtronic Diabetes, Northridge, CA; 
median absolute relative difference: 11.1%] was worn for a 7-day period to measure 
interstitial glucose levels. At the baseline visit, study participants inserted the iPro®2 
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CGM system with the Enlite™ sensor into abdominal subcutaneous adipose tissue. 
Participants were carefully instructed on the use and maintenance of the CGM and 
advised to calibrate the sensor before eating and before bed with an iPro2 compatible 
glucometer (OneTouch® Ultra® 2). The Enlite™ sensor measured interstitial glucose 
level every 5 minutes within the 40-400 [3-147 mmol/mol] range. On the last day of the 
CGM wear week, participants were reminded to send the devices back using a pre-paid 
box/envelope. CGM data were downloaded with CareLink iPro® System and uploaded 
to the coordinating center for data processing. As part of blinding, no communication 
from the device was available to participants. 
 
5.2.3.2 Laboratory data 
 A central laboratory (Northwest Lipid Metabolism and Diabetes Research 
Laboratories, Seattle, WA, USA) provided oversight and conducted all assays. At all 
timepoints, HbA1c was measured in whole blood using an automated nonporous ion 
exchange HPLC system (model G-7; Tosoh Bioscience).  
 
5.2.3.3 Clinical Measures 
 Height was measured using a stadiometer, and weight was measured to the 
nearest 0.1 kg using an electronic scale. Body mass index (BMI, weight (kg) / height 
(m)2) was calculated and then converted to an age- and sex-specific and BMI z-score 
(BMIz) according to the Centers for Disease Control and Prevention growth charts. 
 
5.2.3.4 Questionnaires 
 Standardized questionnaires were used to collect self-reported data including 
race/ethnicity, highest level of parental education, duration of type 1 diabetes, insulin 
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delivery method (pump versus multiple daily injections (MDI)), and previous CGM use. 
Motivation and Intention were measured by a validated questionnaire adapted for 
relevance to type 1 diabetes self-management.294,295 The Social Problem Solving 
Inventory – Revised: Short (SPSI-R:S) was used to assess adolescents’ cognitive, 
affective, and behavioral abilities to resolve problems in everyday living.296 Diabetes 
adherence over the past 3 months was measured with the Diabetes Self-Management 
Profile – Self Report (DSMP-SR).297 Depressive symptoms were assessed using the 
Centers for Epidemiologic Study – Depression Scale (CES-D).298 Health-related quality 
of life was assessed with the Pediatric Quality of Life Inventory™ – Generic Core Scales 
(PedsQL™ Generic).299 Fear of hypoglycemia was assessed by the Hypoglycemia Fear 
Survey (HFS).300 Adolescent-reported diabetes-related family conflict was measured 
with the Diabetes Family Conflict Scale (DFCS).301 
 
5.2.4 Statistical analysis 
 
5.2.4.1 CGM Data Selection of Variables and Pre-processing 
 All CGM-variables were calculated for the 7-day wear time and were stratified by 
day (6:00 AM – 11:59 PM) and night (12:00 AM – 5:59 AM).144 First, a subset of eight 
CGM features recommended by the Advanced Technologies & Treatments for Diabetes 
(ATTD) Congress consensus statement as key metrics to assess glycemic control were 
selected for a total of sixteen variables (see Supplemental Material Section 5.6.1).144 
The variables were pruned to remove highly correlated variables, biological redundancy, 
and degrees of freedom (Supplemental Figure 5.1).302 The remaining eight CGM input 
metrics were selected to comprehensively characterize features of dysglycemia in the 
day and nighttime: area-over-curve (AOC) of hypoglycemia (level 1; 70 mg/dL [3.9 
 
 115 
mmol/L]), incidence of hypoglycemia (level 1; 70 mg/dL [3.9 mmol/L]) lasting 15 minutes 
or longer, area-under-curve (AUC) of hyperglycemia range (level 2; 250 mg/dL [13.9 
mmol/L]), and glycemic variability as coefficient of variation (CV) (Supplemental Table 
5.1). As per exclusion criteria, there were no missing CGM data. All variables were left 
continuous and standardized to be expressed on the same scale. To facilitate clinical 
interpretation, clusters were also characterized by percent of time spent in 
hypoglycemic (<70 mg/dL [3.9 mmol/L]) and hyperglycemic (250 mg/dL [13.9 mmol/L) 
ranges, using the same threshold as the AOC and AUC measures, and time in range 
(70-180 mg/dL [3.9-10 mmol/L]).  
 
5.2.4.2 Clustering Methods 
 The selection of SOM as a clustering algorithm and an in-depth methodological 
description are deferred to the Supplemental Material Section 5.6.2. Briefly, the SOM 
is a neural network290 that serves as a model-based clustering method.302,303 The a 
priori justification for selecting a neural network-based clustering approach was that it 
does not rely on strong assumptions about the underlying data such as the distributional 
assumption of multivariate normality or symmetry.291 For measures of hypoglycemia 
and hyperglycemia, some individuals never experienced time below or above the 
threshold, resulting in severely skewed distributions resistant to transformation. Finally, 
SOMs have strong visualization attributes to understanding complex, multivariate 
relationships and improve the validity of unsupervised learning.303 
 FLEX participants were mapped based on their eight CGM measures to a 5x5 
square grid SOM with a Gaussian neighborhood function using the Package 
‘SOMBrero’ in R version 3.4.2.304 The dimensions of the SOM were selected based on 
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the total sample size.302 1000 iterations (approximately 4.3 cycles through the full data) 
were run to ensure the shape of the grid stabilized. The SOM was randomly initialized 
and re-run 10 times on the full data to check for consistency in parameters and quality 
criteria (see Supplemental Table 5.2). The best out of 10 maps were selected based 
on the lowest quantization error, a measure of the average Euclidian distance between 
a participant’s CGM measures and the codebook vector of their assigned unit 
(Supplemental Material Section 5.6.3). A hierarchical clustering algorithm was applied 
to the codebook vectors of the final map units using the function superclass in the 
SOMbrero package.305 The NbClust package in R guided the selection of the final 
number of clusters, with minimum and maximum number of clusters set to one and ten, 
respectively.256 Clusters from the SOM were validated for internal validity, stability, and 
fidelity to the original data (Supplemental Material Section 5.6.4.)  
 
5.2.4.3 Baseline Characterization and Associations with Longitudinal Clinical Outcomes  
 The baseline correlates of each cluster were summarized using descriptive 
statistics. Overall-tests of difference were carried out using ANOVA and chi-squared 
tests or Kruskal-Wallis and Fisher’s exact tests, where appropriate. Pairwise 
comparisons were performed via unpaired t-tests or Dunn’s test. To discern the 
significance of Dysglycemia Clusters versus subgroups defined by HbA1c, FLEX 
participants were also stratified by baseline HbA1c: (≤ or >75 mmol/mol (8.0%)) and 
described in terms of their baseline characteristics. Significance differences across 
baseline HbA1c groups were tested using chi-squared tests and unpaired t-tests. 
 Mixed effect regression analysis was used to determine whether clusters showed 
differential changes in HbA1c over 18-months. A main effect was fit for visit and cluster 
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and a visit*cluster interaction term. Participants were treated as random effects. All 
models were adjusted for randomization status and site. Post-hoc comparisons by 
cluster were performed within each mixed model analysis and the effects were 
examined at each longitudinal timepoint in the FLEX study. Descriptive statistics and 
multilevel modeling (PROC MIXED) were conducted in SAS 9.4 (SAS Institute, Cary, 
NC).  
 
5.2.4.4 Additional Statistical Considerations 
 SOM has been used previously to cluster small datasets, outperforming k-means 
on data of similar dimensions to the FLEX data.306 P-values were evaluated at the 0.05 




 The final study sample included 234 adolescents with type 1 diabetes. 
Participants were 76.1% non-Hispanic white and 50.0% female with mean age 14.8±1.1 
years and mean diabetes duration was 6.4±3.7 years (Table 5.1). Mean HbA1c was 
9.6±1.2% (81±13 mmol/mol). Participants had blood glucose readings for a median of 
160.0 hours (IQR 24.8) or approximately 6.7 days.  
  Figure 5.1A visualizes the 5x5 SOM grid, where individuals with similar CGM 
measures are assigned to proximal map units. Further visualizations are available in 
Supplementary Figure 5.3. Three clusters were identified, capturing areas of the map 
that were similar to each other regarding the 8 CGM metrics (Figure 5.1B and 5.1C). 
All CGM metrics showed significantly different means and medians across clusters 
(p<0.001) (Table 5.2, Figure 5.1C). Cluster 1 comprised 141 individuals (60.3%) and 
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showed severe daytime hyperglycemia with low exposure to and incidence of 
hypoglycemia relative to other clusters. Cluster 1 also showed the lowest glycemic 
variability (mean (SD) daytime and nightime CV: 35.5% (6.4%) and 35.7% (10.7%), 
respectively). Cluster 2 comprised 53 indiviudals (22.7%) and showed severe 
hyperglycemia, particularly overnight, with moderate hypoglycemia (median (IQR) 
daytime episodes: 4 (3)) and moderate variablity. Cluster 3 comprised 40 individuals 
(17.1%) and showed moderate hyperglycemia with the highest measures of 
hypoglycemia exposure and incidence relative to the other clusters (median (IQR) 
daytime episodes: 8 (5.5)). This group also showed the highest glycemic variability in 
the daytime and overnight (mean daytime and nightime CV: 4..1% (7.0%) and 51.7% 
(12.9%), respectively).  
 Mean baseline HbA1c was highest in Cluster 1 (9.9±1.1% (85±14 mmol/mol)) 
and lowest in Cluster 3 (8.7%±0.8% (72±9 mmol/mol)). In pairwise comparisons, cluster 
3 showed significant differences from clusters 1 and 2 (p<0.001), but clusters 1 and 2 
did not show significant differences from each other (p=0.07). No other baseline 
characteristics were significantly different across clusters, including BMIz. For 
comparison, Table 5.1 also depicts the correlates of subgroups defined by baseline 
HbA1c. Compared to participants with HbA1c ≤9.0% (75 mmol/mol) at baseline, 
participants with a high HbA1c showed lower insulin pump use, greater insulin doses, a 
higher frequency of blood glucose monitoring, and lower motivation and adherence to 
diabetes self-management (all p<0.05).  
 HbA1c measures over 18-months were significantly different across clusters, 
adjusted for study site and randomization (p-for-interaction=0.006; Figure 5.2, 
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Supplemental Table 5.5). Dysglycemia Clusters 1 and 2 showed stable mean HbA1c, 
while Dysglycemia Cluster 3 showed significant increases over the 18-month study 
period (mean baseline HbA1c: 8.7% (71 mmol/mol); mean HbA1c at 18-month visit: 
9.6% (81 mmol/mol). There were no signifiant differences in mean HbA1c level at the 
18-month visit (p=0.71). CGM metrics at the 18-month visit for each cluster are depicted 
in Supplementary Table 5.6. 
 
5.4 Discussion  
 Using 7-day blinded CGM data from 234 adolescents with type 1 diabetes and 
elevated HbA1c, we identified three distinct, clinically-meaningful clusters sharing 
phenotypes defined by different exposure to and incidence of hypoglycemia, exposure 
to hyperglycemia, and glycemic variability. All eight CGM metrics were significantly 
different across clusters and can thus considered to be relevant for the clustering 
definition. Subgroups showed differences in baseline and longitudinal HbA1c but were 
not different not with respect to other baseline characteristics. These results reinforce 
the concept that adolescents with type 1 diabetes and elevated HbA1c do not show 
homogenous patterns in CGM-measures of blood glucose dynamics; this analytic 
approach can help refine understanding of dysglycemia patterns to better identify 
interventions. Interestingly, different patterns in dysglycemia are not explained by the 
individual sociodemographic, clinical, or psychosocial characteristics that typically drive 
treatment recommendations regarding HbA1c.  
 To our knowledge, there is limited data available for comparison because the 
majority of existing CGM data collected in comparable age ranges are from adolescents 
with lower HbA1c levels.143 Patterns in dysglycemia across clusters are consistent with 
 
 120 
other CGM studies suggesting that a positive association between glycemic variability 
and the risk for hypoglycemia.307  
 A previous cluster analysis using 3-days of data from self-monitoring blood 
glucose values provided evidence for distinct glycemic profiles among a small sample of 
adults with type 1 diabetes.308 Although all FLEX participants had elevated HbA1c as 
per inclusion criteria, we found similar evidence for the existence of subgroups typified 
by specific blood glucose dynamics. The striking differences in CGM measures suggest 
that these distinct ‘phenotypes’ are comprised of adolescents who struggle with different 
aspects of their blood glucose control. For example, individuals in Cluster 1 were 
typified by hyperglycemia with fewer episodes of hypoglycemia and less pronounced 
variability, especially overnight, while individuals in Cluster 3 experienced less 
hyperglycemia but a median of 8 episodes of hypoglycemia per week with severe 
variability in the daytime and nighttime (mean CV: 47% and 52%, respectively). 
Measures of variability in the latter group greatly exceeded the CV threshold of 36% that 
has previously been proposed to indicate ‘unstable’ glycemia and increased risk for 
hypoglycemia.307 
 In the analysis to identify potential patient-related drivers of the clusters, there 
were no significant differences in the sociodemographic, clinical, or psychosocial 
measures across Clusters. One possible reason for the lack of statistically significant 
correlates is the small sample size which may limit statistical power. We explored the 
clinical utility of a 2-cluster solution to detect differences but failed to identify significant 
correlates to distinguish the two subgroups (Supplemental Material Section 5.6.6).  
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 Another interpretation of the data is that a broad range of demographic, clinical, 
or psychosocial characteristics do not drive the specific blood glucose issues that may 
be challenging overall glycemic control among adolescents with type 1 diabetes and 
elevated HbA1c. It is particularly interesting that the risk factors of poor glycemic control 
as it is measured by HbA1c do not appear to be risk factors for poor glycemic control as 
it manifests as membership in a Dysglycemia Cluster. Within the FLEX sample, 
participants with a high baseline HbA1c showed lower insulin pump use, greater insulin 
doses, a higher frequency of blood glucose monitoring, and lower motivation and 
adherence to diabetes self-management; none of these associations emerged as 
correlates of Cluster membership. Other well-studied associations of suboptimal HbA1c 
measures in this age range were not replicated as differences across subgroups, 
including nonwhite race,3 lower measures of socioeconomic position,309 and poorer 
psychosocial well-being.309 More work is needed to understand the drivers of 
dysglycemia phenotypes, including significant behavioral mediators or patterns that can 
be addressed clinically such as omitted or ill-timed boluses regarding meal initiation.  
 There are several points of clinical relevance for the findings. Because the 
extraction of key clinical metrics from longitudinal CGM data emulates the process of 
patient care where these measures are used to identify specific issues,7 this study 
offers proof-of-principle for how CGM data may be consolidated and used to identify the 
subgroups of patients within a specific population of individuals with type 1 diabetes that 
are be recognizable to care providers as intuitive clinical phenotypes. With increasing 
availability of CGM data as well as documentation of treatment regime and other 
outcomes in electronic health records, this work may in the future offer an emerging 
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platform to pool data across one or more clinics to test how CGM clusters function as 
predictive or prescriptive phenotypes.  
 Outside of the clinic, the results may be used towards the development of 
effective interventions for this at-risk and challenging adolescent population.5,292 
Although main analysis of the FLEX intervention did not show improvements in HbA1c 
at 18-months,292 a three-way interaction term between cluster, FLEX intervention 
randomization assignment, and timepoint was tested in exploratory longitudinal 
analyses; it was not statistically significant. It is possible that approaches to diabetes 
management in the heterogenous adolescent population are maximally effective as a 
set of interventions tailored to specific issues of dysglycemia, which can then be 
targeted towards phenotypes that are expected to maximally benefit. For example, 
Cluster 3 was the only subgroup to show an increase in HbA1c over 18-months; this 
subgroup also had the highest hypoglycemia and variability at baseline and may 
represent a previously-proposed sequela of recurrent hypoglycemia and overcorrection 
that leads to worsened glycemic control over time.199 Therefore, this group may benefit 
from specific efforts addressing frequent hypoglycemia and its overcorrection early in 
adolescence. By contrast, interventions focused on increasing insulin doses may be 
salient for Cluster 1, who spends most of the time in hyperglycemic ranges with low 
variability, rendering hypoglycemia counseling less immediately relevant.  
 A further aspect of clinical significance is the presumed differential risk for acute 
and chronic diabetes complications across clusters. Aside from well-established risk 
associated with hyperglycemia,260 the high degree of glycemic variability noted in 
Clusters 2 and 3 may confer additional, independent risk for micro- and macrovascular 
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complications, including cardiovascular disease.93,289 Cluster 3’s pattern of 
hypoglycemia may contribute to the development of defective symptomatic responses, 
positioning these individuals at an increased risk for severe hypoglycemia.310 
 The analysis has several limitations. Self-organizing maps are difficult to validate. 
The SOM analysis was repeated to check for consistency, and resulting clusters were 
assessed for stability and validity against other clustering algorithms on the raw data. 
Clusters showed stability in cross-validation studies with preservation of patterns in 
dysglycemia (Supplemental Table 5.3, Supplemental Figure 5.4). The results may be 
affected by the selection of the CGM metrics used to train the SOM. We explored 
dysglycemia clustering derived from a set of 16- and 24- CGM metrics and found that 
the recommended number of clusters and clustering solutions were not significantly 
impacted by additional CGM metrics, although the projection quality of the SOM was 
reduced (Supplemental Table 5.4). In addition, the SOM clusters were compared to 
clusters derived directly from the data.303 Although the assumptions of the hierarchical 
clustering algorithm are not met using the input data, we found similar clusters with both 
algorithms (Supplemental Figure 5.5, Supplemental Figure 5.6). Together, the results 
suggest that the SOM clusters demonstrate internal validity, stability, and accurately 
represented clustering structure present in the raw data. 
 Additional limitations include availability of CGM data spanning 7 days versus the 
14 days recommended for optimal data analysis.144 The small sample size may be 
underpowered to detect differences between clusters. The inclusion and exclusion 
criteria of the FLEX trial limit generalizability, particularly for adolescents with lower 
HbA1c levels. In the present analysis, we constrained CGM metrics to be consistent 
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with standardized practices of CGM reporting.144 However, additional measures of 
glycemic variability such as mean amplitude of glycemic excursion (MAGE) and mean 
of daily differences (MODD) might help to further delineate subgroups. Future work may 
also explore how deep learning can be used to extract hidden layers of the CGM data 
and explore clusters based on those hidden layers.311  
 Despite the aforementioned limitations, here, we elucidated dysglycemia 
phenotypes among a sample of adolescents with type 1 diabetes and suboptimal 
glycemic control, a population with great need for future interventions in which CGM 
data has only recently become available to help.5,292 CGM metrics were selected to be 
consistent with best research practices,144 and a clustering algorithm was selected to 
leverage information from the tails of the distribution to understand underlying cluster 
structure in the data.291 The analytic approach is distinct from but compliments ongoing 
work to model CGM data via temporal analysis regarding the shape of the 
curve/aspects of glycemic variability,312,313 and it may be applied to CGM data from 
variable durations of wear-time. In full, the study represents a novel use of CGM data 
towards broadening the concept of glycemic control from HbA1c to understanding a 
multifaceted profile that includes glycemic excursions and overall variability. 
Understanding of these subgroups is crucial to pave the way for targeted interventions 
to optimize dysglycemia and the associated clinical outcomes in type 1 diabetes. 
 
5.5 Conclusions 
 Among adolescents with type 1 diabetes and elevated HbA1c, CGM data may be 
pooled and analyzed to uncover subgroups displaying distinct dysglycemia phenotypes, 
for which glycemic control is challenged by different patterns in hypoglycemia, 
 
 125 
hyperglycemia, and glycemic variability. More work is needed to understand the risk 
factors for glycemic control as it is represented from CGM data by dysglycemia 
phenotypes for future development of phenotype-specific interventions to improve 








Table 5.1. Baseline Characteristics of FLEX Participants Overall and by Dysglycemia Cluster and Baseline HbA1c 
Subgroup 
 Dysglycemia Cluster Baseline HbA1c Subgroup 
Baseline 
characteristics, n 
(%) or mean (SD) 









p-value  Baseline 














        
Age (years) 14.8 (1.1) 14.8 (1.1) 14.9 (1.2) 15.0 (1.2) 0.60 14.7 (1.1) 14.9 (1.1) 0.09 
Female sex  117 (50.0) 68 (48.2) 30 (56.6) 19 (47.5) 0.55 42 (52.9) 75 (48.1) 0.41 
Non-Hispanic 
White† 
178 (76.1) 104 (73.8) 42 (79.3) 32 (80.0) 0.59 62 (79.5) 116 (74.4) 0.38 
Parental Education         0.16   0.27 
Graduate degree 43 (18.5) 22 (15.8) 10 (18.9) 11 (27.5)   17 (22.1) 26 (16.8)  
College Degree  67 (20.9) 54 (38.9) 21 (39.6) 21 (52.5)   36 (46.8) 60 (38.7)  
Some College 67 (28.9) 44 (31.7) 17 (32.1) 6 (15.0)   18 (23.4) 49 (31.6)  
High School or less 26 (11.2) 19 (13.7) 5 (9.4) 2 (5.0)   6 (7.8) 20 (12.9)  
Private Health 
Insurance 
164 (70.1) 105 (74.5) 35 (66.0) 24 (60.0) 0.16 54 (69.2) 110 (70.5) 0.84 
Single adult home 30 (13.1) 17 (12.4) 8 (15.1) 5 (12.8) 0.88 11 (14.3) 19 (12.5) 0.71 
Clinical 
Characteristics  
        
Duration of diabetes 
(years) 
6.4 (3.7) 6.5 (3.8) 6.4 (3.5) 6.3 (3.8) 0.96 5.8 (3.7) 6.7 (3.7) 0.09 
HbA1c (mmol/mol) 81 (5) 85 (14) 81 (11) 72 (9) <0.001* 68 (6) 89 (11) <0.001* 
HbA1c (%) 9.6 (1.2) 9.9 (1.3) 9.6 (1.0)** 8.7 (0.8)** <0.001* 8.4 (0.5) 10.3 (1.0) <0.001* 
HbA1c above 9.0% 
[75 mmol/mol] 
156 (66.7) 104 (73.8) 38 
(71.7)** 
14 (35.0)** <0.001* 0 (0.0) 156 (100.0) <0.001* 







      Multiple daily 
injection 
68 (29.2) 38 (27.1) 18 (34.0) 12 (30.0)  15 (19.2) 53 (34.2)  
      Pump 165 (70.8) 102 (72.9) 35 (66.0) 28 (70.0)  63 (80.8) 102 (65.8)  
Insulin Dose, total 
(units/kg) 













blood glucose, daily 
2.2 (0.8) 2.1 (0.8) 2.3 (0.9) 2.1 (0.7) 0.47 1.9 (0.67) 2.3 (0.9) 0.004* 
BMI z-score 0.71 (0.91) 0.70 (0.92) 0.78 
(0.88) 
0.71 (0.95) 0.86 0.69 (0.96) 0.73 (0.89) 0.76 
Weight Status      0.94   0.87 
     Under- or normal 
weight 
143 (61.1) 88 (62.4) 30 (56.6) 25 (62.5)  47 (60.3) 96 (61.5)  
     Overweight 56 (23.9) 32 (22.7) 14 (26.4) 10 (25.0)  18 (23.1) 38 (24.4)  
     Obese 35 (15.0) 21 (14.9) 9 (17.0) 5 (12.5)  13 (16.7) 22 (14.1)  
Psychosocial 
Characteristics 
        
Motivation‡  7.6 (1.6) 7.7 (1.4) 7.7 (1.7) 7.5 (1.8) 0.76 7.9 (1.7) 7.5 (1.5) 0.03* 
Intention‡ 9.1 (1.0) 9.2 (0.9) 8.9 (1.1) 8.9 (1.1) 0.22 9.1 (1.1) 9.1 (1.0) 0.96 
















55.2 (11.6) 55.5 (11.9) 53.3 (9.7) 56.7 (12.8) 0.33 59.1 (11.0) 53.2 (11.5) 0.003* 
Depression 
symptoms¶  
9.1 (8.4) 8.6 (7.6) 9.8 (10.0) 10.1 (8.7) 0.47 9.5 (9.2) 8.9 (7.9) 0.65 
Quality of life# 81.0 (12.4) 81.7 (12.0) 79 (12.7) 80.6 (13.3) 0.50 81.1 (13.8) 80.9 (11.6) 0.90 
Fear of 
hypoglycemia††  
        
Maintain High BG 1.2 (0.9) 1.2 (0.9) 1.2 (0.8) 1.2 (0.8) 0.99 1.1 (0.8) 1.2 (0.9) 0.70 










1.1 (0.7) 1.1 (0.8) 1.1 (0.7) 1.1 (0.6) 0.93 1.0 (0.7) 1.41 (0.7) 0.45 
Diabetes Family 
Conflict‡‡ 
1.4 (0.3) 1.4 (0.4) 1.2 (0.3) 1.4 (0.3) 0.57 1.3 (0.3) 1.4 (0.3) 0.14 
Abbreviations: SD – standard deviation. CGM – continuous glucose monitoring. HbA1c – hemoglobin A1c. BMI z-score 
– body mass index z-score.  
For dyslgycemia clusters, p-values are from Chi squared or fisher exact test for categorical variables, and ANOVA or 
Kruskal-Wallis Test for continuous variables. For baseline HbA1c, p-values are from unpaired t-tests. *Denotes 
significance test of overall difference (p<0.05). **Denotes significant difference in unpaired, pairwise t-tests (p<0.05), 
compared to Dysglycemia Cluster 1.  
† Non-Hispanic white race/ethnicity versus non-Hispanic Black, Black, and other including Asian/Pacific Islander, Native 
American, or unknown. 
‡ Motivation and Intention were measured by a validated questionnaire adapted for relevance to type 1 diabetes self-
management. 
§ The Social Problem Solving Inventory – Revised: Short (SPSI-R:S); higher score indicates higher ability to resolve 
problems in everyday living. 
|| Diabetes Self-Management Profile – Self Report (DSMP-SR); higher score indicates higher adherence. 
¶ Centers for Epidemiologic Study – Depression Scale (CES-D); higher score indicates increased depressive 
symptoms. 
# Pediatric Quality of Life Inventory™ – Generic Core Scales; higher score indicates higher quality of life 
†† Hypoglycemia Fear Survey (HFS); fear of hypoglycemia measured in three domains: behaviors used to keep blood 
glucose high to prevent hypoglycemia (Maintain High BG), worry about helplessness (Worry/Helplessness), and worry 
about social consequences associated with hypoglycemia (Worry/Social Consequences); higher scores indicate greater 
fear.  




Table 5.2. Input CGM Metrics at Baseline, Overall and by Dysglycemia Cluster 
Measured Over 7 Days 
 Dysglycemia Cluster 
CGM Metrics, mean (SD), 




































Percent of time below 3.9 











Percent of time below 3.9 












Episodes<3.9 mmol/L (70 
mg/dL) for 15+ minutes, 
Day† 
2 (5) 1 (2) 4 (3)** 8 (5.5)** <0.0001* 
Episodes<3.9 mmol/L (70 
mg/dL) for 15+ minutes, 
Night† 
1 (2) 0 (1) 2 (2)** 3 (2.5)** <0.0001* 
Hyperglycemia Exposure 






















Percent of time above 13.9 










Percent of time above 13.9 


































Time in Rangea 
Percent of time 3.9-10 











Percent of time 3.9-10 













Abbreviations: SD- standard deviation. IQR- Interquartile range. AOC – area over the 
curve. AUC - area under the curve.  
*Denotes significance test of overall difference from ANOVA or Kruskal-Wallis test 
(p<0.05). **Denotes significant difference in unpaired, pairwise t-test or Dunn’s test 
(p<0.05), compared to Dysglycemia Cluster 1. 
†Data were right-skewed and are reported as median (interquartile range). P-value 
from Kruskal-Wallis test. There were no missing data.  
‡To aid in clinical interpretation of hypoglycemia and hyperglycemia exposure, the 
percent of time is provided to address the same threshold as the area-over-the-curve 
and area-under-the-curve measures. For additional clinical context, time in range is 





Figure 5.1. Use of a self-organizing map (SOM) trained by 7-day continuous 
glucose monitoring (CGM) data to identify dysglycemia clusters at baseline of the 
FLEX trial (n=234). The clustering is carried out using a two-level approach, where the 
dataset is first clustered onto the units SOM and then the units SOM is clustered. A 5x5 
SOM with 25 map units and a 3-cluster solution were selected. All CGM-variables were 
calculated for the 7-day wear time and were stratified by day (6:00 AM – 11:59 PM) and 
night (12:00 AM – 5:59 AM). Panel A: Radar plots showing the integrated CGM profile 
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of each of the 25 units on the 5x5 SOM, as determined by the individuals assigned to 
that region. Each input CGM variable is represented by a different color in the radar. 
Input CGM variables were defined as follows: Hypoglycemia Exposure: area-over-the-
curve of 70 mg/dL [3.9 mmol/L], Hypoglycemia Incidence: average number of 
hypoglycemic (<70 mg/dL [3.9 mmol/L]) episodes lasting 15 or more minutes, 
Hyperglycemia Exposure: area-under-the-curve of 250 mg/dL [13.9 mmol/L], and 
Glycemic Variability: % coefficient of variation. Abbreviations: CV – coefficient of 
variation. Panel B: The SOM colored by Dysglycemia Cluster assignments. Each unit 
was assigned to a Dyslgycemia Cluster. Dysglycemia Cluster assignments (Cluster 1, 
Cluster 2, and Cluster 3) are shown by colored boxes. Panel C: CGM measures of 
hypoglycemia, hyperglycemia, and glycemic variability across the 3 Dysglycemia 
Clusters. To aid in clinical interpretation of hypoglycemia and hyperglycemia exposure, 
the percent of time are depicted in place of the area-over-the-curve and area-under-the-
curve measures that were used to construct the SOM. Data represents 7-days of 
blinded CGM wear. All p<0.001. Hypoglycemia Exposure is depicted as percent of time 
<70 mg/dL [3.9 mmol/L]. Hypoglycemia Incidence is depicted as average number of 
hypoglycemic (<70 mg/dL [3.9 mmol/L]) episodes lasting 15 or more minutes. 
Hyperglycemia Exposure is depicted as percent of time >250 mg/dL [13.9 mmol/L]. 
Glycemic Variability is depicted as % coefficient of variation. Abbreviations: CV – 








Figure 5.2. Longitudinal hemoglobin A1c (HbA1c) outcomes of FLEX participants 
by dysglycemia cluster, adjusted for FLEX study site and randomization 
assignment (p-for-interaction=0.006). The p-for-interaction represents Type 3 Test of 
Fixed Effects for timepoint x cluster interaction term. Missing data— Baseline: n=0; 3-
month HbA1c: n= 10; 6-month HbA1c: n= 14; 12-month HbA1c: n=20; 18-month HbA1c: 













5.6 Supplemental Material  
 
5.6.1 Pruning of CGM data for cluster analysis: selection of variables  
All CGM-variables were calculated for the 7-day wear time and were stratified by 
day (6:00 AM – 11:59 PM) and night (12:00 AM – 5:59 AM).144 These included median 
glucose, area-under-curve (AUC) of level 1 hyperglycemic range (10.0 mmol/L (180 
mg/dL), AUC of level 2 hyperglycemic range (> 13.9 mmol/L (250 mg/dL)), area the over 
curve (AOC) of level 1 hypoglycemic range (<3.9 mmol/L, 70 mg/dL), AOC of level 2 
hypoglycemic range (<3.0 mmol/L (54 mg/dL)), incidence of level 1 hypoglycemia 
lasting 15 minutes or longer over, incidence of level 2 hypoglycemia lasting 15 minutes 
or longer, and glycemic variability was reported as coefficient of variation (CV). Cut-
points for glucose used to describe hypoglycemia were established according to 
recommended values,144,314 CV represents the standard deviation corrected for the 
mean and was chosen as a primary measure of glycemic variability because the 
magnitude of glycemic variability is highly correlated with the level of the mean.144 AOC 
and AUC was used in the place of duration of time for measures of hypo- and 
hyperglycemia as this measure integrates the severity of a high or low glucose along 
with the duration of the abnormality.144 Time-in-range (i.e. percentage of time between 
70 mg/dL and 180 mg/dL) was not included due to overlap in information with the 
selected AOC and AUC variables. 
Data were then examined to remove highly correlated variables, biological 
redundancy, and degrees of freedom in the variables used to construct the SOM 
(Supplemental Figure 5.1).302 First, a subset of eight CGM features recommended by 
the Advanced Technologies & Treatments for Diabetes (ATTD) Congress as key 
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metrics to assess glycemic control, reported by day and night, were selected for a total 
of sixteen variables.144 Examination of correlation matrices indicated that CGM median, 
AUC of level 1 hyperglycemia, and AUC of level 2 hyperglycemia were highly correlated 
(r>0.90, p<0.001). AUC of level 2 hyperglycemia (13.9 mmol/L, 250 mg/dL) was 
retained to assess hyperglycemia in the day and nighttime. AOC of level 1 and level 2 
hypoglycemia were highly correlated (r>0.90, p<0.001). AOC of level 1 hypoglycemia 
(3.9 mmol/mol, 70 mg/dL) was retained to more broadly capture hypoglycemia. Finally, 
the daytime incidence of level 2 hypoglycemia was correlated with both the daytime 
incidence of level 1 hypoglycemia (r=0.81, p<0.001) and daytime AOC level 1 
hypoglycemia (r=0.83, p<0.001) and was dropped. This left eight variables in the final 
analysis intended comprehensively characterize features of dysglycemia including 
hypoglycemia, hyperglycemia, and glycemic variability. The final CGM input variables 















Supplemental Table 5.1. 8 Continuous Glucose Monitoring (CGM) Metrics for SOM 
Analysis, Selected to Capture Glucose Exposure, Hyperglycemia, Hypoglycemia, 






Area above curve 3.9 mmol/L (70 mg/dL), day 
Area above curve 3.9 mmol/L (70 mg/dL), night 
Hypoglycemia 
Incidence 
Number of 15 min or longer periods with glucose <3.9 mmol/L (70 
mg/dL) 




Area under curve 13.9 mmol/L (250 mg/dL), day 
Area under curve 13.9 mmol/L (250 mg/dL), night 
Glycemic 
Variability 
Coefficient of variability, day  
Coefficient of variability, night 























Supplemental Figure 5.1. Flow chart for selection of the final eight Input CGM 
Metrics used to train the SOM. A: Full sixteen CGM metrics selected to capture 
glucose exposure, hyperglycemia, hypoglycemia, and glycemic variability, in the day 
and nighttime. B: Pruned CGM metrics for SOM analysis. Data were pre-processed to 
remove highly correlated variables, biological redundancy, and degrees of freedom in 
the variables used to construct the SOM. 
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5.6.2 Selection of the clustering algorithm 
 
5.6.2.1 Explanation of the Self-Organizing Map (SOM) algorithm 
SOMs are a neural network approach that serves as a model-based static 
clustering method.290,315 The SOM is particularly useful for clustering high dimensional 
data. SOMs may be used to identify clusters via a 2-step clustering approach. After the 
map units of the SOM have adapted to the topological shape of the dataset, each map 
unit reflects a cluster. The SOM map units can then be to identify larger clusters, with 
the benefit of noise reduction compared to the raw data (Supplemental Figure 5.2, 
adapted).316 
 The main function of the SOM is to map the CGM input data from an 8-
dimensional space to a two-dimensional space while maintaining the original 
relationships as the topological structure of the map.290,291 The size of the SOM and 
number of map units is pre-specified by the researcher. Each unit contains an ‘8-
dimensional’ codebook vector; each dimension corresponds to one of the eight CGM 
metrics available for each participant. The SOM network learns the shape of a dataset 
by repeatedly adjusting the codebook vectors to move its map units closer to the data 
points.290 At first, each of the units are randomly positioned. Individual data points are 
then randomly fed into the algorithm. Each new data point funds the closest map unit, 
which is called the Best Matching Unit (BMU). By adjusting the codebook vectors, the 
BMU moves closer to the new data point. The learning rate, which measures the 
distance that the BMU moves with each new data point, decreases with each iteration 
and eventually stabilizes at a minimum value. The BMU’s neighbors within a given 
radius move closer to the new data point as well; the value for the radius decreases 
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after each iteration. After the map has been trained, the map units coalesce around 
areas with high density of data points and thus reflect the overall topological shape of 
the data.303 The SOM captures similarities between participants in the arrangement of 
the final map units such that individuals that are near each other in the input space (i.e. 
have similar CGM measures) are mapped to nearby units in the SOM, while those with 
dissimilar measures are mapped to more distant units.290 Through multiple iterations, 
the units of the SOM will coalesce around areas with high density of data points and can 
be regarded as mini-clusters.303 The SOM can serve as a clustering technique when 




Supplemental Figure 5.2. 2-step clustering using SOM. The clustering is carried out 
using a two-level approach, where the dataset is first clustered using the SOM and then 
the SOM is clustered. 
 
5.6.2.2 SOMs for dimension reduction and clustering of non-normally distributed or non-
symmetrical data 
 
Briefly, examination of individual variable distributions revealed that several of 
the raw data were not normally distributed with severe right-skew and clumping at zero, 
including measures of hypoglycemia and hyperglycemia for which some individuals 
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never experienced time below or above the threshold. The resulting data is not 
appropriate for clustering algorithms that invoke assumptions the normality or the 
symmetry of the data, including k-means and hierarchical approaches. Since the 
information contained in the skew was considered central to the understanding the 
distinct subgroups of youth who may experience different aspects of dysglycemia, 
categorization was not an appropriate option.  
The SOM is an unsupervised, machine learning technique that is robust to 
different distributions of data when uncovering underlying clusters. Compared to other 
unsupervised machine learning methods, SOM is appropriate non-linear data reduction 
(unlike principle components analysis) and robust to skewed input data (unlike k-means 
or hierarchical clustering algorithms), with the benefit that it controls dimension 
reduction and grouping at the same time.291 SOM clustering solutions have been shown 
to provide more accurate recovery of underlying cluster structure in the context of 
skewed input data.291 The ability of the SOM to accommodate skewed input data and 
capture information in the tails of the distribution was considered critical to 
understanding the range of dysglycemia in the sample. 
 
5.6.2.3 SOMs for visualization of data 
In addition, the SOM allows for the visualization of complex multivariate 
relationships represented by the high-dimensional input space.303,315 The prominent 
visualization capacities may be used to first examine the multivariate relationships 
represented in the high-dimensional input space prior to clustering.303,315 This step helps 
to ensure that the resulting clusters are valid regarding each of the input metrics.316 This 
was considered a key strength of the method in the context of the present analysis, 
 
 141 
where there were data labels to guide the formation of clusters but reasonable 
assumptions about how the CGM metrics may be co-distributed across the study 
sample.  
 
5.6.3 Selection of final map  
A symmetrical 5x5 square grid SOM was selected based on the sample size and 
checked that it was optimized to prevent empty cells, at least 5-10 observations per 
cell.302 Based on observed stability of the map across testing and training partitions. The 
final map was run on the full dataset to maximize statistical power. The SOM was 
created and re-run 10 times on the full data to check for consistency in parameters 
(neighborhood size, topographic error, quantization error (Supplemental Table 5.2). 
For every SOM instance, we shuffled the training set, randomly initializing the map from 
the training set, and incrementally trained a SOM with map size of 5x5 using 1000 
iterations (~4.3 times through the data). Each SOM map that was trained interpedently 
on the same input data, but from different random initializations. The best out of 10 
maps were selected (based on the lowest quantization error, defined as the average 
Euclidian distance of all segments to the prototype vector of their assigned unit. The 
quantization error calculates the mean squared Euclidean distance between the sample 
vectors and their respective cluster prototypes. It is a decreasing function of the size of 
the map.305 The quantization error is an unbounded positive number. The closer it is 
from 0, the better the projection quality. The topographic error, or vector projection, is 
the simplest measure of topology preservation. It calculates the ratio of sample vectors 
of which the second BMU is not in the direct neighborhood of the best matching unit.305 
The topographic error value varies between 0 (good projection quality) and 1 (poor 
 
 142 
projection quality). There is a tradeoff between measures, as increasing projection 
quality decreases the projection properties.305 The quantization error of the final map 
4.7 and the topographic error was 0.0, suggesting that all observations have a second-
best unit which is in the neighborhood of the best matching unit.  
 
Supplemental Table 5.2. Topographic Error and Quantization Error for the Chosen 
Ap and Average Over 10 Trained Maps 
 Topographic Error Quantization Error 
Chosen Map 0.004 4.117 
Average (10 Maps) 0.003 ± 0.003 0.118 
Quantization error is defined as the average Euclidian distance of all segments to the 
prototype vector of their assigned unit; decreasing values indicate higher map quality.  
Topographic error is a measure of topology preservation measure defined as the ratio 
of sample vectors for which the second-best matching unit is not in the direct 
neighborhood of the best matching unit. 
 
 
 Supplemental Figure 5.3 depicts the final map. Supplemental Figure 5.3A 
visualizes the 5x5 SOM grid and the relative frequency of individuals assigned to 
resulting 25 map units. Individuals with similar CGM measures are assigned to proximal 
map units (Supplemental Figure 3B). Measures of hypoglycemia exposure and 
incidence were highest in the upper right corner of the map, while measures of 
hyperglycemic exposure were greatest along the bottom left side of the map 
(Supplemental Figure 5.3C). Daytime and overnight measures of each CGM metric 






Supplemental Figure 5.3. The self-organizing map (SOM) trained by 7-day 
continuous glucose monitoring (CGM) data from the baseline of the FLEX trial 
(n=234). A 5x5 SOM with 25 map units was constructed. All CGM-variables were 
calculated for the 7-day wear time and were stratified by day (6:00 AM – 11:59 PM) and 
night (12:00 AM – 5:59 AM). Panel A: Frequency map of showing the relative proportion 
of individuals assigned to each unit on the SOM. Each unit is represented by a colored 
square with a region corresponding to the relative number of data points it represents 
(bottom). The larger the colored square, the more datapoints are represented by that 
unit. Panel B: The SOM colored to represent the average distance between neighboring 
units, integrating distance between all eight CGM metrics. The map is colored by 
distance between 8 input CGM metrics at each of the 25 units. Units representing 
similar datapoints are separated by shorter distances and are shown in blue, while units 
corresponding to vastly different sets of data points are separated by larger distance 
and are denoted by a pink color. Panel C: Colors of eight CGM-input metrics on the 
SOM. The map in Figure 5.1A can be re-printed for each input variability colored 
according to the characteristics of the participants assigned to each of the 25 units of 
the map. The patients that are located on a given unit determine the color for the 
respective area of the SOM. The color scale indicates the mean of each variable, where 
high values are represented by red and low values are represented by light yellow. 
Each of the 8 maps is colored for a single CGM metric.  
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5.6.4 Validation studies  
Clusters from the SOM were validated for internal validity, stability, and fidelity to 
the original data. Each validation study is outline below.  
 
5.6.4.1 Internal Validation 
We performed 5-fold cross-validation to assess stability of the clusters derived 
from the SOM. The full dataset was segmented into 5 random partitions and the effect 
of leaving out 1 partition of data was analyzed by retraining SOMs on the remaining 4 
partitions. The Rand Index and Adjusted Rand Index was used to assess the overlap 
between ‘trained’ clusters, derived from the test data on the trained map, and ‘test’ 
clusters, derived directly from a SOM in the testing data.317 The Adjusted Rand Index 
accounts for the number of clusters ranges from 0 to 1 and provides a measure of how 
"similar" the units within a cluster grouping are, where 1 would indicate that all of the 
stores in each given cluster assignment are similar, negative numbers of close to 0 
suggest poor agreement and 1 is the maximum that reflects identical clustering.318 
The mean Adjusted Rand Index of the 5-fold cross-validation study was 0.56 ± 
0.16, suggesting acceptable stability of clusters derived from each training 
iteration.258,317,319  
To further explore the stability of clusters from the SOM, the ARI calculated from 
a 3-6-fold cross validation, although sample size is limited for larger partitions of data. 
The results are shown in Supplemental Table 5.3. The Adjusted Rand Index was 
sustained as the size of the testing set decreased, suggesting stability across varying 
sizes of testing and training data partitions.  
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Supplemental Table 5.3. Cross-Validation Results from Various Data Partitions 
(full sample size, n=234) 
Cross-Validation n of testing set Adjusted Rand Index, mean 
(SD) 
3-Fold 75 0.54 (0.12) 
4-Fold 63 0.59 (0.19) 
5-Fold 46 0.56 (0.15) 
6-Fold 41 0.54 (0.25) 
 
 
The distribution of each of the eight input CGM metrics were examined across 
the trained and test clusters (shown in Supplemental Figure 5.4). This data suggested 
that the relative meaning of each cluster was preserved between iterations with respect 




Supplemental Figure 5.4. Distribution of each of the 8 CGM metrics across trained 
and test clusters 
 
 
5.6.4.2 Clustering Stability 
Dysglycemia Clusters derived from the eight input CGM metrics were compared 
to Dysglycemia Clusters derived from a SOM trained with a larger amount of metrics, 
including input datasets of 16 and 24 total CGM metrics. All metrics were selected to be 
















































































































































































































































































































































































Dyslycemia Clusters from each SOM were compared for evidence of stability across a 
larger subset of CGM input variables (Supplemental Table 5.4). 
The Adjusted Rand Index for each clustering solutions derived from the 
additional CGM metrics were approximately 0.4, suggesting sufficiently stability across 
larger input datasets. An examination of the distribution of the 8-input CGM variables 
consistent across all maps revealed nearly identical patterning of variables across 
Dysglycemia Clusters, suggesting that addition CGM metrics did not contribute 
variability to disrupt the clustering solution. In addition, the SOM trained on larger input 
datasets showed significantly higher quantization error, suggesting low projection 
quality of the resulting SOM.320  
 
Supplemental Table 5.4. Clusters Derived from 8, 16, and 32 CGM Metrics 





Adjusted Rand Index,* 
mean (SD) 
Quantization Error,* mean 
(SD) 
8† 3 N/A 4.46 (0.17) 
16‡ 3 0.43 (0.05) 9.08 (0.21) 
24§ 3 0.38 (0.12) 15.16 (0.22) 
Abbreviations: CGM – continuous glucose monitoring. SD – deviation. 
*represents the mean of 10 random, iterative SOM trained on the same data 
†8 CGM input metrics included: Area above curve (AOC) <3.9 mmol/L (70 mg/dL), 
day; AOC 3.9 mmol/L (70 mg/dL), night; Number of 15 min or longer periods with 
glucose <3.9 mmol/L (70 mg/dL), average per day; Number of 15 min or longer 
periods with glucose <3.9 mmol/L (70 mg/dL), average per night; Area under curve 
(AUC) 13.9 mmol/L (250 mg/dL), day; AUC 13.9 mmol/L (250 mg/dL), night; 
Coefficient of variability, day; Coefficient of variability, night. 
‡16 CGM input metrics included: AOC <3.9 mmol/L (70 mg/dL), day; AOC 3.9 mmol/L 
(70 mg/dL), night; AOC 3.0 mmol/L (54 mg/dL), day; AOC 3.0 mmol/L (54 mg/dL), 
night; Number of 15 min or longer periods with glucose <3.9 mmol/L (70 mg/dL), 
average per day; Number of 15 min or longer periods with glucose <3.9 mmol/L (70 
mg/dL), average per night; Number of 15 min or longer periods with glucose <3.0 
mmol/L (54 mg/dL), average per day; Number of 15 min or longer periods with 
glucose <3.0 mmol/L (54 mg/dL), average per night; AUC 10 mmol/L (180 mg/dL), 
day; AUC 10.0 mmol/L (180 mg/dL), night; AUC 13.9 mmol/L (250 mg/dL), day; AUC 
13.9 mmol/L (250 mg/dL), night; Coefficient of variability, day; Coefficient of variability, 
night; Median glucose, day; Median glucose, night. 
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§24 CGM input metrics included: AOC <3.9 mmol/L (70 mg/dL), day; AOC 3.9 mmol/L 
(70 mg/dL), night; AOC 3.0 mmol/L (54 mg/dL), day; AOC 3.0 mmol/L (54 mg/dL), 
night; Number of 15 min or longer periods with glucose <3.9 mmol/L (70 mg/dL), 
average per day; Number of 15 min or longer periods with glucose <3.9 mmol/L (70 
mg/dL), average per night; Number of 15 min or longer periods with glucose <3.0 
mmol/L (54 mg/dL), average per day; Number of 15 min or longer periods with 
glucose <3.0 mmol/L (54 mg/dL), average per night; AUC 10 mmol/L (180 mg/dL), 
day; AUC 10.0 mmol/L (180 mg/dL), night; AUC 13.9 mmol/L (250 mg/dL), day; AUC 
13.9 mmol/L (250 mg/dL), night; AUC 16.6 mmol/L (300 mg/dL), day; AUC 16.6 
mmol/L (300 mg/dL), night; Coefficient of variability, day; Coefficient of variability, 
night; Standard deviation, day; Standard deviation, day; Mean rate of glucose change, 
day; Mean rate or glucose change, Night; Median glucose, day; Median glucose, 
night; Percentage of time in range 3.9-10 mmol/L (70-180 mg/dL), day; Percentage of 
time in range 3.9-10 mmol/L (70-180 mg/dL), night. 
 
 
5.6.4.3 Fidelity to the Original Data  
The SOM approach to clustering is only valid if the clusters found using the SOM 
are similar to those of the original data.321 Therefore, the SOM clusters were compared 
to clusters derived directly from the data to ensure that the SOM clusters accurately 
represented clustering structure present in the raw data.303 
A hierarchical clustering algorithm was applied to the 8 CGM metrics as raw 
variables in the full dataset. All CGM Metrics were standardized to be unit-free. A 
hierarchical clustering algorithm with Ward’s D2 method and a Euclidean distance was 
used. The number of clusters was selected to be 3 to facilitate comparison with the 
SOM clusters. Three clusters were produced, with n of 117, 60, and 57, respectively. 






Supplemental Figure 5.5. Dendrograms produced by agglomerative hierarchical 
clustering algorithms, using the raw data (panel A) and the SOM (panel B). Three 
clusters were specified for both algorithms. 
 
 
Hierarchical clustering solution was compared to the SOM clustering solution, 
using the full dataset. The mean ARI for 10 iterations of the SOM was 0.3±0.1.In 
addition, the distribution of each input CGM metric was visually inspected, using the 
final SOM presented in the main results (Supplemental Figure 5.6).  
Although the assumptions of hierarchical clustering algorithm are not met using 
the input data, we found similar clusters with both algorithms. Together, the results 
suggest that the SOM clusters are consistent with clusters derived from the original 
data. This result is consistent with previous studies showing clustering results using 






Supplemental Figure 5.6. Distribution of 8 CGM metrics across clustering solution 




5.6.5 Further characterization of longitudinal outcomes 
 
5.6.5.1 Characterization of 18-mo changes in HbA1c 
Mixed effect regression analysis was used to determine whether clusters showed 
differential changes in HbA1c over 18-months. A main effect was fit for visit and cluster 
and a visit*cluster interaction term. Participants were treated as random effects. All 
models were adjusted for randomization status and site. Post-hoc comparisons by 
























































































































































































































































































































































































examined at each longitudinal timepoint in the FLEX study. These data are visualized in 
Figure 5.2. 
 
Supplemental Table 5.5. Longitudinal Hemoglobin A1c (HbA1c) Outcomes of 








































Baseline, % and 
mmol/mol 
9.8 (0.9) 9.5 (1.0) 8.7 (0.5)  
84 (10) 80 (11) 71 (6)  
3-month, % and 
mmol/mol 
9.7 (0.9) 9.6 (1.0) 9.1(0.5)  
82 (10) 81 (11) 75 (6)  
6-month, % and 
mmol/mol 
9.8 (0.9) 9.6 (1.0) 9.2 (0.5)  
83 (10) 81 (11) 77 (6)  
12-month, % and 
mmol/mol 
9.6 (0.9) 9.7 (1.0) 9.4 (0.5)  
82 (10) 83 (11) 80 (6)  
18-month, % and 
mmol/mol 
9.8 (0.5) 9.5 (0.6) 9.6 (0.3)  
84 (6) 80 (7) 81 (3)  
Abbreviations: HbA1c- hemoglobin A1c. SE – standard error.  
All estimates are adjusted for FLEX study site and randomization assignment. Missing 
data— Baseline: n=0; 3-month HbA1c: n= 10; 6-month HbA1c: n= 14; 12-month 
HbA1c: n=20; 18-month HbA1c: n=16. 






5.6.5.2 Characterization of CGM Metrics at the 18-month timepoint 
The 8 CGM metrics that were used at baseline to train the SOM, were 
characterized at the 18-month time point (Supplemental Table 5.6). All measures were 
derived from 7-day blinded CGM wear, using an identical protocol to the baseline visit. 
At the 18-month study visit, Dysglycemia Clusters retained significant differences in 
hypoglycemia exposure, hypoglycemia incidence, and daytime glycemic variability. 
There were no longer significant differences in hyperglycemia or overnight glycemic 
variability. Dysglycemia Cluster 3 showed higher measures of hyperglycemia exposure 
at the 18-month visit, consistent with the concurrent increase in HbA1c over the study 
period.  
 
Supplemental Table 5.6. Key CGM Metrics at the FLEX 18-Month Timepoint 
Measured from 7-Days of Blinded CGM Wear, Overall and by Dysglycemia Cluster 
 Dysglycemia Clusters 
CGM Metrics, mean (SD), 













Hypoglycemia Exposure      




















Hypoglycemia Incidence      
Episodes<3.9 mmol/L (70 
mg/dL) for 15+ minutes, 
Day† 
1 (3) 1 (3) 1 (3) 3 (1)* 0.008* 
Episodes<3.9 mmol/L (70 
mg/dL) for 15+ minutes, 
Night† 
0 (2) 0 (2) 0 (1) 1 (3) 0.019* 
Hyperglycemia 
Exposure 
     
























Glycemic Variability      






















Abbreviations: SD- standard deviation. IQR- Interquartile range. AOC – area over 
the curve. AUC - area under the curve.  
*Denotes significance test of overall difference from ANOVA or Kruskal-Wallis 
test (p<0.05). **Denotes significant difference in unpaired, pairwise t-test or 
Dunn’s test (p<0.05), compared to Dysglycemia Cluster 1. 
†Data were right-skewed and are reported as median (interquartile range). P-
value from Kruskal-Wallis test. There were no missing data. 
 
 
5.6.6 Characterization of the 2-Clustering Solution 
The results from a clustering solution that considers 2 Dysglycemia clusters was 
explored. Supplemental Figure 5.7 compares the dendrograms and visualizes the 
cluster assignments on the SOM for both the 2- and 3- cluster solutions. Dysglycemia 
Clusters 1 and 2 were combined to give the new Dysglycemia Cluster 2.  
Main tables were re-run to compare the CGM features and baseline 
characteristics of the 2-clustering solution (Supplemental Tables 5.7- 5.9). No 
significant differences were detected across clusters regarding sociodemographic, 






Supplemental Figure 5.7. Comparison of 2-cluster versus 3-cluster solution for 
the self-organizing Map (SOM) trained by 7-day continuous glucose monitoring 
(CGM) data to identify dysglycemia clusters at baseline of the FLEX trial (n=234). 
A: 3-Clustering Solution: Dendrogram from hierarchical clustering algorithm performed 
on the SOM. 3 clusters were selected. Final Dysglycemia Cluster assignments (Cluster 
1, Cluster 2, and Cluster 3) are shown by colored boxes. B: The SOM colored by 3 
Dysglycemia Cluster assignments. Clusters are also shown across a frequency map, in 
which each map unit is represented by a colored square with a region corresponding to 
the relative number of data points it represents. The larger the colored square, the more 
datapoints are represented by that map unit. C: Distribution of each input CGM variable 
across 3 Dysglycemia Clusters. All p<0.001. D: 2-Clustering Solution: Dendrogram from 
hierarchical clustering algorithm performed on the SOM. 2 clusters were selected. Final 
Dysglycemia Cluster assignments (Cluster 1 and Cluster 2) are shown by colored 
boxes. E: The SOM colored by 2 Dysglycemia Cluster assignments. Clusters are also 
shown across a frequency map, in which each map unit is represented by a colored 
square with a region corresponding to the relative number of data points it represents. 
The larger the colored square, the more datapoints are represented by that map unit. F. 




Supplemental Table 5.7. Baseline Characteristics of FLEX Participants Overall 
and by Dysglycemia Cluster from a 2-Cluster Solution 
 Dysglycemia Cluster 













    
Age (years) 14.8 (1.1) 14.8 (1.1) 14.9 (1.2) 0.39 
Female sex  117 (50.0) 68 (48.2) 49 (52.7) 0.50 
Non-Hispanic White† 178 (76.1) 104 (73.8) 74 (79.6) 0.31 
Parental Education      0.20* 
Graduate degree 43 (18.5) 22 (15.8) 21 (22.6)  
College Degree  67 (20.9) 54 (38.9) 23 (24.7)  
Some College 67 (28.9) 44 (31.7) 23 (24.7)  
High School or less 26 (11.2) 19 (13.7) 7 (7.5)  
Private Health Insurance 164 (70.1) 105 (74.5) 59 (63.4) 0.07 
Single adult home 30 (13.1) 17 (12.4) 13 (14.1) 0.70* 
Clinical Characteristics      
Duration of diabetes (years) 6.4 (3.7) 6.5 (3.8) 6.3 (3.6) 0.76 
HbA1c (mmol/mol) 81 (13) 85 (14) 77 (11)  
HbA1c (%) 9.6 (1.2) 9.9 (1.3) 9.2 (1.0) <0.001 
HbA1c above 9.0% [75 mmol/mol] 156 (66.7) 104 (73.8) 52 (55.9) <0.001 
Insulin Regimen    0.40 
  Multiple daily injection 68 (29.2) 38 (27.1) 30 (32.6)  
  Pump 165 (70.8) 102 (72.9) 63 (67.7)  
Insulin Dose, total (units/kg) 0.98 (0.33) 1.01 (0.36) 0.93 (0.30) 0.10 
Average frequency of self-
monitoring blood glucose, daily 
2.2 (0.8) 2.1 (0.8) 2.2 (0.8) 0.38 
BMI z-score 0.71 (0.91) 0.70 (0.92) 0.75 (0.91) 0.69 
Weight Status     0.85 
  Under- or normal weight 143 (61.1) 88 (62.4) 55 (59.1)  
  Overweight 56 (23.9) 32 (22.7) 24 (25.8)  
  Obese 35 (15.0) 21 (14.9) 14 (15.1)  
Psychosocial Characteristics     
Motivation‡  7.6 (1.6) 7.7 (1.4) 7.6 (1.7) 0.72 
Intention‡ 9.1 (1.0) 9.2 (0.9) 8.9 (1.1) 0.09 







Adherence to Diabetes self-
management||  
55.2 (11.6) 55.5 (11.9) 54.7 (11.2) 0.63 
Depression symptoms¶  9.1 (8.4) 8.6 (7.6) 79.9 (12.9) 0.23 
Quality of life# 81.0 (12.4) 81.7 (12.0) 79.9 (12.9) 0.28 
Fear of hypoglycemia††      
Maintain High BG 1.2 (0.9) 1.2 (0.9) 1.2 (0.8) 0.94 
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Helplessness/Worry  1.1 (0.6) 1.1 (0.6) 1.1 (0.6) 0.67 
Worry about negative social 
consequences 
1.1 (0.7) 1.1 (0.8) 1.3 (0.3) 0.79 
Diabetes Family Conflict‡‡ 1.4 (0.3) 1.4 (0.4) 1.3 (0.3) 0.43 
Abbreviations: SD – standard deviation. CGM – continuous glucose monitoring. 
HbA1c – hemoglobin A1c. BMI z-score – body mass index z-score.  
P values are from Chi squared or fisher exact test for categorical variables, and t-tests 
or Kruskal-Wallis Test for continuous variables. *Denotes p value from Fisher’s exact 
test. **Denotes significant difference in unpaired, pairwise t-test (p<0.05), compared 
to Dysglycemia Cluster 1.  
Missing data— insulin dose: n=4; parental education: n=2; motivation: n=3; intention: 
n=3; problem solving: n=1; diabetes adherence: n=1; quality of life: n=2; fear of 
hypoglycemia: n=2; diabetes family conflict: n=1. 
† Non-Hispanic white race/ethnicity versus non-Hispanic Black, Black, and other 
including Asian/Pacific Islander, Native American, or unknown. 
‡ Motivation and Intention were measured by a validated questionnaire adapted for 
relevance to type 1 diabetes self-management. 
§ The Social Problem Solving Inventory – Revised: Short (SPSI-R:S); higher score 
indicates higher ability to resolve problems in everyday living. 
|| Diabetes Self-Management Profile – Self Report (DSMP-SR); higher score indicates 
higher adherence. 
¶ Centers for Epidemiologic Study – Depression Scale (CES-D); higher score 
indicates increased depressive symptoms. 
# Pediatric Quality of Life Inventory™ – Generic Core Scales; higher score indicates 
higher quality of life 
†† Hypoglycemia Fear Survey (HFS); fear of hypoglycemia measured in three 
domains: behaviors used to keep blood glucose high to prevent hypoglycemia 
(Maintain High BG), worry about helplessness (Worry/Helplessness), and worry about 
social consequences associated with hypoglycemia (Worry/Social Consequences); 
higher scores indicate greater fear.  






Supplemental Table 5.8. Input CGM Metrics at Baseline Measured from 7-Days of 
Blinded CGM Wear, Overall and by Dysglycemia Cluster from a 2-Cluster Solution 
 Dysglycemia Cluster 
CGM Metrics, mean (SD), 
or median (IQR) 
All (n=234) Cluster 1 
(n=141, 
60.3%) 




Hypoglycemia Exposure     
AOC 70 mg/dL [3.9 
mmol/L], Day* 
0.15 (0.52) 0.03 (0.14) 0.65 (1.0) <0.001 
AOC 70 mg/dL [3.9 
mmol/L], Night* 
0.11 (1.31) 0.00 (0.11) 1.65 (3.01) <0.001 
Hypoglycemia Incidence     
Episodes <70 mg/dL [3.9 
mmol/L] for 15+ minutes†, 
Day* 
2 (5) 1 (2) 5 (6) <0.001 
Episodes <70 mg/dL [3.9 
mmol/L] for 15+ minutes†, 
Night* 
1 (2) 0 (1) 2 (3) <0.001 
Hyperglycemia 
Exposure 
    
AUC 250 mg/dL [13.9 
mmol/L], Day* 
26.9 (21.1) 29.9 (27.4) 24.8 (23.1) 0.018 
AUC 250 mg/dL [13.9 
mmol/L], Night* 
13.0 (21.1) 13.3 (21.8) 12.2 (18.0) 0.131 
Glycemic Variability     
Coefficient of Variation, %, 
Day 
39.8 (7.4) 35.5 (6.4) 44.0 (7.9) <0.001 
Coefficient of Variation %, 
Night 
38.8 (11.9) 32.7 (10.7) 48.6 (10.2) <0.001 
Abbreviations: SD- standard deviation. IQR- Interquartile range. AOC – area over the 
curve. AUC- area under the curve.  
*Data were right-skewed and are reported as median (interquartile range). P-value 
from Kruskal-Wallis test. There were no missing data.  
†Average number of hypoglycemic (<70 mg/dL) episodes lasting 15 or more minutes 
per 24-hr period 
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Supplemental Table 5.9. Longitudinal Hemoglobin A1c (HbA1c) Outcomes of 
FLEX Participants by Dysglycemia Cluster from a 2-Cluster Solution, Adjusted for 
FLEX Study Site and Randomization Assignment 
Mean HbA1c (SE), 









Baseline 84 (10) 77 (3) 0.002 
9.8 (0.9) 9.2 (0.3) 
3-month 82 (10) 79 (3) 
9.7 (0.9) 9.4 (0.3) 
6-month 83 (10) 79 (3) 
9.8 (0.9) 9.4 (0.3) 
12-month 82 (10) 81 (3) 
9.6 (0.9) 9.6 (0.3) 
18-month 84 (6) 80 (3) 
9.8 (0.5) 9.5 (0.2) 
Abbreviations: HbA1c- hemoglobin A1c. SE – standard error.  
All estimates are adjusted for FLEX study site and randomization assignment. Missing 
data— Baseline: n=0; 3-month HbA1c: n= 10; 6-month HbA1c: n= 14; 12-month 
HbA1c: n=20; 18-month HbA1c: n=16. 






CHAPTER 6: EVALUATION AND SYNTHESIS  
This chapter provides an overview of the dissertation including its limitations and 
strengths, proposed future studies, a discussion of the several aspects of broad 
significance with the theoretical implications, and closing remarks. 
 
6.1 Overview of the Dissertation 
Three dissertation studies presented the novel application of statistical methods 
to identify distinct clinical phenotypes of type 1 diabetes. Chapter 3 and Chapter 4 
demonstrated that within the SEARCH population of youth and young adults with type 1 
diabetes, there are distinct subgroups sharing a phenotype defined by their weight 
status and glycemic control; subgroups show different susceptibility to early and 
subclinical complications of diabetes including hypertension, hyperlipidemia, 
retinopathy, and nephropathy within the first decade of having diabetes. Chapter 5 
demonstrated that continuous glucose monitoring data may be used to identify 
subgroups of adolescents with type 1 diabetes based on minute-to-minute aspects of 
dysglycemia that represent discrete clinical issues, including hypoglycemia and 
glycemic variability; subgroups showed differences in longitudinal patterns of HbA1c. 
Together, the studies provide proof-of-principle for the existence of subgroups which 
can be used to inform a precision medicine approach to optimize weight management 
concurrent with glycemic control in a population at an exceedingly high risk for 




6.2 Limitations of Dissertation  
A discussion of the limitations for each study can be found in their respective 
chapters (see Sections 3.4, 4.4, and 5.4). However, there are several overarching 
limitations to the dissertation that warrant discussion, including restrictions of the data 
and methodologic considerations.  
The study designs and their respective study populations limit the inferences that 
may be made. For example, the data posed challenges with regards to the ages of the 
participants. Analyses in SEARCH bridged youth and young adults, raising issues with 
combining participants of different developmental stages and providing challenges for 
the selection of measures of weight status (i.e. BMIz versus BMI). Due to the inclusion 
criteria of the FLEX trial, participants represented a very restricted age range (13-16 
years old), which may introduce a form of selection bias and limits generalizability. In 
addition, pieces of potentially informative data were not available. For example, tanner 
stage data may have lent insights into developmental-specific changes in adiposity over 
puberty in Chapters 3, while interim measures of BMIz or HbA1c may have revealed 
non-linear longitudinal trajectories in those outcomes in Chapter 4. Granular insulin 
dosing data, such as the frequency of boluses and timing of boluses relating to major 
meals, may have provided a diabetes-specific behavioral correlate to better understand 
the different patterns of dysglycemia in Chapter 5.  
The family of methods employed in these studies, cluster analysis, is an 
exploratory technique; none of the studies represent deterministic analyses.322 Further, 
there are highly subjective aspects of cluster analysis where researcher decisions may 
bias the results, including the specification of the distance matrix or the selection of the 
final number of clusters.323 Because clusters reflect the datasets on which they are 
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derived, the generalizability of results is limited by the inclusion and exclusion criteria 
specified for the analysis. Finally, establishing cluster nomenclature is challenging and 
often represents a trade-off between interpretability and accurate labeling of all 
individuals within that subgroup.  
In all studies, the statistical precision was limited by sample size, particularly with 
regards to adjusted modeling (i.e. logistic regression modeling in Chapter 4 and mixed 
effect regression analysis in Chapter 5). The small sample size also prevented 
adjustment for numerous additional covariates, which may result in biased effect 
estimates due to residual confounding.  
An additional, significant limitation of the dissertation relates to the analytic 
approach and concerns the interpretation of the resulting phenotypes. The objective of 
the dissertation was to use machine learning approaches to identify patient phenotypes 
of type 1 diabetes based on key, pre-specified clinical feature and evaluate the utility of 
data-driven phenotypes to predict different clinical outcomes. Therefore, all analyses 
are descriptive in nature; by design, the resulting clusters represent prognostic 
subgroups and cannot be used to properly infer response to a given intervention nor 
selection of an optimal intervention.324 An ideal phenotypic system should capture 
heterogeneity in individualized treatment or intervention approaches in addition to 
heterogeneity in prognosis to identify candidates for individualized treatment.241 
 Finally, these studies were not designed nor powered to study underweight in the 
setting of type 1 diabetes, although this phenotype may be related to the DSM V-
recognized diagnosis of ‘diabulimia’192 or other disordered eating behaviors that are 
prevalent in this population.197,198  Sensitivity analyses revealed that the proportion of 
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youth and young adults with type 1 diabetes who are classified as underweight was very 
small, comprising less than 2% of the study samples. 
 
6.3 Strengths of Dissertation  
Despite the limitations, there are also several overarching strengths of the 
dissertation. First, the studies integrate two distinct datasets and leverage the strengths 
of each to derive patient subgroups. For example, the SEARCH study represents the 
largest population-based studies of childhood diabetes in the United States.325 This 
nationally-representative cohort is thus ideal for an epidemiologic approach to 
characterize the significant weight-glycemia phenotypes across the population. 
Although CGM data is readily becoming more available, the 7-day CGM wear-time 
outlined in the FLEX protocol yielded a highly novel dataset due to the high mean 
HbA1c of the study sample at baseline, providing an opportunity to characterize 
dysglycemia among youth with elevated HbA1c. Despite differences in sample size and 
availability of measures, both datasets provided the unique opportunity to evaluate the 
real-life utility of the computationally derived phenotypes for predicting longer term 
clinical outcomes, including the emergence of early/subclinical diabetes complications 
after approximately eight years of diabetes in Chapter 4 and 18-month changes in 
HbA1c in Chapter 5. In addition, the entire dissertation focused on youth and young 
adults, a highly relevant age range for future interventions towards weight management 
and glycemic control given data showing puberty is a challenging time for both glycemic 




 The three studies address specific gaps in the scientific literature. Measures of 
weight and glycemic control have not been integrated previously to describe the weight-
glycemia phenotypes of type 1 diabetes. This approach is timely given epidemiologic 
data showing suboptimal glycemic control3-5 and adverse changes in body weight1,2 
among youth and young adults with type 1 diabetes. In addition, the framework is 
flexible and may be easily adapted in the future to accommodate greater heterogeneity 
in weight, ranging from underweight to obesity, and glycemic control. The use of CGM 
data to derive dysglycemia phenotypes is opportune given an increase in CGM uptake 
among adolescents with type 1 diabetes143 and the increasing availability of these data 
for research purposes.144 To this end, the unsupervised approach to CGM data analysis 
may facilitate its application to a broad range of CGM datasets for future work.  
These studies also address a larger gap in the field of diabetes research. Despite 
the establishment that a precision health system of care for diabetes needs more 
precise disease subtypes240,241 that can be used to accurately predict clinical 
outcomes,324 work in this area has remained largely theoretical. Results from Chapters 
3-5 represent early steps towards a precision medicine framework for type 1 diabetes 
and offer pragmatic examples of “precision” diabetes care, an otherwise largely vague 
notion.  
Finally, although the statistical methods are innovative, the concept of patient 
phenotyping reflects how clinicians work to intuitively deliver individual care plans for 
patients. This approach is specifically consistent with medical standards of care for 
patients with diabetes, which acknowledge the profound inter-individual differences  and 
suggest individualized care according to  clinical needs, attitudes and preferences, 
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expected treatment effects, disease duration and comorbidities or complications, 
resources and support system, and lifestyle.80,85  
 
6.4 Proposed Future Studies 
The following section describes studies that could be undertaken in the future to 
address limitations of the dissertation studies and build on novel findings, including 
epidemiologic and statistical analyses of existing data and new data collection for 
prescriptive discovery. 
 
6.4.1 Related epidemiologic and statistical analyses 
 Existing data could be used to further understand and validate the findings from 
this research in several additional studies outlined below.  
 
6.4.1.1. Studies related to the weight-glycemia phenotypes of type 1 diabetes 
There are several studies that could be undertaken to explore and improve upon 
results presented in Chapters 3 and 4 (i.e., the weight-glycemia phenotypes of type 1 
diabetes). Phenotypic subgroups warrant external validation studies in different cohorts 
of youth and young adults with type 1 diabetes. For example, it would be interesting to 
study these subgroups in other US datasets, such as the clinic-based T1D Exchange 
Registry,326 as well as international datasets, such as the Prospective Diabetes Follow-
up (DPV) registry in Germany and Austria.327 This platform may also be expanded to 
study weight-glycemia phenotypes of long-standing diabetes in adults and their 
association with hard clinical outcomes328 versus the surrogate outcomes available in 
the early natural history, such as cardiovascular disease events and death. The 14+ 
years of follow-up available on DCCT participants enrolled in the Epidemiology of 
 
165 
Diabetes Interventions and Complications (EDIC) cohort study could be used for this 
purpose,329 although substantial changes in the clinical care of type 1 diabetes may 
decrease the relevance of this dataset looking forward.   
Because BMI is limited in its ability to describe differences in fat mass,262,263  
particularly among males,330,63 these phenotypes could likely be improved by the use 
more precise measures of body composition that compartmentalize adiposity versus 
lean mass. For example, future work could use validated predictive equations to 
estimate body fat percentage331 and derive ‘adiposity-glycemia’ clusters using the 
predicted variable. (Of note, we have previously used these equations to study 
longitudinal patterns of adiposity among youth and young adults with type 1 diabetes in 
the SEARCH study.165) Ideally, clustering could be based on direct measures of body 
composition, such as those collected from dual energy X-ray absorptiometry. 
 
6.4.1.2. Studies relating to the dysglycemia phenotypes of type 1 diabetes 
 The results described in Chapter 5 (i.e. the dysglycemia phenotypes of type 1 
diabetes) also warrant additional studies. As with the weight-glycemia subgroups, the 
dysglycemia phenotypic subgroups warrant external validation in other large CGM 
datasets to understand their durability and the influence of other patient factors (i.e. age, 
diabetes duration) on the major phenotypes. Data from 14 or more days of CGM data 
would be ideal to understand the accuracy of data-driven subgroups using 7 versus 14 
days of data, as the latter was suggested as a minimum requirement by the ATTD 
Consensus statement.144 In addition, CGM data in the setting of a large clinical trial for 
different antihyperglycemic therapies or diabetes technology could be analyzed with 
these methods to reveal nuanced patterns of response that may be missed with HbA1c. 
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Additional data on dietary intake could be used to study specific postprandial response 
related to the timing, frequency, and composition of meals. Finally, the dysglycemia 
phenotypes may be improved with deep learning to extract hidden layers of the CGM 
data. 311 Hidden layers may yield more homogenous or predictive clusters compared to 
those derived from the clinical measures outlined in the ATTD consensus statement.  
 
6.4.2 Prescriptive discovery and clinical trials  
A clinically-actionable understanding of disease subtypes involves a classification 
system which not only predicts outcomes but one which also confers information about 
targeted therapies that are appropriate for each subtype.324 Although the studies 
presented here are descriptive in nature, this dissertation give premise for larger and 
intentionally-designed trials to move from understanding observational phenotypes to 
devising their therapeutic approaches.  
 
6.4.2.1 Possible trial designs and their limitations 
There are conceivable several ways to design a clinical trial to study differential 
response across a set of baseline phenotypes previously demonstrated by 
observational studies (i.e. the weight-glycemia phenotypes or the dysglycemia 
phenotypes).  
One option is to run a fixed intervention for all study participants, and in the 
analysis phase, test for a phenotype*intervention interaction for predicting the primary 
outcome. If the interaction is significant, one could subsequently examine differences in 
intervention response between subgroups to determine which phenotypes may also 
serve as markers for specific response patterns. This analysis could be conducted in 
any randomized trial testing a single intervention delivered consistently across arms. 
 
167 
Several studies that used computationally-generated clusters to predict response to 
trials have shown significant results,332-334 although this work requires large, sometimes 
pooled data from multiple intervention studies to lend adequate statistical power and 
sufficient generalizability.332,334 It is also possible to test the efficacy of phenotype-
specific interventions by a-priori designing and assigning phenotype-specific 
interventions to the subgroups expected to benefit with a comparison of outcomes 
against a less-tailored standard of care.  
Although the trials above would address differential response (either through 
analytic approach or design), the scientific conclusions may be flawed for several 
reasons. First, their conception and execution are directly based on phenotypes 
established from observational data, which may suffer from selection bias, residual 
confounding, and lack of randomization. Second, and most importantly, these designs 
skip the step of prescriptive discovery; they do not explicitly test what the optimal 
intervention is for a given subgroup given a range of possible options. Therefore, a 
better use of the observational studies is for the generation of a discovery hypotheses 
which can be tested via estimation of a dynamic treatment regime for this population.12 
As discussed in Chapter 2, a dynamic treatment regime formalizes precision medicine 
as a sequence of decision rules that are used to assign a patient to an intervention or 
series of interventions based on their unique covariates, which are denoted as “tailoring 
variables” in the context of treatment estimation.12  
There exist clinical trial designs that are constructed to generate maximally-
informative and scientific valid data for this purpose; these trials are referred to as 
Sequential Multiple Assignment Randomized Trial (SMART) designs.12 SMART designs 
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have been described extensively elsewhere.226 Briefly, after baseline data collection and 
initial randomization, the SMART embeds multiple decision points over the course of a 
longitudinal trial. At each decision point, new patient data are collected and intervention 
assignments may be re-randomized based on patient response with respect to a set of 
a-priori established rules for re-randomization. The primary outcome or outcomes are 
often observed after the last decision point. The SMART design allows for several 
important analyses upon completion: 1) the comparison of outcomes with different 
interventions assignments; 2) comparison of outcomes under different sequences of 
interventions, and 3) the estimation of an optimal dynamic treatment regime for the 
population under study, from which responders and non-responders to each 
intervention can be inferred and characterized.12,226  
Although an optimal dynamic treatment can be estimated from the observational 
data, an advantage of SMART designs is that they address limitations of observational 
data described above including lack of randomization and unmeasured confounders.12 
In addition, compared to traditional single-stage randomized trials, SMARTs can be 
used to characterize delayed effects (i.e. intervention effects which show a long-term 
effect only when followed by a second intervention or lasting side-effects which inhibit 
future intervention) and diagnostic effects (i.e. an intervention which may not be 
effective towards the primary outcome but reveals patient data to optimize the selection 
of subsequent interventions).12,226  
 
6.4.2.2 SMART trial design for prescriptive discovery  
A SMART is proposed as an avenue of significant future work for the dissertation 
studies. There are three main stages of proposed future studies, including formative 
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work, an Exploratory SMART, and a Confirmatory Trial, depicted in Figure 6.1 and 
described in detail below. The three stages are designed to be executed in sequential 
order, with reiteration of previous steps as necessary.  
Briefly, formative work would build towards an Exploratory SMART, designed to 
test multiple, diverse interventions (i.e. pharmaceutical, technological, and behavioral 
approaches) to co-optimize weight management and glycemic control across a range of 
clinical needs. Participants would be recruited with a need to improve body weight, 
HbA1c, or both, to lend variability in the sample. Interventions will be selected based on 
analysis of patient data, their perceived benefit and acceptability to clinicians and 
patients, and the strength of the evidence base. Q-learning, a reinforcement learning 
method that is used for sequential decision-making,335 would be used to estimate an 
adaptive intervention strategy to co-optimate weight and glycemia over the course of the 
trial.335 Findings from the Exploratory SMART may be explored through further iterations 
of formative work and, eventually, a confirmatory phase 3-type randomized trial or 
hybrid confirmatory SMART design.  
In the context of the dissertation studies, the significant advantages of the 
SMART design include:  
1) The ability to assess major patterns of response and non-response to multiple 
interventions with multiple outcomes. There exists a very large range of 
clinical approaches for both diabetes management80,86 as well as weight 
control,16,206,207,336 with evidence of highly variable response.208 In addition, 
composite outcomes can be intentionally constructed to represent the co-
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optimization of BMIz and HbA1c, accounting for their co-evolution and 
situations in which one outcome may need to be prioritized. 
2) The ability to account for and reveal possible positive and negative synergies 
between sequentially assigned interventions,226 which may be critical given 
the potentially antagonistic relationship between weight and glycemic control 
outcomes.267  
3) A design that recapitulates real-life clinical practice, where individuals have 
the chance to be re-randomized if an intervention is not successful rather than 
continue an ineffective intervention or drop out.12,226  
Although analyses in Chapters 3-5 focused on youth and young adults with type 
1 diabetes, the proposed studies are outlined in an adult cohort. The reason for this is 
twofold; first, physiologic features (i.e. insulin sensitivity, hormone regulation) are highly 
dynamic in puberty and health behaviors (i.e. activity levels) are irregular and evolve 
significantly in adolescence, resulting in decision rules that may be uninterpretable or 
limited in generalizability. Studies in an adult cohort may lend a more stable study 
sample from which Candidate Interventions can be rigorously characterized and refined 











Figure 6.1. Overview of proposed future studies, informed by dissertation studies. Abbreviations: SMART – 
sequential multiple assignment randomized trial. EHR – electronic health record.  
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Stage 1: Formative Work  
The goal of formative work would be to narrow in on a subset of evidence-based 
‘Exploratory Interventions’ to co-optimize weight and glycemic control. This stage would 
use a combined approach of patient data analysis, qualitative studies with patients and 
care providers, and a rigorous review of the scientific and medical literature.  
The selection of Exploratory Interventions from a broad range of available, 
feasible interventions would be guided by age-appropriate current standards of care for 
type 1 diabetes80 337 and obesity338 339 management with an emphasis to avoid any 
intervention with significant risk for adverse effects. The selection and comparison of 
different clinical approaches is highly consistent with the current American Diabetes 
Association Standards of Care, which, as outlined in Chapter 2, acknowledge the 
profound inter-individual differences that exist between patients and suggest 
individualized care for each patient, considering patient factors and preferences in the 
selection of clinical goals, glycemic targets, and therapeutic approach.80,85  
 
Stage 1A: Phenotyping studies in Electronic Health Record (EHR) Data 
Data in electronic health records (EHR) is being increasingly leveraged for 
secondary uses ranging from biomedical studies to comparative effectiveness.340 This 
form of ‘big data’ offers tremendous potential towards the identification of hypothesized 
patient phenotypes (i.e. subgroups characterized in Chapters 3-5) or latent, previously 
uncharacterized patient phenotypes in ‘real’ patient data across large inpatient and 
outpatient hospital networks.  
First, the clustering analyses described in Chapters 3 and 4 could be replicated 
using relevant and available measures in EHR from individuals with type 1 diabetes, 
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pulled from one or more large health systems. The resulting subgroups could be studied 
with attention to their basic demographic characteristics, co-morbidities and other 
diagnosis codes, and treatment regime as it is represented by pharmaceutical 
prescriptions recorded elsewhere in the medical charts.  
In addition, data-driven phenotyping methods can be used to read various data 
elements and discover underlying clinically meaningful latent patient states or 
phenotypes from EHR data.341 To this end, there are emerging techniques for the large-
scale discovery of computational models of disease, including subtypes or phenotypes, 
from this data. The literature contains multiple examples of analytic tasks that can be 
applied to entire EHR patient populations, including predicting disease progression, 
comparing effectiveness of treatments, and studying disease interactions.342-347 For 
example, a recent study demonstrated the ability to identify temporal phenotypes within 
a population from EHR by identifying differences in the evolution of clinical states or 
care flow over time.348 A different study provided a model for EHR-based phenotyping 
from heterogeneous patient record data (notes, laboratory tests, medications, and 
diagnosis codes), modeling disease subtypes in an unsupervised fashion; this model 
could be applied to EHR data from individuals with type 1 diabetes to identify novel 
computational phenotypes. Phenotypes derived from EHR could be compared to those 
derived from other datasets, such as observational cohort data or existing trial data, and 
characterized according to demographic characteristics, other health outcomes, and 
clinical care as outlined above.   
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Stage 1B: Qualitative work with patients 
Parallel focus group studies with 1) individuals with type 1 diabetes and 2) 
endocrinologists and certified diabetes educators be used to collect data to further 
refined an understanding of major phenotypic subgroups and potential interventions, 
including their patient-perceived and clinician-perceived advantages and barriers and 
the main reasons why a given intervention is initiated, continued, or discontinued in real 
life. Qualitative methods would allow individuals with type 1 diabetes and their care 
providers to express views and experiences in their own words,349 lending depth to 
develop a more complete understanding of the potential interventions. Patients would be 
queried regarding their perception of their weight and glycemic control, barriers to both, 
and tools and clinical strategies that they would perceive to be helpful. Specific 
questions may address potential interventions. Care providers would be asked to 
discuss their perception of major subgroups within their own patient populations that 
drive systematically different treatment recommendations in addition to the 
interventions. Discussions would be guided by a standardized set of questions, audio-
taped, transcribed, and analyzed thematically using inductive qualitative methods, 
following a protocol previously operationalized at UNC to study barriers to weight 
management among youth with type 1 diabetes as pilot work for these dissertation 
studies.193  
 
Stage 1C: Critical review of the evidence base 
Exploratory Interventions identified in Stages 1A and 1C would be subject to 
thorough review of the relevant literature for evidence of benefit without major adverse 
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risk, including clinical trials, standards of care or other clinical consensus guidelines, 
and epidemiologic reports.  
 
Stage 2: Exploratory SMART 
Once the Exploratory Interventions have been identified, the Exploratory SMART 
design can execute ‘pure discovery’ science to inform the precision medicine 
prescription of the interventions.  
When designing a SMART, there is flexibility regarding the time between 
randomization, the outcomes used to assess response and the a-priori rules used to re-
randomize participants, the sequence of interventions that are possible, and the set of 
interventions available at each decision point. It has been suggested that these 
decisions should be designed to most closely mimic decisions that would be considered 
in clinical practice.12,226  
Based on the actions identified to be effective as Exploratory Interventions in 
Phase 1, individuals with type 1 diabetes and suboptimal weight status or glycemic 
control (or both) will be randomized among interventions to test for precision medicine 
rules to guide optimal interventions for weight and glycemia. The Exploratory SMART 
will be adaptive to individual responses to interventions at each decision point through a 
set of a priori decision rules; rules will govern sequential randomizations based on 
towards optimizing weight and glycemic control, as well as patient satisfaction. The goal 
of the Exploratory SMART is to identify an optimal dynamic treatment rule for the data, 
from which the maximally-effective interventions can be identified as Candidate 
Interventions. Patient subgroups for whom specific Candidate Interventions are 
beneficial may also be revealed. All results would be tested in a follow-up, Confirmatory 
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Trial (see Stage 3). Based on findings from Stage 1, the Exploratory SMART may 
include some of the following design elements: 
• Recruitment of individuals with type 1 diabetes and a need to for improvement in 
weight status, glycemic control, or both. Adults (>18 years of age, with possible 
further age restriction such as 30-60 years) with a diagnosis of type 1 diabetes 
and at least 1-year duration of diabetes could be recruited from EHR based on 
demonstrated suboptimal weight (BMI ≥25; i.e. overweight or obese) or glycemic 
control (HbA1c ≥8.0%). This recruitment approach would increase the variability 
in baseline weight and glycemic control and a range of individual-specific goals 
for interventions to inform decision rules surrounding the Exploratory 
Interventions (i.e. which Exploratory Intervention is most beneficial towards 
weight management and glycemic control individually or together). Exclusion 
criteria could include other characteristics including diagnosed eating disorder, 
celiac disease, or other serious conditions that render study participation 
inappropriate. Sample size calculations for the SMART design are not standard 
sample size calculations.350 There are few established methods for calculation of 
sample size for the estimation of an optimal dynamic treatment regime; sample 
sizes can be calculated based on data from a pilot 351 or by the use of simulation 
studies to select the smallest sample size the an acceptable estimated 
outcome.352 The latter approach may be used in the setting of the Exploratory 
SMART. As a pilot study to inform the Confirmatory Trial (see Stage 3), the 




• Treatment outcomes that integrate weight status with glycemic control and 
represent individual needs. Instead of universal weight loss or HbA1c reduction, 
weight and glycemic control outcomes could be designed to reflect clinical 
priorities for each individual (i.e. personalized co-optimization). For example, the 
weight outcome could vary based on previous BMIz: weight loss could be 
prioritized for individuals with a previous BMIz measure categorized as 
overweight or obese, while weight maintenance could be prioritized for 
individuals with a previous BMIz measure categorized as normal weight. 
Similarly, HbA1c reduction could be prioritized for individuals with previous 
HbA1c ≥8.0%, while HbA1c maintenance could be prioritized for those with 
previous HbA1c <8.0%. The main treatment outcome could be represented by a 
composite outcome of the priorities defined above for BMIz and HbA1c given a 
participant’s current weight and glyemia, requiring the use of SMART analysis 
methods for balancing competing outcomes.353 
• Exploratory Interventions that represent a mix of cutting-edge and established, 
major treatment regimens for type 1 diabetes with potential benefit for weight 
management, spanning from technologic interventions and therapeutic 
interventions to behavioral approaches. An impactful trial design could 
simultaneously test novel clinical care paradigms including hybrid closed-loop 
insulin delivery systems,170,354,355 adjuvant non-insulin therapeutics such as the 
addition of a sodium–glucose cotransporter-2 (SGLT-2) inhibitor drug,84 and 
behavioral interventions such as structured eating throughout the day.356-358 Of 
interest, the adaptive aspects of the SMART may reveal interesting positive and 
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negative synergies over time between sequentially assigned interventions; it is 
possibly that these synergies may be maximized by integrating a breadth of 
approaches as Exploratory Interventions rather than a series of closely related 
treatments. Final selection of the Exploratory Interventions would be informed by 
extensive formative work in Stage 1 to represent evidence-based, clinically- and 
patient-accepted treatment regimens with demonstrated and/or hypothesized 
benefit towards glycemic control and weight status in all or subgroups of 
participants.  
• Longitudinal trial with built-in decision points for re-randomization when 
intervention assignments do not show efficacy or acceptability. The Exploratory 
SMART could last 12-months to allow adequate time for change in weight and 
glycemic control outcomes. Following the first randomization at baseline, 
participants could be re-randomized at one of 2 visits occurring at 4- and 8- 
months post-randomization based on a priori decision rules. The decision criteria 
for re-randomization could integrate clinical and patient-centered outcomes, 
including weight status (BMIz; weight loss or weight gain prevention, depending 
on current BMIz), glycemic control (HbA1c; reduction in HbA1c or maintenance 
of good control, depending on current HbA1c, without increase or unacceptably 
high CGM-derived measures of the incidence and duration of level 1 and 2 
hypoglycemia), and patient satisfaction (questionnaire data; maintenance above 
unacceptably low patient satisfaction). 
• Extensive data collection for deep phenotyping. Extensive baseline data 
collection to capture multiple levels of patient information, including demographic 
 
179 
characteristics, social determinants of health, health status and other clinical 
information, psychosocial and behavioral measures, and genomic data could 
facilitate enriched understanding of responders and non-responders to candidate 
interventions.  
• Statistical analyses to estimated tailored interventions and treatment strategies. 
Data from the SMART can be analyzed with typical intent-to-treat analyses to 
compare initial intervention assignments regarding the means in primary 
outcome at trial end, with or without adjusting for confounders. In addition, 
precise interventions to optimize BMIz and HbA1c over the trial duration 
according to outcomes defined above (i.e. maximize weight loss or HbA1c 
reduction as needed) could be estimated using Q-learning with linear 
models.227,359,360 Q-learning is a reinforcement learning technique involving a 
sequence of recursive regressions to model the relationship between the 
intervention and outcome, conditional on the patient covariates, and to ultimately 
select an intervention to optimize expected outcome(s) given the patient 
covariates.335 The recursively estimated Q-functions are used to generate a 
decision rule, which is used to infer Candidate Interventions and the patient or 
subgroup characteristics to guide their optimal delivery regarding the estimated 
treatment effects. With the longitudinal design and multiple opportunities for 
possible re-randomization the decision rule may also confer information about 
the order effects of the interventions for the co-optimization of BMIz and HbA1c.   
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Stage 3: Confirmatory Trial 
The Exploratory SMART may yield information on Candidate Interventions and 
the specific subgroups estimated to benefit most that ultimately inform a confirmation 
hypothesis. Based on the novelty and nature, results can be explored through further 
iterations of Stage 1 if necessary. The Candidate Interventions could then be tested in a 
confirmatory phase-3 type randomized trial or confirmatory hybrid SMART design that is 
designed to compare the precision medicine interventions against standard of care and 
characterize other aspects of care that are necessary, including potential adverse 
reactions. The objective of this stage is implementation and confirmation of precision 
medicine interventions. There are several special design considerations for the 
Confirmatory Trial.  
• Comparison to Standard of Care: The Confirmatory trial design can be built to 
embed an intervention that closely resembles current standards of medical care. 
If the trial is adequately powered, this design will offer a head-to-head 
comparison of precision medicine treatments versus standards of care for a 
given subgroup.  
• Enrichment for rare subgroups: Upon completion of the Exploratory SMART, the 
optimal treatment rule may reveal subgroups for whom a precision delivery of a 
Candidate Intervention makes a large (positive) difference. If those interesting 
and potentially-informative subgroups are rare, (i.e. occur at a lower frequency or 
comprise a small proportion of the overall patient population), it may be 
necessary to enrich for the phenotype in the Confirmatory Trial. Subgroups could 
represent biological subtypes of diabetes (i.e. monogenic forms) or clinical 
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phenotypes (i.e. small clusters discovered in Chapters 3-5). Oversampling can 
be accomplished with pre-designated quotas for a block design framework and 
recruitment using a specific biomarker or multiple biomarkers361 for the subgroup 
of interest. Of note, an enrichment design is feasible only in a population in which 
oversampling is possible. In the case of type 1 diabetes, rare subgroups may be 
recruited from larger EHR networks or collaborating clinical sites.  
Reassessment over time 
Precision medicine is a state of continually reassessing and relearning to ensure 
that optimal dynamic treatment regimens are representative of the patient population 
and available interventions.12 Throughout the confirmatory study (and in future studies), 
efforts would be focused on improving subgroup classification, which may include 
combining subgroups, dividing subgroups, or monitoring subgroups over time to assess 
for newly-emerged subgroups with changing technology and society. In addition, 
longitudinal studies of the same study population could be used to study how individual 
change over time how patterns in change impact the overall stability of precision 
medicine subgroups. 
Finally, further studies could be developed to extend work to other age ranges 
such as youth and adolescents with type 1 diabetes as well as older adults.  
 
6.4.2.3. Significance of prescriptive phenotypes  
One of the most important results would be whether patterns of response to the 
Candidate Interventions are driven by complex or high dimensional features versus 
single biomarkers. While the former may be interesting for hypothesis-generation, the 
latter would be equally important and ideal for clinical utility, scalability, and 
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implementation. The relationship of the proposed SMART to the dissertation studies is 
that it is a reasonable hypothesis that observational phenotypes from Chapters 3-5 may 
integrate and sort themselves as prescriptive phenotypes towards specific interventions 
in the SMARTs. (For example, subgroups with excessive hypoglycemia may benefit 
substantially from the predictive insulin-suspension systems or hybrid closed loop 
pumsp,362 while subgroups with high BMI and HbA1c concurrently may benefit from 
SGLT-2 inhibitors.363,364) In addition, the SMARTs may generate novel, hypothesis-
generating biomarkers for low acceptability or adverse effects of the interventions, for 
example relating to diabetes technology in youth365-367 or non-insulin adjuvants368 in the 
hypothetical interventions described above.   
However, the SMART trial may also reveal non-biomedical ontologies of type 1 
diabetes. Ontologies are systematic representations of knowledge that can be used to 
integrate and analyze large amounts of heterogeneous data, allowing precise 
classification of a patient.220 If the SMART design is built to be pragmatic trial (i.e. 
designed to test the effectiveness of the intervention in a broad routine clinical 
practice369), it is possible that the major prescriptive phenotypes could be based in other 
patient-factors including other social determinants of health that affect obesity and 
diabetes care such as socioeconomic disparity in housing, education, and access to 
care.216-218 To this end, integrating broad sources of patient data capturing economic 
status, resources and access to clinical care, and social support with the scientific data 
from the trial outcomes has the potential to create a precision health system that better 
matches interventions to specific subgroups that are rendered vulnerable to health 
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disparity, thereby working towards health equity in addition to tailoring based purely on 
clinical needs and underlying mechanisms of disease.220 
Finally, public health resources and clinical practice alike ultimately rely on 
algorithms that operationalize different actions based on established boundaries or cut-
points that balance the scientific evidence with an appropriate distribution of resources. 
The responder and non-responder subgroups to Candidate Interventions would also be 
an important step towards the development of a “precision continuum,” or a scalable, 
clinically-functional version of the optimal dynamic treatment regimen; these subgroups 
may provide biomarkers and cut-points using existing patient data sources like EHR for 
algorithms to be scaled in public health and clinical practice. To this end, additional 
major challenges in the future will be how to 1) integrate formats and structures from 
different sources of patient data to make them compatible220 and 2) use the data 
elements in relation to a relevant decision rule to make discrete decisions for an 
individual in such a way that is cost-effective across the population.  
 
6.5 Significance and Implications 
 
6.5.1 Multiple approaches for heterogeneity in observational data  
Observational studies allow for the study of human health over long periods of 
times, across entire populations, and with respect to multiple variables associated with 
human diseases.370 Although these studies contain an implicit degree of uncertainty 
owing to ‘the incompleteness of models and the imperfections of data’370, observational 
data and its analysis remain at the forefront of public health planning and policies to 
minimize epidemics in infectious diseases and decrease morbidity and mortality in no-
communicable disease.370 The analytic methods selected for the dissertation studies 
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demonstrate how the fundamental approach to heterogeneity in observational data can, 
and should, vary to reflect the goals of the paradigm they inform. 
The discipline of epidemiology is central to observational data analysis.371 
Epidemiology is a quantitative science focused on identifying the population-level 
distribution of diseases, factors underlying their source and cause, and methods for 
their control.371 It is also a method of causal reasoning based on developing and testing 
hypotheses pertaining to disease determinants and significant outcomes of morbidity 
and mortality.371 By informing preventative programs and interventions, epidemiology 
has prevented innumerable cases of disease and saved millions of lives.370 
A traditional epidemiologic analysis might focus on how an exposure-outcome 
relationship manifests across the population; the outcome could represent risk for 
adverse outcome or treatment response. Heterogeneity is largely determined by the 
researcher to be meaningful or not meaningful with the use of tools such as directed 
acyclic diagrams (DAG) prior to analysis,371 which are used to clarify the causal 
relationship between exposure and outcomes, including the relevant confounders, 
mediators, and moderators of the association. Adjusting for confounders attempts to 
move towards causality by removing heterogeneity in an effect that may be due to other 
factors with a variable co-distribution with the outcome of interest. On the other hand, 
effect modification attempts to characterize meaningful or actionable heterogeneity in 
the form of stratified analyses; effect modifiers are specified a-priori.  
Although the epidemiologic approach to the analysis observational data is 
extremely powerful for its goals, there are also limitations. First, models to describe 
population-level associations combine large groups of people by necessity, which may 
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underemphasize within-group heterogeneity and mask important subgroups within. The 
process of adjusting for other confounders to produce adjusted estimates of effect 
further diminishes the signal from heterogeneity in other individual-level characteristics. 
Additionally, effect modifiers have to be specified a-priori, relying on some knowledge 
base that the researcher may or may not have.  
 In contrast to epidemiology, where heterogeneity is treated as a challenge for the 
researcher to measure, categorize, and handle in analysis, a precision medicine 
approach directly leverages heterogeneity as an actionable aspect of intervention work 
to inform optimal treatment recommendations for an individual.12 This paradigm, which 
focuses on treatment selection as a function of patient factors, gives an opportunity to 
use combine non-outcome data elements from observational data in a more flexible way 
than exposure, confounder, moderator, or mediator, accommodating the use of more 
data towards the understanding of heterogeneity in presentation and therapeutic 
response. The resulting output may better match what clinicians do intuitively by 
capturing distinct subtypes that lack causal interpretation but may better reveal 
variability that may be clinically-significant or meaningful regarding treatment 
recommendations. It also may yield an enhanced understanding the co-distribution of 
classical confounders or mediators across subgroups.  For example, the study 
presented in Chapter 5 characterized heterogeneity in terms of clinical presentation but 
found other significant differences in the distribution of patient factors across the 
subgroups; these associations are important for understanding subgroups of type 1 
diabetes and may be masked in adjusted models. Finally, heterogeneity can also be 
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represented in the estimation of optimal treatment rules for different populations, from 
which distinct biomarkers can be ascertained for implementation of precision medicine.   
Of note, the larger idea of inter-individual variability transcends its representation 
in observational data; it is pervasive throughout public health and clinical care under 
slightly different, although it is operationalized and labeled differently. The ways in which 
heterogeneity is conceptualized and quantitatively handled carries implications for the 
policies and care guidelines that it informs. This is depicted in Figure 6.2, which is not 
meant to be an exhaustive list but instead a reinforcement of the possibilities, 





Figure 6.2. Heterogeneity in observational data represented across different fields 
of science and applied in health practice 
 
 
6.5.2 Causality and clinical utility 
The results presented in Chapters 3-5 also point towards a distinction between 
analyses that are causal and analyses that are clinically-useful. Although definitions of 
causality vary within the discipline of epidemiology,372 causation typically describes 
 
188 
exposure-outcome relationships that show temporality, positivity, exchangeability, and 
consistency.373 Outcomes may be described in terms of sufficient causes, necessary 
causes, and component causes.374 Whereas a model to explain a given population-
level, causal association of an exposure is an incredibly powerful tool towards large 
policy or health recommendations, it does not necessarily provide information about 
multifactorial determinants of a health outcome and their interactions, especially in 
chronic disease.375 In particular, salient patient features that act as important aspects of 
the problem representation used in clinical practice, such as demographic information 
and co-morbidities, are typically some of the first covariates to be adjusted in 
epidemiologic modeling; the resulting effect estimate is interpreted as if variation from 
those features has been neutralized when, in reality, information about the patient and 
the clinical syndrome are central to diagnostic reasoning and further decision making. 
Rather, clinical medicine is rich with concepts and language that implicates 
stratification for more precise prognosis, prediction, and prescriptions. A precision 
medicine analysis designed to explore population stratification in a rigorous and 
reproducible may lack the qualifications for causal inference but it can place the patient 
in the context of his or her larger patient population,12,15,215,218  yielding the data to 
answer three significant questions that are highly clinically-relevant upon new diagnosis 
or updated health state. First, a question of phenotype: Who else looks like the patient? 
Second, a question of prognosis: What happens to that subgroup? Finally, and most 
importantly, a question of optimal treatment: Which treatments have historically and 
reproducibly been helpful or harmful?  
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In all, the results from a study that lacks causality itself may retain clinical 
significance via accessibility to the clinical audience charged the task of estimating 
patient prognoses and optimal treatments day in and day out. Evaluation of such 
studies in conjunction with other available data may inform an understanding of not only 
the causal or probabilistic determinants of disease, but also the significant, holistic 
patterns of disease and their treatment. In the future, knowledge gain may be 
specifically maximized by study designs developed with expert input from biostatistics 
as well as causal epidemiology to ensure sufficient data collection to enable precision 
medicine analyses and address explicitly causal questions within the same study 
sample.  
 
6.5.3 Value of intuitive versus novel subgroups for precision medicine 
Recall from the Chapter 2 that although precision medicine is an emerging field 
of research, the idea at its core is not new; physicians routinely target treatments to 
individual patients to account for patient heterogeneity as an implicit part of clinical 
practice.13,211 The increase in precision medicine is novel in that it provides data to 
extend personalized medicine to a population level for the targeting of treatments to 
subgroups of patients in an empirically-based, scientifically-rigorous, reproducible, and 
generalizable way.12 
This type of phenotyping work, in some cases, may shift the expectation and 
perceived value of an analysis output from novel to intuitive subgroup identification. For 
example, this dissertation focused on clinical phenotypes of type 1 diabetes, or 
subgroups within the larger population defined by a diabetes diagnosis who sharing a 
subset of significant clinical features. In this setting, an appropriate goal may be to 
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generate computation phenotypes that are biologically plausible but also recognizable 
and familiar as tangible subgroups to the clinical audience who cares for this population. 
The innovation of the program of research is thus less contingent on the discovery of 
new disease subtypes and instead reflects the novel use of data to reproducibly identify 
phenotypic subgroups that clinicians intuitively know exist (and possibly approach 
differently for aspects of care). This type of analysis also facilitates the characterization 
of such subgroups to support anecdotal evidence or clinical intuition with new data, 
including different outcomes and major treatment recommendations.  
However, the expectations of an analysis may change based on the data 
elements used for phenotype generation. When using novel or unseen biological 
markers, such as genomic or proteomic data, the objective of an analysis may be more 
centered on the identification of novel disease subtypes or latent phenotypes which 
have not previously been characterized and are not distinguishable by other, more 
accessible clinical data.  
Together, the intended nature of computationally-derived phenotypic subgroups 
and their anticipated reception among the scientific or clinical community is largely 
dependent on the goals of the analysis and data elements used. Importantly, the 
broader precision medicine framework both accommodates and needs studies that fall 
along this spectrum. To reform and advance healthcare in the future, the field of 
research may benefit from an enrichment of methods to identify both intuitive and novel 
subgroups from varied sources of data, as both flavors of disease ontology may 
represent actional phenotypes in different clinical and community settings.  
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6.5.4 The false antagonism of ‘data-driven versus a-priori’ as analytic approaches 
Completion of the dissertation studies, including engagement in the literature and  
participation in conversations along the way, has revealed several specific aspects of 
research that may be perceived as in opposition or fundamentally incompatible. For 
example, as machine learning methods grow in scope and use, the conversation of how 
these methods fit within traditional epidemiology or biostatistics has generated a sense 
of tension between ‘data-driven’ and ‘a-priori’ analyses. For the ease of discussion 
below, data-driven is a label to encompass exploratory or discovery analyses meant to 
understand characteristics or structure of high-dimensional data, while a-priori refers to 
the family of analyses designed to test the validity of one or more pre-specified 
hypotheses given available data. 
This sense of antagonism is misguided for several reasons. First, it fails to 
recognize the spectrum that is encompassed by the term ‘machine learning.’376 Rather 
than exclusive aspects, Beam et al. recently described a continuum between fully 
human-guided and fully machine-guided data analysis, along which there is an evolving 
trade-off between human specification of a predictive algorithm’s properties versus 
learning those properties from data.376 
Second, this antagonism operationalizes an oversimplified form of a research 
hypothesis, one which only describes the testable type which is used to generate and 
evaluate a p-value for statistical significance. The issue of hypothesis testing is part of a 
larger conversation377,378 in the scientific community surrounding flawed research and 
publication practices which drive and promote false positive results379,380 (also known as 
‘P-hacking’ or ‘p-hacked’ results’381,382). In that context, it is undeniably important that 
the upfront and intentional statement or registration of hypotheses, adherence to pre-
 
192 
specified study protocol, adjustment for multiple comparisons, and encouragement of 
replication from multiple research groups is part of best practices to increase the rigor 
and reproducible of observational findings.377  
However, not all discrepant scientific results reflect foul play, as there are 
instances in which a perceived lack of reproducibility may be driven by important 
heterogeneity in an effect of interest across one or more other aspects. For this 
occasion, and others, science is also advanced by discovery-oriented research in which 
the design and execution of a study is guided by a broader discovery hypothesis. 
Although the discovery hypothesis does not have an associated p-value to confirm 
statistical significance, this is where the line between the a-priori and data-driven 
becomes more blurred in real life; all data-driven analyses need a hypothesis to make 
sense. Moreover, hypotheses in these settings must be similarly researched and 
clearly-defined to produce a strong scientific study. For example, an extensive amount 
of time and research went into the construction the clustering framework for studies 
presented in Chapters 3-5, including defining a phenotype that would be maximally 
useful for precision heath care and selecting the variables and methods to best capture 
that phenotype from the data.  
This brings forward the last and final misinformed aspect of the perceived 
distinction between data-driven and a-priori analyses, which is the implication that a 
maximum amount of data is used at once in the former but not the latter approach. In a 
recent perspective article, Haendel et al. recently wrote, ‘data without interpretation are 
facts without understanding.’ The authors then go on to point out that methods of 
inference towards understanding patient phenotypes of disease ontologies, such as 
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statistical analyses or machine learning, require categorizing subjects according to 
covariates, features, or both.220 Just like traditional epidemiology or biostatistics, data-
driven analyses such as clustering require a strong conceptual framework from which 
available measures can be designated as clustering versus characterizing variables, 
based on the both clinical context and the research question. Put otherwise, the use of 
machine learning methods also does not alleviate the researcher of the need to check 
the distribution pattern of the data and critically evaluate the results; in fact, just the 
opposite can occur. 
 
6.6 Closing Remarks 
A body of epidemiologic data reveals a need to improve clinical outcomes in type 
1 diabetes, particularly among youth and young adults.  This dissertation offers 
evidence that this heterogenous, complex patient population could be approached in a 
subgroup-based manner to address the unique goals and needs of phenotypic 
subgroups, based on novel approach that integrates weight with glycemic control. 
These studies represent an important first step towards a paradigm that offers a 
comprehensive and patient-centered approach to cardiovascular health in type 1 
diabetes. The science integrates tenants of public health and clinical medicine with 
innovations in biostatistics, representing one of the earliest efforts to apply precision 
health towards a population who is very likely to benefit from new approaches to 
optimize multiple clinical outcomes for the best possible long-term health outcomes. 
Looking forward, any program of research to inform a patient-oriented and 
pragmatic approach to medicine should incorporate individual-level physiological, 
clinical, and behavioral factors as well as a consideration of the larger structural 
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determinants of health. In diabetes care, however, it is likely that directly leveraging 
heterogeneity across these factors will transform outcomes on a population level. 
Central to this task is the integration and translation of major concepts from of 
epidemiology, precision medicine, public heath, and clinical medicine to address inter-
individual differences both analytically and in practice. In the future, these studies and 
conversations could build a precision health system for diabetes care in the form of a 
collaborative pipeline, one that is designed to bridge the translation of new, cutting-edge 
device, drug, and nutrition research to its equitable and patient-oriented application to 
improve health across the entire population. 
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CHAPTER 7. THE EMERGENCE OF PRECISION PUBLIC HEALTH 
The following essay was co-authored with Michael T. Lawson, a doctoral student 
in the UNC Department of Biostatistics. It is included here based on its relevance to the 
overall dissertation.  
As personalized and precision medicine research have expanded across medical 
research, an international conversation has unfolded regarding its public health 
implications. Skeptics of precision medicine have pointed to several aspects of the 
precision medicine paradigm presumed to limit its applicability to public health. This 
section offers an alternative perspective: the goals of public health and precision 
medicine dovetail in precision public health, a broader category within which precision 
medicine lies.12 As in precision medicine, the goal of precision public health is to 
discover treatment rules which leverage heterogeneity to improve clinical outcomes in a 
reproducible, generalizable, and adaptable way, while the scope is expanded to 
encompass the clinical outcomes of the whole population.12 
Recent publications offer a variety of public health-based challenges to precision 
medicine, which we summarize here. First, it has been noted that precision medicine 
has dealt with the treatment of disease at the expense of prevention, which is equally if 
not more crucial to public health.215,383 Second, precision medicine can lack rigor and 
reproducibility, opting for data mining techniques rather than tests of explicit hypotheses 
and relying on convenience samples.384-386 Third, there may be an inherent tradeoff 
between precision medicine and evidence-based medicine—the two paradigms 
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inversely prioritize individualized versus generalizable knowledge when determining 
best clinical practice.387 Fourth, due to precision medicine’s emphasis on specimens 
relevant to the mechanism of disease, its purview may be limited to diseases with 
simple pathogenesis.218,383 Fifth, any precision medicine scheme enacted in practice will 
require large-scale collection of genomic and other sensitive biological data, which 
raises a host of legal and ethical issues.383 Sixth, and perhaps most damningly, 
precision medicine neglects the social determinants of health in favor of genomic and 
biological data, when the social determinants of health provide a stronger, sweeping 
gradient across which health outcomes are distributed.384,388 
The picture these criticisms paint is grim. Should precision medicine unfold as 
outlined, using genomic markers with little direct utility towards effective treatment of 
disease in individual patients and ignoring the rest of human health, it would provide 
minimal gains to public health, if any, while diverting resources away from research and 
programs that could do more. 
However, this course is far from the only one precision medicine is equipped to 
take, and farther still from the course it ought to take. Consider instead an approach that 
segments the population into subgroups, which in turn receive targeted interventions 
rather than a “one-size-fits-all” policy.15,215-217 This is precisely the precision health 
paradigm, and it offers a middle ground between the population- and individual-centric: 
this approach relies on population data to measure outcomes in all subgroups, but it 
capitalizes on new data sources and modern statistical methods to tailor 
interventions.12,15,215,218 In this paradigm, the goals of public health and the precision 
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medicine framework are synergistic rather than antagonistic,216 allowing disease 
prevention to advance alongside treatment.217 
Although of central importance to the precision public health paradigm,15 the 
question of how to stratify the population into subgroups has received little attention 
thus far. To this end, we propose three key criteria for subgroup determination. 
First, subgroups must be determined reproducibly. The reproducibility crisis in 
modern biomedical sciences has highlighted the importance of research that 
emphasizes scientific consistency at every stage, from study design to data 
management to the selection of analysis method.12,361 This concern extends to the 
political sphere as well—failures in reproducibility threaten a breach of the public 
confidence and buy-in that are critical for any public health approach to succeed.389 
Second, subgroups should be determined using socially responsible data. 
Precision public health cohorts ought to be large, inclusive, and diverse.215 Machine 
learning methods provide avenues to utilize data-rich datasets and explore trends 
across the population, but they rely on the existence of such datasets.389 This issue is 
not unique to the precision public health paradigm but falling short of inclusivity will 
undercut precision public health’s vast potential to characterize health disparities. 
Third, subgroup stratification should rely on biomarkers that inform the efficacy of 
intervention, rather than biomarkers that may be artifacts of broader social or economic 
health inequity.390,391 As described in Chapter 2.3.2.2, biomarkers can serve a 
prognostic role, forecasting a patient’s long-term prognosis or disease status, a 
predictive role, illuminating the likelihood that a given intervention will benefit or harm a 
patient, or a prescriptive role, providing information on which course of intervention is 
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preferred for a patient.12 Prognostic biomarkers may define heterogeneous subgroups 
of patients within diseases, but they have limited public health utility.1 Stratifying the 
population on prognostic markers that are distributed unequally across race or 
socioeconomic status but do not clarify treatment decisions may increase health 
disparities, or at the least invite fatalistic misinterpretations. Predictive and prescriptive 
biomarkers, on the other hand, provide directly actionable health information12 that 
inform intervention implementation in addition to risk stratification.217 This usefulness 
only grows when the concept of biomarker is enlarged to include data beyond a 
patient’s –omics, such as information representing the social determinants of health 
well-determined by epidemiological studies, when biomarkers inform the logistics 
associated with determining optimal delivery of care, and when considering complex 
diseases, in which the environment may play a large role in reinforcing the beneficial 
effects of therapeutic or preventative intervention.389 
With these criteria met, precision public health can respond to each criticism 
raised previously. Precision public health does not focus on treatment of disease at the 
exclusion of all else—the fact that much of precision medicine research to date pertains 
to treatment may be a symptom of the natural evolution of the field; early investigators 
have focused on treatment whereas the paradigm lends itself equally well to prevention. 
Additionally, precision population screening and prevention interventions may result in 
substantial cost-of-care savings. For instance, the Diabetes Prevention Program (DPP), 
a multisite clinical trial randomizing a multiethnic population at high risk of type 2 
diabetes between different preventative treatments, demonstrated unique metabolic 
signatures of diabetes risk both prior to and during preventative interventions.392 A 
 
199 
precision public health platform offers the best chance to capitalize on findings like 
these. Regarding concerns about lack of rigor and reproducibility, the answer is not to 
shy away from new methods and study designs, but to embrace those that offer 
scientifically principled solutions.393 Moreover, obtaining results that are consistent and 
reliable across cohorts is a challenge common to all of medical science, not one that 
haunts precision medicine alone. The priorities of evidence-based medicine and 
precision medicine cooperate in precision public health, which accounts for the needs of 
the population by tailoring decisions to subgroups within. As with any health data that 
uses sophisticated and sensitive data sources, precision public health research should 
rely on the legal and technical best practices that govern data management and 
security,361 which may well be simplified by future advances in computation and 
encryption. Finally, by incorporating the social determinants of health, a stratified 
approach to complex diseases offers a platform to study both biologically and non-
biologically based etiology, as well as one equipped to explore real-life phenotypes and 
differential response patterns.  
Despite the consensus that improvements in access to certain basic needs 
including preventative medicine are necessary and must be applied across an entire 
population for true public health impact, a way to operationalize that consensus eludes 
us. Precision public health provides one possible avenue forward. A society that truly 
cares about the health outcomes of its entire population should be willing to allocate 
resources to those who need them, and can benefit from them, the most. Stratifying a 
diverse, complex population based on socially responsible, scientifically rigorous 
predictive or prescriptive biomarkers may help guide the efficient use of resources to 
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help those at highest risk.216-218 In this light, precision medicine appears not inimical, but 
complementary, to the tenets of public health. Used in conjunction with modern 
biostatistics, evidence-based clinical practice, and best practices of preventative 
medicine, the precision medicine paradigm provides a powerful tool to account for the 
fact that the biggest chronic diseases worldwide are tied to barriers stemming from 
racial, socioeconomic, and other forms of health disparity. This task is far from trivial. It 
will require close collaboration across science, mathematics, and policy, and innovation 
within all of them. But, in the end, that will likely prove to be a strength, not a weakness, 
of the paradigm: precision public health offers an inclusive, interdisciplinary space 
where the cutting edge of science intersects with the urgency to correct the most 
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